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Abstract 
 
The design and synthesis of a new class of G-quadruplex DNA recognition agents are 
discussed in this thesis along with their binding abilities to both duplex and G-quadruplex 
forming DNA.  A selection of G-quadruplex binders reported in the literature to date have 
been reviewed and their interactions with the quadruplex DNA structure analysed.   
         
The biisoquinoline ligand used to incorporate into the metal complexes synthesised in this 
thesis was chosen because of its large aromatic surface area which is ideal for end stacking 
onto G-quartets.  Both the palladium and platinum biisoquinoline complexes bind to 
quadruplex forming DNA, monitored by UV-vis and circular dichroism.  The platinum 
complex has the most promising DNA binding results showing a selectivity for quadruplex 
DNA over duplex DNA when examined by gel electrophoresis.  
      
Biisoquinoline complex interactions with RNA G-quadruplexes have been investigated to 
make comparisons of that with DNA.  The palladium complex binds less well to parallel 
quadruplex conformers suggesting its mode of interaction differs from that of the platinum 
complex.  A toxicity assay against two cancer cell lines showed the platinum and 
palladium complexes to have IC50 values in the nM range.   
 
Modifications to the biisoquinoline structure were also attempted in order increase the 
specificity of the complex to G-quadruplexes by incorporating components that could 
interact with the quadruplex loops.  
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Abbreviations 
 
13
C NMR carbon nuclear magnetic resonance  
1
H NMR proton nuclear magnetic resonance 
2D-COSY two dimensional correlation spectroscopy  
A adenine 
A2780 ovarian cancer cell line 
ATP adenosine triphosphate 
BF4 tetrafluorborate 
br broad - IR 
C cytosine 
CD circular dichroism 
CD3CN deuterated acetonitrile 
c-myc oncogene DNA sequence 
ct-DNA calf thymus DNA 
d doublet 
dd doublet of doublets 
D2O deuterated water 
d6-DMSO deuterated dimethyl sulfoxide 
DC50 concentration required to decrease fluorescence by 50 % 
DFT density functional theory 
DMF dimethylformamide 
DNA deoxyribose nucleic acid 
DOSY diffusion ordered spectroscopy 
ds26 self complementary (26 base) duplex forming DNA 
EI electron impact - mass spectrometry 
ESI electrospray ionisation - mass spectrometry 
FAM 6-carboxyﬂuorescein 
FID fluorescent indicator displacement 
FRET förster resonance energy transfer  
G guanine 
G4 guanine quartet 
h hour 
H3PO4 phosphoric acid 
HMG high mobility group 
htelo telomeric DNA sequence  
ibiq 3,3-biisoquinoline 
IC50 half maximal inhibitory concentration 
ICD induced circular dichroism 
ILD induced linear dichroism 
IR infrared 
J coupling constant - NMR 
K kelvin 
K
+ 
potassium cation 
kb kilobase 
KCl potassium chloride 
LD linear dichroism 
LiOH lithium hydroxide 
m medium - IR 
M molar 
m multiplet - NMR 
m/z mass to charge ratio 
mdeg millidegrees 
MeOD deuterated methanol 
min minute 
mM millimolar 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium bromide 
Na
+ 
sodium cation 
NH4OH ammonium hydroxide 
nm nanometre 
NMR nuclear magnetic resonance 
NOESY nuclear overhauser effect spectroscopy 
os circular  
PAGE polyacrylamide gel electrophoresis 
PF6 hexafluorophosphate 
ppm parts per million 
PQS putative quadruplex sequences 
RNA ribonucleic acid 
s singlet 
s strong - IR 
sc supercoiled 
SPR surface plasmon resonance 
T thymine 
t triplet 
T47D breast cancer cell line 
TAMRA 6-carboxytetramethylrhodamine 
THF tetrahydrofuran 
TLC thin layer chromatography 
Tm melting temperature 
TO thiazole orange 
TRAP-LIG modified telomere repeat amplification protocol 
UV ultraviolet 
UV-vis ultraviolet-visible 
vs very strong - IR 
w weak - IR 
δ chemical shift - NMR 
ε molar absorption coefficient 
λ wavelength 
λmax maximum wavelength 
μM micromolar 
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Chapter 1: Introduction 
This thesis will explore the design and activity of a new class of G-quadruplex DNA 
recognition agents.  To contextualise why such agents are so important, existing structures 
of DNA and the agents that bind to them first need to be considered.  
 
Part A: DNA Structures, Recognition Sites and Binders 
1.1  DNA and its Structure 
 
Deoxyribonucleic acid (DNA) is fundamental to life as it encodes all of our genetic 
information and is responsible for the function and development of living organisms.  
Understanding processes that occur when the DNA is active, such as replication and gene 
expression, can help with the diagnosis of diseases such as cancer where the rate of these 
processes is much higher.  Already there is a library of metallo-anticancer agents that have 
been shown to interact with duplex DNA in order to alter its function, the most famous 
metallo-drug being cisplatin.  The emergence however of more unusual types of DNA as 
targets has led to the creation of new more specialised complexes that are more specific for 
one type of DNA over another.  The goal therefore is to now create an effective anticancer 
agent that has a specific DNA structure target and is highly potent to cancerous cells whilst 
minimising its effect on healthy cells.  
 
1.1.1  Duplex DNA Structure 
DNA is composed of three components; a pentose sugar, a phosphate group (which 
connects the sugars by phosphodiester bonds to form the sugar phosphate backbone) and a 
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heterocyclic base which can be either guanine (G), thymine (T), cytosine (C) or adenine 
(A).
[1] 
Specific base pairings between adenine to thymine and cytosine to guanine arise due 
to hydrogen bonding between the two bases, Fig. 1.1.  These interactions are more 
commonly known as Watson Crick base pairings and were first elucidated in 1953.
[2]  
The 
two scientists, Watson and Crick, discovered the double helical B-form of DNA where one 
strand runs anti-parallel to the other.
[1][2]
 Grooves of different magnitudes in the DNA 
(major or minor) are created because of the spatial arrangement of the base pairs.
[3][4]
    
 
 
 
 
 
 
 
 
 
There are three common types of duplex DNA; B, A and Z (Fig. 1.2), differing in direction 
of winding and number of bases in one helical turn.  B-DNA exists as a right handed 
helical structure and is the most common form of helicate in biological systems.
[3]
  A-DNA 
is also right handed however forms a shorter and fatter type of helix that is seen in DNA-
Figure 1.1  a. The structure of the DNA sugar phosphate backbone with the base sequence TTA, b. 
Base pairs that link the two strands of DNA and the hydrogen bonds that hold them together. 
(a) 
(b) 
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RNA hybrids and dehydrated DNA duplexes.
[4]
  Z-DNA is left handed and is also seen in 
biological systems.
[3][5]  
 
 
 
 
 
 
 
 
 
 
1.1.2  Other Types of DNA Structures 
DNA is also seen in a variety of other structures other than the duplex form when 
processes such as replication, transcription and recombination are occurring.
[7][8] 
The 
structures that emerge during these active processes may prove to be more effective targets 
for anticancer drugs as it is the loss of control in these processes (over expression of 
proteins or enzymes) which account for the proliferation of cancer.
[9][10]
   
 
1.1.2.1  Replication Forks 
Replication will see the formation of a Y shaped junction as the duplex DNA strands 
uncoil and separate in order for transcription to start.  The separated parent strands act as a 
template against which the DNA polymerase can match complementary nucleotides 
(synthesizes new strand in a 5' to 3' direction) in order to create a copy of the DNA.  The 
branch point created consists of four bases which creates a cavity that has the potential to 
Figure. 1.2 a. B-DNA right handed helicate, b. A-DNA shorter and fatter right handed helicate, c. 
Z-DNA left handed helicate. [Reproduced from Ref 
6
] 
(a)
1 
(c) (b) 
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be targeted by specific synthetic agents that can bind to and halt the replication 
processes.
[11]
           
 
1.1.2.2  Three Way Junctions 
Three way junctions are formed from the convergence of duplex DNA strands that meet to 
produce a Y shaped structure (Fig. 1.3) creating a hydrophobic cavity at the centre.
[12][13]
 
The formation of the three way junction has been linked to diseases such as Huntington's 
when found in genetically unstable genomic DNA which can accommodate looped out 
triplet-repeat expansions.
[12][14]
 Sinden et al reported fourteen genetic neurodegenerative 
diseases in which the expansion of mutated DNA triplet repeat tracts occur.
[14]
  In such 
diseases three way junctions are likely to emerge from mis-paired hairpins introducing 
considerable kinks or bends into the DNA.
[14]    
 
 
 
 
 
 
 
Figure 1.3 a. Representation of a three-way junction showing its formation from three separate strands; 
S1 (yellow), S2 (red) and S3 (green) [Reproduced from Ref 
13
], b. Slipped strand structure formed 
within repeated DNA sequences from a misalignment of complementary duplex strands resulting in the 
formation of loops. [Reproduced from Ref 
14
] 
(a)
1 
(b) 
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1.1.2.3  Holliday Junctions 
Holliday junctions, also known as four-way junctions, are the result of homologous 
recombination which occurs during the repair of collapsed replication forks.
[3][15]
 This 
mechanism of recombination was proposed by Holliday in 1964 and involves an X-shaped 
structure, formed from two duplexes which have come together and exchanged genetic 
material with four duplex arms that emerge from its convergence point (Fig 1.4).
[16]
 
 
 
 
 
 
 
 
 
1.1.2.4  G-Quadruplexes and the i-motif 
Interactions available to a guanine base, other than Watson-Crick base pairing, arise from 
the heteroatoms N7 and O6 along its Hoogsteen face (Fig. 1.5). The hydrogen bonds 
formed along this face with other guanine bases allow the formation of 3D DNA structures 
called G-quadruplexes.
[18]
  A G-quadruplex is composed of layers of G-quartets (first 
reported by Gellert et al)
[19]
 where each quartet is formed from four guanine molecules 
assembled into a planar structure.  The guanine bases interact through hydrogen bonds 
involving the Watson-Crick edge of one guanine and the Hoogsteen edge of its neighbour 
as shown in Fig. 1.5.
[20][21]
 The quartet is stabilised further by the electrostatic interactions 
between the oxygen atoms from the guanines and the metal ion (Na
+
 or K
+
) at the 
Figure 1.4  Crystal Structure of a Holliday junction showing the central branch point with four duplexes 
emerging from it. [Reproduced from Ref 
17
] 
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centre.
[18]
  The ability of the alkali metal ions to stabilise the quadruplex is dependent on 
the amount of energy released when electrostatic bonds are formed with the inside oxygen 
atoms of the guanine bases and the energy required to desolvate the cation.
[22]
 The π 
surface of a G-quartet is about twice as large as a Watson-Crick base pair, therefore 
burying hydrophobic groups increases the stability of the structure as it forms a G 
quadruplex.
[18]
  The biological relevance of G-quadruplexes, further structural analysis, 
types of binders (organic and metal based) and experimental monitoring will be discussed 
in subchapters 1.3, 1.4, 1.5, 1.6, 1.7 and 1.8 respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
i-Motif 
The i-motif is another type of tetraplex this time formed from a cytosine rich sequence of 
DNA.
[24]
  The cytosine rich sequence, under slightly acidic conditions, can form two 
Fig. 1.5 a. Guanine base showing the two bonding faces that interact in a G-quartet,  b. Structure of  
a G-quartet made up of four guanine moieties showing the position of the hydrogen bonds and the 
electrostatically stabilising cation, c. Parallel G-quadruplex structure of a guanine rich strand of 
DNA. [Reproduced from Ref 
23
] 
(b) 
(c) 
(a) 
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parallel duplexes where the cytosine bases can interact with each other through hydrogen 
bonds and also intercalate between each other in an antiparallel fashion, see Fig. 1.6.
[24][25]
  
Where there is a G-rich duplex section of DNA that has the potential to refold into a G-
quadruplex there will also be a C-rich section of DNA that has the potential to fold into the 
i-motif.  Attention has been drawn to the i-motif as it may also be present in transcription, 
replication and negative supercoiling where G-quadruplexes are usually found.
[24]
 The 
thermal stability of the i-motif however is much less than that of the G-quadruplex 
therefore more attention has been focused on the G-rich sequences than the C-rich ones. 
[25][ 26]
  
 
 
 
 
 
 
 
 
 
1.1.2.5  Mismatches and Bulges 
Bulges in DNA are usually formed as a consequence of DNA mismatches.
[27]
  Single base 
errors (Fig. 1.7) are normally corrected by a mismatch repair pathway.
[27]
  However, when 
Figure 1.6 a. DNA duplex made up of a guanine rich strand and its complementary cytosine 
rich strand  (top), during biological processes conditions arise that enable secondary structures 
to form i-motifs (left) and G-quadruplexes (right) [Reproduced from Ref 
24
], b. Hemiprotonated 
C-C
+
 base pair. 
(a) (b) (a) 
H+ 
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left uncorrected the mismatches can be replicated creating a mutated form of the DNA.
[27]
  
The mutation rate, and therefore the onset of cancer, is elevated when the mismatch repair 
pathway breaks down.
[27] 
 
 
       
 
 
 
 
1.2  Anticancer Drugs and Their Mode of Action 
 
The structure of biologically relevant B-DNA has five different molecular recognition sites 
available for potential binding events which are the major groove, the minor groove, 
intercalation between base pairs, the sugar phosphate backbone and covalent or metallo 
interactions directly with the bases.
[3]
  The mode of action of an anticancer drug is dictated, 
to a certain degree, by its molecular structure and will be aimed at a specific recognition 
site.  This becomes more apparent when searching for a binder that is specific to secondary 
DNA structures.
[29]
 
 
1.2.1  Cisplatin and Other Coordinative Binders 
Cisplatin, cis-[Pt(NH3)2(Cl)2], (Fig. 1.8) is one of the most recognisable anticancer agents 
as its ability to cause cell death by direct DNA base binding is unsurpassed.
[30]
  The 
Figure 1.7  Examples of DNA hairpins and a duplex containing single base bulges. 
[Reproduced from Ref 
28
] 
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effectiveness of the drug lies in its ability to hinder the replication process, to which cancer 
cells devote much of their energy.
[30]
   
 
 
 
 
Once administered by injection into the bloodstream it is able to access cells across the cell 
membrane by passive diffusion or possibly by active transport.
[30]
  The complex is then 
able to hydrolyse due to the lower chloride concentration in the cell (high concentration of 
chloride ions in plasma prevents the drug hydrolysing before it has entered the cell) 
allowing it to coordinatively bind to DNA through the interaction of two adjacent guanine 
bases (through N7) from the same strand.
[31]
 This process leaves a {Pt(NH3)2} unit on the 
DNA and causes the DNA to kink (Fig. 1.9).
[31]
  The kinked DNA is recognised by a high 
mobility group protein (HMG) which binds to the kinked DNA and prevents it from being 
repaired.
[30][32]
   
 
 
 
 
 
 
Figure 1.8 Chemical structure of cisplatin.  
Figure 1.9 a. Kinking of DNA after the binding of cisplatin through N7 of two adjacent guanine 
bases, brominated oligo used to follow the kinking process. [Reproduced from Ref 
31
] b. Structure of 
guanine showing the location of N7. 
(a) (b) 
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Despite its medical success, its use can lead to 'cisplatin resistant' cancers and prevents its 
re-administration.  The drug also causes many side effects due to its unspecificity and the 
platinum's favoured binding to sulfur residues on amino acids rather than the DNA.
[32]
 
Other platinum binders include carboplatin and oxaliplatin which have been developed 
from the cisplatin model in that they also have two cis-amine groups and two leaving 
groups (Fig. 1.10).
[32] 
 
 
 
 
 
 
Carboplatin shows lower toxicity levels than cisplatin due to its less labile leaving group 
making it a good choice of drug when the patients are too ill to cope with the toxic effects 
of cisplatin.
[30]
  Despite this, it is not effective against cisplatin resistant tumours because it 
leaves the same {Pt(NH3)2} unit on the DNA.
[31]
  Oxaliplatin has been found to be more 
effective than cisplatin against breast cancer, melanoma and colorectal cancer due to its 
bidentate diaminocyclohexane ligand which causes different DNA adducts to be 
formed.
[32]
  Some side effects associated with cisplatin are also eliminated with oxaliplatin 
and it has the capability to treat some cisplatin resistant tumours.
[33]
 
 
Other transition metals that can be used in anticancer agents have also been investigated, 
two of which are shown in Fig. 1.11.
[34][35]
  Ruthenium(II) is particularly useful as it 
possesses similar ligand exchange kinetics to platinum(II) and mass spectrometry 
Figure 1.10  Structure of carboplatin (left) and oxaliplatin (right).
[32] 
 
Chapter 1: Introduction 
 
11 
 
experiments have shown that guanine is the preferred binding partner for both metals when 
forming adducts.
[36][37]
 Two ruthenium based complexes that show anticancer activity are 
indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1019) and imidazolium 
trans-[tetrachlorido(1H-imidazole)(S-dimethylsulfoxide)ruthenate(III)] (NAMI-A).
[34][35]
   
 
 
 
 
 
 
 
 
 
 
KP1019 has anticancer activity against primary tumours and works by causing 
programmed cell death by a mitochondrial pathway
[34]
 while NAMI-A is inactive against 
primary tumours but displays anti-metastatic properties.
[35]
 It has been postulated that 
protein binding may play a part in their overall activity as the ruthenium complex DNA 
adduct formation occurs more slowly than with cisplatin.
[37][38][39]
 
 
Iridium is another transition metal that has demonstrated anticancer activity through the 
formation of guanine adducts
[40]
.  A collection of novel half-sandwich organometallic 
iridium(III) cyclopentadienyl complexes have been synthesised (an example is shown in 
Fig. 1.12) that are potent cytotoxic and cytostatic agents showing submicromolar 
Figure 1.11 Two ruthenium complexes, KP1019 and NAMI-A, that demonstrate anticancer activity.
[34][35]
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activity.
[41]
 The complexes are able to bind to the DNA bases directly through N7 in 
guanine and intercalate between the bases also.
[40]
 Despite this class of complexes being 
monofunctional (only one chloride ligand to hydrolyse) they can disrupt the replication 
process when iridium(III) binds to the DNA.
[41] 
 
 
 
 
 
 
 
 
1.2.2  Intercalators 
Intercalation, initially proposed by Lerner in the 1960s
[42]
, involves the non-covalent 
binding of a planar aromatic π system that is able to insert in between stacked base pairs of 
a DNA double helix from either the major or minor groove.
[3]
 Heterocyclic aromatic 
systems possess large hydrophobic surfaces that can be efficiently buried within the DNA 
structure.
[43]
  The electrostatics of the system, induced through the binding of a metal 
cation to the heterocyclic aromatic group, can further promote this form of binding.
[3]
  
When intercalation occurs it disrupts the normal DNA structure causing it to unwind (the 
degree of which is determined by the intercalator), stiffen and lengthen.
[44]
 Changes such 
as this to the DNA can result in the disruption of replication and transcription.
[44]
 
 
Figure 1.12  Iridium(III) cyclopentadienyl complex that shows submicromolar activity in the human 
ovarian cancer cell line.
[41]
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Anthracycline antibiotics are planar aromatic compounds that can intercalate into DNA 
and in doing so act as anticancer agents.
[45]
 The drug doxorubicin (which is classified as an 
anthracycline antibiotic) is a particularly good anticancer agent and acts by inhibiting 
topoisomerases causing the disruption of replication that leads to cell death.
[45][46]
  It shows 
a preference for intercalation between the bases guanine and cytosine and also interacts 
with the bases in the minor groove through its amino sugar (Fig. 1.13).
[46] 
 
 
 
 
 
 
 
 
Metallo intercalators are another sub-group of binders that can encompass more easily the 
positive charge required to provide favourable electrostatic interactions and therefore a 
higher binding affinity with the DNA.
[47]
 The metal also creates new geometries for 
binding, compared with the organic compounds, providing new and more specific ways 
that the metal complex can be specially adapted to target the DNA.
[47]
  
 
The types of ligand that are used as duplex DNA intercalators include phen, phi and dppz 
shown in Fig. 1.14 as part of rhodium and ruthenium complexes.
[44]
  Incorporating metals 
Figure 1.13  a. The structure of doxorubicin, b. Intercalation of two doxorubicin drugs between 
the base pairs of DNA. [Reproduced from Ref 
3
] 
(a) (b) 
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such as ruthenium can be particularly useful due to the luminescent properties of 
ruthenium(II) providing diagnostic value.  Rhodium(III) complexes have the added benefit 
of performing DNA cleavage by undergoing photoinduced oxidation.
[3]
   
 
 
 
One of the first studies investigating the intercalation of metal complexes with DNA was 
conducted by Lippard et al in the 1970s and involved the intercalation of platinum 
terpyridine complexes (Fig. 1.15) into calf thymus DNA (ct-DNA).
[47][48]
 The aromatic 
hydrophobic group on the complex can be effectively buried in the DNA resulting in a 
strong binding interaction between the DNA and the complex.
[43] 
 
 
 
 
 
 
 
Figure. 1.14  Types of heterocylic ligands that can be used to intercalate between bases in 
duplex DNA: [Rh(phen)3]
3+ 
(left), [Rh(bpy)2phi]
3+
 (middle), [Ru(bpy)2dppz]
2+ 
(right).
[44]
  
Figure 1.15  Platinum(II) terpyridine DNA intercalating complex reported by Lippard.
[48] 
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1.2.3  Major and Minor Groove Binders 
Major Groove 
The major groove of the DNA double helix (Fig.1.16) is able to interact with both proteins 
and oligonucleotides.
[3]
 It has a width of 11.6 Å and depth of 8.5 Å providing easy access 
for bulky molecules.
[49]
 Hydrogen bond donor and acceptor interactions are important for 
DNA-protein recognition as they allow the DNA bases and amino acids to interact with a 
degree of specificity.
[50]
 Hydrophobic contacts and other water mediated hydrogen bonds 
also influence the binding between the DNA and proteins.
[51]
  
 
 
 
 
 
 
 
 
 
The most frequently used secondary structure of protein for major groove DNA 
recognition is the α-helix.[51] An example of a protein structure with an α-helical binding 
domain is a zinc finger which is able to make sequence specific contacts with the DNA 
bases, often matching one finger motif with four or more bases.
[51]
 Other structures with an 
α-helical binding domain include leucine zipper proteins and helix-loop-helix motifs.[51]     
 
Figure 1.16  Major groove of B-DNA. [Reproduced from Ref 
50
] 
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Oligonucleotides can bind to DNA within the major groove to generate triple-helical 
nucleic acids stabilised by hydrogen bonds (Hoogsteen or reverse Hoogsteen) between the 
outer groups on the purine strand of the duplex DNA and the bases from the new strand.
[52]
 
The new strand can be added in either a parallel or anti-parallel fashion, the parallel form 
being the most stable where guanine-cytosine pairs are recognised by a protonated cytosine 
(C
+
.GC) and adenine-thymine pairs are recognised by thymine (T.AT), (Fig.1.17).
[52]
 
     
 
 
 
 
 
 
 
 
The formation of triplexes are linked to gene expression therefore the development of 
oligonucleotides for use in gene therapeutics is important.
[53]
 DNA oligonucleotides 
however are not the best candidates as they suffer from biological degradation, difficult 
synthesis, poor cellular uptake and lack of solubility.
[53]
 Peptide nucleic acid (Fig. 1.18 - a)  
is an alternative type of structure that can be used to substitute a DNA oligonucleotide in a 
triplex, although cell uptake is a problem.
[54]
 Despite it replacing the sugar phosphate 
backbone with a sequence of (2-aminoethyl) glycine units it is able to mimic the base 
pairing interactions with a strand of complementary DNA creating triplexes that are 
thermally stable with a high degree of specificity.
[53][54]
  However, it preferentially forms 
Figure 1.17  Chemical structure of the base triplets formed when a parallel triplex motif is formed.  a. 
AT base pair from duplex bound to thymine from new third strand, b. GC base pair from duplex bound 
to protonated cytosine from new third strand.
[52] 
(a) (b) 
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(PNA)2(DNA) over (PNA)(DNA)2 triplexes.
[3]
 LNA (locked nucleic acid) is another 
nucleic acid analogue which is composed of conformational restricted sugar groups.
[55]
  
When bound to DNA it is responsible for the A conformation of the heteroduplex due to its 
ribofuranose sugars which become locked in a 3'-endo conformation (additional bridging 
exists between 2O and 4C on the ribose, Fig. 1.18 - b).  The structure has a very high 
affinity for both RNA and DNA.
[55]
    
 
 
 
 
 
 
 
The major groove has also been shown to interact favourably with a selection of natural 
and synthetic products (Fig. 1.19) including pluramycins, aflatoxins (both natural) and 
ditercalinium (synthetic).
[50]
 However research into major groove binding is less studied 
for synthetic agents due to the availability of the smaller minor groove that is a better fit 
for smaller synthetic agents.
[50] 
 
 
Figure. 1.18  a. The structure of peptide nucleic acid (PNA)
[54]
, b. LNA monomer with bridge between 
2O and C4 atoms of the ribose.
[55]
  
Figure 1.19  The structures of two major groove binders; aflatoxin B1 (left) and ditercalinium 
(right).
[50]
 
(a) (b) 
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Minor Groove 
The minor groove is more narrow and so better suited to small organic synthetic agents.
[49]
 
Minor groove binders frequently consist of an aromatic structure that is concave in shape 
(in order to match the convex shape of the groove) and can form hydrogen bonds with the 
bases and has amine groups capable of protonation under physiological conditions to form 
favourable interactions with the sugar phosphate backbone.
[49]
 
 
Distamycin A fulfils the brief of minor groove binder with its three pyrrole rings connected 
by amide bonds and an amidino side chain that interacts electrostatically with the DNA 
(Fig. 1.20).
[56]
  The amidino group helps the compound bind to the groove by interacting 
with the tightly packed phosphate groups in the backbone, thereby acting as an anchor.
[49]
  
It is able to hold the compound in place through electrostatic interactions while the rest of 
the compound sits in the groove interacting with the A and T rich DNA bases.
[49]
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.20  a. The structure of Distamycin A, b. X-ray structure of B-DNA with the binding 
mode of distamycin A in the minor groove. [Reproduced from Ref 
54
] 
(a) (b) 
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The cytotoxic activity of distamycin is limited as it lacks a permanent anchor to the minor 
groove.  Alkylating agents can be attached to the N-terminus of the structure producing 
benzoyl N-mustard and substituted acetamide type compounds.
[57]
 The compound shown 
in Fig. 1.21, a tetrapyrrole which possesses a α-bromoacryloyl alkylating group, is 
approximately 1000 times more cytotoxic than distamycin demonstrating the effectiveness 
of incorporating additional alkylating agents.
[56]
   
 
 
 
 
 
 
 
 
 
Tallimustine (Fig. 1.22) is a derivative of distamycin that displays a higher activity than 
the parent compound in a broad range of antitumor activities.
[49][59]
  As well as having the 
essential distamycin framework it also contains a benzyl nitrogen mustard for alkylating 
functionality.
[49]
  This was chosen because it is less likely to react with biological 
nucleophiles such as thiols.
[49][56]
 The increased cytotoxic behaviour stems from the ability 
of the drug to locate in the minor groove while the benzyl nitrogen mustard, after 
producing aziridium, alkylates the DNA at different positions.
[49]
 
 
 
Figure 1.21  Modified distamycin compound with an additional pyrrole group and an α-
bromoacryloyl alkylating group
[58] 
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Another binder of the minor groove is Hoechst 33258 (Fig. 1.23) which is a synthetic 
compound that is particularly interesting due to fact it becomes strongly fluorescent when 
it binds to DNA.
[60]
 The Hoechst dye selectively binds to A-T rich sequences with a 
binding site of four or five A-T base pairs stabilised by the burial of hydrophobic groups as 
the minor groove is largely hydrophobic.
[43]
  The hydrogen bonds occur between the amine 
protons in the compound and the oxygen and nitrogen atoms from the thymine and adenine 
bases.
[61]
 This fluorescent agent can be used in live cells.
[56]
   
  
 
 
 
 
 
 
 
 
Figure 1.22  The structure of tallimustine.
[49]
 
Figure 1.23  a. The chemical structure of Hoechst 33258, b. The structure of a segment of 
duplex DNA with Hoechst 33258 bound in the minor groove. [Reproduced from Ref 
60
] 
(a) (b) 
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1.2.4  Sugar Phosphate Backbone Binders 
A degree of backbone binding is exhibited in most of the non-covalent binders discussed 
so far, as most of the binders carry positive charges.  The binders are electrostatically 
attracted to the negatively charged sugar phosphate backbone, helping to anchor them in 
place.  A novel phosphate backbone binder has been reported by Farrell and co-workers 
which acts as a 'phosphate clamp' (Fig 1.24).
[62]
  
 
 
 
 
 
 
 
 
 
In the complex, shown in Fig 1.24, the three platinum(II) groups are connected by flexible 
hydrophobic spacers that allow the phosphorus binding platinum to be matched up with the 
phosphate groups of the DNA backbone.
[62]
 The Pt(II) amine and ammine units will then 
coordinate through hydrogen bonds to the phosphate oxygen atoms to form bidentate 
interactions (Fig 1.25).
[54]
  The lack of any potential covalent interactions or aromatic 
heterocyclic regions allows it to be specific only for backbone binding.
[62]
  
 
 
        
Figure 1.24  The chemical structure of 'phosphate clamp'  [{trans -Pt-
(NH3)2(NH2(CH2)6(NH3
+
)}2-µ-{ trans -Pt(NH3)2(NH2(CH2)6NH2)2}].  
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1.2.5  Anticancer Agents that Target Other DNA Structures 
Three-Way Junction Binder 
Potential binders for three way junctions require a good size fit for the internal cavity of 
the structure in order to stall the replication process in cancerous cells; providing 
selectivity for this structure over the more common duplex form.
[54]
  Hannon and co-
workers have shown how supramolecular divalent iron triple helicates can bind in the 
cavity of the three way junction (Fig. 1.26).
[11]
  The three fold symmetry of the three-way 
junction matches with that of the iron supramolecular helicate allowing efficient burial of 
hydrophobic surfaces at the branch point.
[63]
  The non-covalent interactions are stabilised 
further by the cationic nature of the complex and the anionic nature of the DNA.
[63]
  
 
The cylinder has also been shown to bind to DNA dimers which are another type of Y 
shaped junction where at the branch point there are four bases instead of six.
[11]
  The 
complex may bind in a similar way to both types of Y shaped junctions however three way 
Figure 1.25  a. The hydrogen binding interactions which occur between the platinum ligands and 
the phosphate backbone groups,  b. Structure of the platinum(II) complex binding to DNA. 
[Reproduced from Ref 
54
] 
(a) (b) 
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junction binding does not alter the DNA structure whereas dimer binding has more of an 
effect on the dimers shape and flexibility.
[11]
  
 
 
 
 
 
 
 
 
 
 
Holliday Junction Binder 
Holliday junction binders in the literature employ a bis-intercalator design binding to two 
DNA sites that are close together in a cooperative manner.
[64]
 The compound bis-acridine 
has been successful at binding to the four way junction, shown in Fig 1.27.
[15]
  The 
acridine units interact favourably with the DNA bases through the efficient burial of 
hydrophobic surfaces.
[15][43]
  The hydrophobic side chains reside in the minor grooves of 
the junction and the charge on the protonated molecule stabilises the structure through 
electrostatic interactions.
[15] 
 
 
 
 
Figure 1.26  a. The structure of the cylinder  [Fe2L3]
4+
, b. Diagram based on X-ray 
crystallographic results of the iron supramolecular cylinder binding in a three way junction. 
[Reproduced from Ref 
11
] 
(a) (b) 
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DNA Mismatch and Bulge Binders 
The bulges created, due to DNA mismatches, are able to accommodate the binding of 
larger aromatic structures as they do not have the same Watson-Crick pairing interactions 
that normal duplex DNA has.  As a result, metallo-complexes with larger aromatic groups 
have been synthesised that have the potential to be selective for mismatches over duplex 
DNA as they would be too big to fit between the bases in a normal double helical 
structure.
[65] 
     
Complexes based on chrysi ligands have been synthesised by Barton and used for 
mismatch DNA targeting.
[27]
  Their octahedral bulky rhodium complexes, an example of 
which can be seen in Fig 1.28, preferentially bind to the DNA at sites where there is a 
thermodynamically destabilised mismatch.
[27]
 [Rh(bpy)2chrysi]
3+
 has been found to bind 
specifically to 80% of mismatches, with binding constants of 10
6
 M
-1
, through the insertion 
of the chrysi ligand into the duplex DNA at the mismatched site from the side of the minor 
Figure 1.27  a. The structure of a bis-acridine compound, b. Diagram based on X-ray 
crystallographic results of bis-acridine binding to the four way junction. [Reproduced from 
Ref 
54
] 
(a) (b) 
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groove.
[27]
 This in turn causes the mismatched bases to be pushed out of the DNA stack 
allowing the chrysi ligand to fully interact with the base pairs.
[27]
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.28  a. Structure of the bulge binder [Rh(bpy)2chrysi]
3+ synthesised by Barton, 
b. Crystal structure of the Rhodium complex (red) bound to a CA mismatch (A - blue, 
C - yellow). [Reproduced from Ref 
27
] 
(a) (b) (a) 
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Part B: Structure, Chemistry and Function of G-Quadruplexes 
 
The presence of G-quadruplexes in the human genome has sparked great interest in the 
study of quadruplex formation, function and targeting.  Their formation is linked to active 
DNA processes and therefore they offer a way of selectively targeting DNA instead of 
targeting the duplex structure which can be described as DNA in 'sleep mode'.  The rest of 
the introduction will give a detailed review on the structure of G-quadruplexes, where and 
why they form and examples of binders and experimental techniques that are being used to 
study them.     
 
1.3  G-Quadruplex Conformations: Loops and Metal Ions  
 
The introduction to G-quadruplexes covered in 1.1.2.4 only touches the surface on the 
types of structure a G-quadruplex can form.  G-quadruplexes can be formed from a number 
of strands of either one, two (dimeric) or 4 (tetrameric) strands (Fig 1.29) (intramolecularly 
or intermolecularly) and arranged in either a parallel or antiparallel fashion.
[23]  
 
 
 
 
 
 
 
(a) (b) (c) 
Fig. 1.29  Three types of G-quadruplex: a. Parallel tetrameric (four strands), b. Antiparallel dimeric 
(two strands), c. Parallel, intramoleculary folded single strand. [Reproduced from Ref 
66
] 
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The overall conformation of the quadruplex stems from the arrangement of the strand(s) 
and in the process produces loops that further differentiate one type of quadruplex from 
another providing extensive structural diversity.
[66]
 Fig. 1.30 shows a selection of 
intramolecular G-quadruplex structures that can be formed from a guanine rich DNA 
sequence found in telomeric regions.
[23]
 For each conformation the loop positions differ 
because of strand stoichiometry, strand polarities, glycosidic torsion angles and location of 
loops that link the guanine strands.
[23][66]
  
 
 
 
 
 
 
 
 
 
 
There are three main types of loops that are formed which influence the overall topology of 
the quadruplex.  Propeller type loops are formed from adjacently linked parallel strands 
where the loop is required to link the bottom G-tetrad with the top G-tetrad in a medium 
groove
[67]
 (Fig 1.30 - c). Parallel complexes have all of their guanine glycosidic angles in 
an anti-conformation.
[68][69]
 Lateral loops are found in antiparallel structures (where at least 
Figure 1.30  Five conformational analogues of one G-rich telomeric DNA sequence. a. Basket type 
(antiparallel), b. Chair type (antiparallel), c. Propeller type (parallel), d. Mixed type (antiparallel 
hybrid), e. Mixed type (antiparallel hybrid). [Reproduced from Ref 
23
] 
(a) (b) (c) 
(d) (e) 
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one of the four strands is antiparallel to the others) and join adjacent G-strands forming 
either narrow grooves (syn-anti) or wide grooves (anti-syn) (Fig 1.30 - d and e). 
[66][68][70]
 
Diagonal loops are also found in antiparallel structures and join opposite G strands; the 
direction of adjacent strands must alternate between parallel and antiparallel (Fig 1.30 - a 
and b).
[66]  
Antiparallel quadruplexes possess both syn and anti-guanine 
conformations.
[66][71]
  The two types of conformations are shown in Fig 1.31, where 
interconversion occurs by rotation about the glycosidic bond.
[18]
   
 
 
 
 
 
 
Another important factor in the formation of a G-quadruplex is the type of cation present.  
In the G-quadruplex structure the cations are located in the central cavity, along the helical 
axis and form interactions with the carbonyl oxygen of the guanine bases (Fig 1.32).
[72]
   
 
 
 
 
 
Figure 1.31  The interconversion between the syn and anti conformations of guanine (both C2'-
endo) which occurs by rotation around the glycosidic bond X (angle O4’-C1’, N9-C4).[18] 
Figure 1.32. Side view of a G-quadruplex structure showing the potassium ions in the central 
cavity between the G-quartet planes produced by single crystal X-ray diffraction analysis. 
[Reproduced from Ref 
72
] 
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The exact location of the cations depends on the size of the ion.  Na
+
 has been observed in 
the plane of the G-tetrad in some structures and between two G-tetrads in others
[18]
 while 
K
+
 ions are always found equidistant between each tetrad plane giving the K
+ 
ion a 
distorted square antiprism coordination geometry.
[71][72]
  The type of cation present has 
been found to influence the conformation of quadruplex formed as in telomeric G-rich 
DNA Na
+
 stabilised quadruplexes are antiparallel conformers whereas K
+
 stabilised 
quadruplexes are antiparallel hybrids (showing both antiparallel and parallel 
characteristics).
[73]
  The position of the cation may also affect the planarity of the top G4 
tetrad.  The cation is optimally positioned between the O6 atoms of the guanine bases in 
order to interact electrostatically which may result in the tetrad becoming slightly 
twisted.
[22] 
 
Potassium ions are known to be much more abundant than sodium ions in intracellular 
environments and therefore it is believed that the K
+
 stabilised quadruplexes are more 
biologically relevant.
[72][74]
  This can be rationalised by the best size fit along the helical 
axis (Fig 1.33), evidence for which has been provided by Wu et al, where a NMR solid 
state experiment was conducted using a guanosine 50-monophosphate composed guanine 
tetrad.
[75]
  The result showed that the affinity of monovalent cations for the G-quadruplex 
cavity follows this order K
+
 > NH4
+
 > Rb
+
 > Na
+
 > Cs
+
 > Li
+
.
[75]
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In some parts of the human genome there are guanine rich sequences present in double 
stranded DNA.
[18]
  In order for intramolecular G-quadruplexes to form in this region the 
stability of the duplex DNA needs to be compromised (Watson-Crick base paring made 
less favourable).  The stability of the single stranded structure (quadruplex) must also be 
encouraged.
[18]
 When exposed to additional factors from within the cell, the equilibrium 
can be shifted from the double stranded structure towards quadruplex formation.
[18]
 These 
additional factors can include; duplex supercoiling, molecular crowding and the presence 
of specific complexes or proteins that can interact with the quadruplexes.
[18]
 
 
1.4  Biological G-Quadruplexes and their Function 
 
G-Quadruplexes are an emerging target for anticancer complex development and are 
presently attracting the attention of many research groups trying to find the best specific 
binder.  In order to target such a structure, the rationale for G-quadruplex formation and 
the conditions under which this occurs need to be examined.  G-quadruplex structures have 
been found throughout the human genome in telomeric regions, oncogene promoter 
regions, immunoglobulin switch regions and areas where mutation is high (see subchapter  
1.4.2).
[23] 
Figure 1.33.  Arial view of G-quadruplex structure showing the central channel of potassium 
ions. (PDB 1KF1)
[76] 
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The number of putative quadruplex sequences (PQS) that exist in the genome has been 
studied by Huppert and Balasubramanian.
[77]
  Together they developed the 'folding rule' 
with the formula d(G3+N1–7G3+N1–7G3+N1–7G3+) which is used in a computer generated 
quadparser algorithm.
[77]
  The results after the analysis of the whole human genome with 
the quadparser algorithm found 376,000 PQS that may be capable of forming G-
quadruplexes.
[77]
  Telomeres, consisting of a simple repeat sequence, were found to 
account for around 20,000 of the PQS found.
[77]
  This indicates that there is likely to be 
many more quadruplexes found in other areas such as oncogene promoter regions.
[77]
     
 
1.4.1  Telomeric DNA 
Chromosome ends are protected by a single stranded DNA sequence (telomere) that holds 
no genetic information, unlike the rest of the chromosomal DNA.
[78]
  Telomeres are 
necessary due to the nature of the replication process because after every successive cycle 
the DNA is shortened.
[79]
 They also prevent the ends from being recognised as broken 
DNA and being 'stuck together' by specific repairing proteins.
[79]
   
 
When DNA unwinds in order to replicate, one strand becomes the leading strand and the 
other the lagging strand.  This occurs because DNA polymerase III (an enzyme that builds 
the new strand in humans) synthesises in the 5'→ 3' direction which is the same direction 
that the DNA is being unwound.
[80]
 Therefore the strand being created in the direction of 
unwinding is the leading strand and the strand running in the opposite direction has to be 
synthesised in fragments (Okazaki fragments) hence called the lagging strand (Fig 
1.34).
[80]
 The shortening occurs due to the RNA primers that are required to initiate the 
new strand synthesis as they provide the 3'-hydroxyl group to attach the next DNA 
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fragment.  Once strand formation is complete the RNA primers are removed and replaced 
by DNA however any RNA primer at the 5' end of the new daughter strands cannot be 
replaced as there are no hydroxyl groups to attach the DNA to.
[80]
   
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.34.  Process of telomere shortening during replication. a. Growing strand elongated in 5' 
to 3' direction in both strands; RNA primer required to start strand as it provides a 3'-OH group. 
Leading strand forms quicker than lagging strand as DNA polymerase works in the same direction 
as the double helix is being unwound. b. New strand formation has to be done in pieces in lagging 
strand as DNA polymerase works in opposite direction; it begins with the creation of RNA 
primers, c. Short segments of DNA are synthesised between primers, d. The RNA primers are 
then removed, e. And replaced with DNA, f. Replication results in two new daughter strands 
shorter than the parent strands.  This is because DNA cannot be replicated at the 5' ends where the 
first RNA primer was added as there is no 3'-OH group to build from.  
1 
(b) 
3 
(d) 
(e) 
(f) 
(a) 
(c) 
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They are therefore essential for a normal healthy lifespan as they allow our genetic 
information to be repeatedly copied until the telomeres reach a critical length which then 
causes the cell to undergo apoptosis.
[81]
  
 
Human telomeric DNA is made up of a repeat base sequence, 5'-TTAGGG-3', which 
varies in length between 5 and 10 kilobases.
[81][82]
 The guanine rich nature of this segment 
of DNA means it is able to fold into the intramoleculary stable G-quadruplex structure and 
has been proven to do so under cellular conditions.
[83]
 The formation of G-quadruplexes is 
particularly useful in this area as it is believed that their formation inhibits the action of the 
enzyme telomerase which acts to extend the length of the telomere by adding on TTA-
GGG repeats to the ends of the DNA.
[84]
   
 
Telomerase is essential for the lifespan of frequently replicated cells such as white blood 
cells and embryonic stem cells.  However, in tumour cells it becomes over-expressed and 
indeed it is up regulated in 85-90% of cancers.
[84]
 This normally occurs when a mutated 
form of DNA has reached a critical length and instead of undergoing apoptosis telomerase 
is introduced and the system continues to replicate indefinitely (Fig 1.35).
[85] 
 
 
 
 
 
 
 
Figure 1.35.  Summary of telomerase presence and its consequence. 
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1.4.2  Oncogene Promoter Regions 
Other areas of DNA that possess G-quadruplex motifs can be found in oncogene promoter 
regions.
[23]
 This region of DNA can be found upstream of a gene (5' end) and is the control 
point for regulated transcription.
[86]
  Specific DNA sequences can be recognised by 
specific proteins leading to the activation of RNA polymerase and the creation of RNA 
from the coding part of the gene.
[86]
  
 
Mutated genes that have the potential to cause cancer are called oncogenes.  Their 
transformation leads to the abnormal regulation of cellular processes which can result in 
the loss of control of growth signals, the disruption of anti-growth signals, avoidance of 
apoptosis, continuous angiogenesis, unlimited replication abilities and metastasis.
[86]
 Stable 
G-quadruplexes are able to form in oncogene promoter regions and as a consequence they 
can be linked to the genes altered expression when associated with critical proteins (Fig 
1.36).
[86]
  
 
 
 
 
 
 
 
 
 
 
Figure 1.36.  a. The binding of proteins CNBP (zinc finger protein 9) and hnRNP K 
(heterogeneous nuclear ribonucleoprotein K) to a promoter region causing transcription to be 
turned on, b. When the G-quadruplex and also i-motif are able to form in the G-rich sequences 
the protein can no longer bind and transcription is turned off. [Reproduced from Ref 
87
] 
(a) 
(b) 
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The structural diversity of G-quadruplex structures due to differing loop lengths, loop 
bases and folding patterns in the different oncogene gene promoter regions, potentially 
allows selective targeting to be accomplished.
[88]
  Examples of specific oncogene promoter 
regions where G-quadruplex formation is beneficial to their regulation are shown in Table 
1.1.   
 
Promoter 
Region 
Effect of 
Transformation 
(Deregulation) 
Quadruplex Effect 
c-myc, c-kit 
and KRAS 
Loss of control of 
growth signals 
The formation and stabilisation of G-quadruplexes in 
these areas causes gene silencing, therefore 
preventing the activation of a specific process such as 
uncontrolled cell growth.
[86]
 
pRb 
Disruption of 
anti-growth 
signals 
If an oncogenic protein binds to this DNA region it 
can stop the tumour repressor protein from being 
transcribed which would normally prevent excessive 
cell growth.
[88]
  G-quadruplexes formed in this region 
help to prevent the binding of oncogenic proteins 
preventing insensitivity to tumour growth.
[88]
 
Bcl-2 
Avoidance of 
apoptosis 
Up regulation can play a role in the resistance of 
conventional cancer treatments and deregulation of 
cell death.
[89]
  G-quadruplex formation upstream of 
the P1 promoter can help prevent Bcl-2 
transcription.
[89]
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hTERT 
Uncontrolled 
replication 
Stabilization of G-quadruplexes formed in this area 
leads to the inhibition of gene expression.
[86]
  This 
directly inhibits telomerase expression instead of 
preventing actual telomerase binding to the 
telomeres.
[86]
  
PDGF-A Metastasis 
This gene plays and essential role in cellular growth, 
proliferation, diﬀerentiation and development which 
when over expressed causes tumour growth.
[90]
   
DNA G-quadruplexes formed in this region of the 
human gene promoter have also been found to inhibit 
transcriptional activity.
[90]
 
   
 
 
The formation of quadruplexes which turn on and off transcription factors can be better 
understood when considering the well studied oncogene c-myc.
[87]
 C-myc expression has 
been linked to several cancers including breast, cervix, colon, small cell lung cancers, 
glioblastomas, osteosarcomas and myeloid leukemias.
[87][91]
 As a proto-oncogene it has a 
crucial role in the regulation of cellular processes controlling cell growth, cell cycle 
progression and apoptosis.
[92]
  Strict regulation of c-myc transcription is essential for the 
role it plays in biological processes.
[92]
 Deregulation can occur when there are alterations in 
upstream promoter region signalling pathways which in turn leads to an increase in 
transcription.
[92]
   
 
Table 1.1 Examples of oncogene DNA regions where G-quadruplexes are able to form due to 
their guanine rich compositions and the transformations that occur due to deregulation of the 
oncogene.  
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The c-myc promoter region DNA is able to exist in alternate forms to the normal double 
helical B-DNA structure.
[93]
  The transition from B-DNA to single stranded DNA and other 
non-B-DNA forms such as G-quadruplexes and the i-motif can only occur when 
accompanied by localised unwinding or melting of the double helix.
[93]
  Negative 
supercoiling stress (under winding, Fig 1.37) facilitates this unwinding (melting) process 
which is naturally formed behind the RNA polymerase complex during gene transcription. 
[93][94]
  
 
 
 
 
 
 
 
 
 
The area of most interest in the c-myc promoter region is the nuclease hypersensitive 
element III1 region (NHE III1) as it is here where the G-quadruplexes have the ability to 
form.
[87]
  The slow equilibrium between duplex B-DNA, single stranded DNA and tetra 
stranded DNA is essential for controlling the binding of proteins in this area as up to 90% 
of c-myc transcription has been shown to be regulated by this part of the gene.
[87][93]
 
            
 
 
Figure 1.37.  The unwinding of supercoiled DNA demonstrated with a Del4 wild type 
plasmid with NHE III1 element showing the difference between the supercoiled and partially 
relaxed forms that occur during negative superhelical stress. [Reproduced from Ref 
93
] 
 
Chapter 1: Introduction 
 
38 
 
1.5  Proteins that Bind G-Quadruplexes 
 
In the oncogene cases put forward so far (in the Subchapter 1.4.2) the formation of the G-
quadruplex structure prevents the binding of proteins, which require a single stranded 
binding site, and in doing so are able to alter transcription.  There are however proteins that 
favour G-quadruplex binding over other types of DNA conformations.
[95]
   
 
Interactions with some proteins help to stabilise the G-quadruplex structure and are 
reported to play a role in transcription and the control of cellular cycles.
[95]
  RecA is one 
such repair protein that catalyses DNA strand exchange reactions between homologous 
double stranded DNA and single stranded DNA (homologous recombination).
[96]
  The 
RecA protein is able to bind to single stranded DNA forming a nucleoprotein and it is this 
ATP dependent process that maintains genomic stability in both prokaryotic and 
eukaryotic cells.
[96]
  More than 50% of the total genomic DNA is made up of repeat DNA 
sequences many of which form the majority of non-B DNA type structures.
[96]
  Research 
into RecA-DNA interactions has been primarily focused on single stranded DNA that is 
able to form duplexes; understanding the interactions that evolve between proteins and 
non-B DNA forming sequences could be more biologically important.
[96]
   
 
Further research has found that a labelled human telomeric sequence can preferentially 
bind to a RecA protein in the presence of K
+
 ions in its G-quadruplex state over its single 
stranded from (Fig. 1.38).
[96]
 The nucleoprotein structure formed between the RecA protein 
and the single stranded telomeric sequence (in the absence of K
+
 ions) will dissociate in the 
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presence of K
+
 ions with the single stranded sequence folding into its G-quadruplex 
structure before again forming a nucleoprotein structure with the RecA protein.
[96]
       
 
 
 
 
 
 
 
 
 
 
 
Another G-rich sequence of interest (5’-GGTTGGTGTGGTTGG-3’) that folds into an 
antiparallel G-quadruplex structure, TBA (thrombin binding aptamer), is of particular 
interest as it is known to bind specifically to the protein thrombin (a coagulation protease) 
inhibiting it (Fig. 1.39).
[97]
  Under molecular crowding conditions in a cell mimicking 
environment (reflects osmotic pressure which changes in live cells where altering water 
activity can affect biomolecule hydration); binding experiments were conducted to 
examine the thermodynamics of TBA-thrombin interaction.
[97]
 The investigation revealed 
that both the binding affinity of the TBA-thrombin interaction and the G-quadruplex 
stability decrease when conducted in molecular crowding conditions.
[95]
  This leads to the 
assumption that water is required for G-quadruplex-protein binding.
[95]
   
 
Figure 1.38.  Escherichia coli RecA protein and dye-labelled human telomeric sequence (Cy5-
5′- TAGGG-(TTAGGG)3-TT-3′-Cy3) binding preferences with and without the presence of K
+
 
ions. [Reproduced from Ref 
96
] 
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This type of binding system can be exploited in order to provide a sensor for thrombin at 
low detection limits.
[98]
  Hemin is an iron-containing porphyrin (Fig 1.40) which has been 
found to bind to TBA in an end stacking mode interacting through electrostatics and 
hydrophobic interactions, resulting in a complex with horseradish peroxidase type 
activity.
[98]
  The complex formed between the DNA and hemin is known as a DNAzyme 
and has been used for the detection of metal ions, small molecules, DNA and proteins.
[99]
  
 
 
 
 
 
 
 
The TBA-hemin system is particularly useful as it is able to catalyse the H2O2 mediated 
oxidation of potential fluorophores.
[99]
  In the presence of thrombin the activity of the 
TBA-hemin system is further increased giving rise to a strong fluorescent emission 
Figure 1.40.  Structure of hemin, chloro(protoporphyrinato)iron(III). 
[98]
 
Figure 1.39. Structure showing the interaction between G-quadruplex (TBA) and thrombin.  Binding 
occurs through two TT loops and one TGT loop of the quadruplex.  [Reproduced from Ref 
95
] 
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signal.
[99]
 Advantages of fluorescence detection include low reagent concentrations as the 
method is highly sensitive, simple experiment set up and quick result turnaround.
[99]
  This 
system therefore is very attractive in the generation of biological sensors.
[99]
 The potential 
fluorophore of interest is that of thiamine which is itself non-fluorescent however after 
oxidation with H2O2 it transforms to the strongly fluorescent compound thiochrome (Fig 
1.41).
[98][99]  
 
Using this method of fluorescence detection for thrombin, concentrations as low as 1 pM 
can be recorded creating a highly sensitive thrombin aptasensor.
[99]
  This type of 
interaction can also be exploited in nano device protein sensors.
[95][96]
  
  
 
 
1.6  G-Quadruplex Binders: Organic Compounds 
 
There are many ligands that have been reported to bind to G-quadruplexes; the appearance 
of which came after a selection of organic amido-anthraquinone derivatives were found to 
inhibit telomerase through quadruplex formation.
[100]
 The basic requirements for G-
Figure 1.41.  The production of fluorescent thiochrome through the hydrogen peroxide 
mediated oxidation step initiated by the formation of TBA-hemin complex and thrombin.  
This results in the fluorescent detection of thrombin. [Reproduced from Ref 
99
] 
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quadruplex binding include a planar heteroaromatic system which interacts by stacking 
with the G-quartets and terminal basic groups for favourable interactions with the DNA 
loop sugar phosphate backbone.
[20]
    
 
1.6.1  BRACO-19 
BRACO-19 is a 3,6,9-trisubstituted acridine compound (Fig 1.42) that interrupts 
telomerase function, hence showing promising tumour inhibition.
[101]
 When assessing its 
binding affinity to different types of DNA using surface plasmon resonance (SPR) studies 
it was found to bind to G-quadruplexes 40 times more strongly than duplexes.
[102] 
When 
exposed to human uterus carcinoma cells in a non cytotoxic concentration the telomeres 
were found to have shortened from 2.7 to 2.3 kb after 15 days.
[101]
 The same effect has 
been seen in breast cancer cells with a 17% decrease in telomere length after 39 days, 
reducing telomere length from 6 kb to 5 kb.
[101]
  The crystal structure of the complex with a 
telomeric sequence of DNA revealed a parallel topology with the complex end stacked 
between two quadruplexes (Fig 1.42).
[100]
 
 
 
 
 
Figure 1.42  a. Organic compound, BRACO-19, b. Crystal structure of two parallel 
G-quadruplexes with BRACO-19 stacked in-between. [Reproduced from Ref 
100
] 
(a) (b) 
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TTA loop conformations in these types of structures allow the formation of pockets in 
which the complexes side groups can reside.
[100]
  The crystal structure obtained for this 
system is also heavily hydrated thereby demonstrating how important water molecules are 
in the attraction between the two components.
[100]
  No direct electrostatic interactions can 
be formed between the positively charged ligand substituents and the negatively charged 
DNA backbone.
[100]
  Acridine ligands, in general, show anticancer activity because of their 
ability to interact with nucleic acids.
[101]
  This can be achieved by intercalation between 
DNA base pairs and dissociating the catalytic subunit of telomerase (hTERT) from its 
capping function or by stabilisation of quadruplex formation preventing telomerase 
action.
[101][103][104]
 BRACO-19 is in the latter category and due to its significant anticancer 
activity it is now being adapted to incorporate a monomethine cyanine dye which will 
enable the system to act as a pH-sensitive, fluorescent and colorimetric G-quadruplex 
binder.
[103]
   
 
1.6.2  TMPyP4 
Porphyrins have large aromatic surfaces and four meso positions that can be substituted to 
functionalise the complexes for specific binding making them ideal G-quadruplex 
binders.
[105]
 TMPyP4 is a tetra-N-methyl-pyridyl porphyrin (Fig. 1.43) that is able to bind 
to G-quadruplexes and consequently probe the quadruplex structure due to its high positive 
charge.
[100][105]
 
 
Investigations have primarily taken place with c-myc quadruplexes and they have been 
shown to repress c-myc transcription.
[106]
  The ligand-DNA interaction is believed to stem 
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from the N-methyl pyridyl rings of the ligand which are close (3.5 Å) to the terminal G-
quartet for effective stacking interactions.
[100]
  
 
 
 
 
 
 
 
 
A problem with this ligand arises because it isn't very selective for G-quadruplex DNA 
over duplex DNA.
[107]
  Alterations to the porphyrin complex design are being achieved by 
incorporating cationic substituent's at the meso positions and metal ions in the central 
cavity in order to provide better selectivity.
[107]
 
 
1.6.3  TQMP 
A porphyrin derivative which has been shown to bind to G-quadruplexes inhibiting 
telomerase is the phenol quaternary ammonium porphyrin, TQMP (5,10,15,20-tetra[4-
hydroxy-3-(tri-methylammonium)methyl-phenyl]porphyrin, Fig. 1.44).
[108]
  A SPR study 
has shown that it binds to G-quadruplexes 35 times more strongly than to DNA 
duplexes.
[108]
  The complex is believed to be a cross linking agent which could cross link 
G-quadruplexes that form in the telomeric region through an o-quinone methide 
intermediate when photoactivated.
[108]
  The enhanced selectivity of TQMP for 
quadruplexes over duplexes reported, when compared with TMPyP4, may be because it 
Figure 1.43  a. Cationic porphyrin TMPyP4, b. Structure of a parallel G-quadruplex binding to TmPyP4. 
[Reproduced from Ref 
100
] 
(a) (b) 
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has more flexible appendages and additional hydroxyl groups which can participate in 
further potentially stabilising hydrogen bonding.
[108]
      
 
 
 
 
 
 
 
 
1.6.4  Telomestatin 
Telomestatin is a natural product that has been isolated from the micro-organism 
Streptomyces anulatus 3533-SV4.
[109]
 Its structure consists of eight heterocyclic rings 
including a thiazoline, two methyloxazoles and ﬁve oxazoles all joined together in a 
macrocycle (Fig. 1.45).
[110]
  The naturally occurring compound is one of the tightest known 
binders to G-quadruplexes.
[66]
 It is able to bind to the basket structure of a G-quadruplex 
found in the telomeric region, TTAGGG repeats, of DNA.
[110]
  The anti-parallel 
quadruplex that it stabilises prevents the binding of telomerase to the ends of the DNA 
thereby preventing the extension of telomeres allowing the cell to eventually succumb to 
apoptosis.
[110]
   
 
 
 
 
Figure 1.45  Structure of Telomestatin. 
Figure 1.44  Structure of phenol quaternary ammonium porphyrin, TQMP. 
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The macrocycle is reported to have an EC50 (concentration for half maximum effect) of 0.9 
- 1.2 µM inducing the apoptosis of various cancer cells.
[66][109]  
An important advantage of 
this drug is its 70-fold selectivity for intramolecular G-quadruplex DNA structures over 
that of duplex DNA.
[111]
  This can be attributed to its circular shape and its ability to 
coordinate a monovalent cation such as K
+
.
[112]
 When telomestatin stacks on top of a G-
quartet the K
+
 cation is likely to reside between the two units.
[112]
 The molecule is also too 
large to intercalate in between the duplex base pairs.  Fig. 1.46 shows the results of the 
density functional theory calculations used to optimise the telomestatin - cation - G-quartet 
geometries.
[112]
           
   
 
 
 
 
 
 
 
 
1.7  Using Metal Complexes to Target G-Quadruplexes 
 
The incorporation of a metal into the structure of a potential G-quadruplex binder has a 
number of advantages which include: 
-  Providing a structural centre: The electronic configuration of the metal is able to dictate 
and organise the geometry of the ligands surrounding it, Pt
2+
 for example is a d
8
 metal and 
Figure 1.46  a. Overlaid structure of telomestatin (yellow) over a G-quartet (blue) with a potassium 
ion in the central cavity, b. The location of the potassium ion sits directly between the two layers 
(telomestatin and G-quartet) mimicking the position of the cation between two G-quartet layers. 
[Reproduced from Ref 
112
  both generated by DFT analysis using B3LYP and 6-31G(d,p)]. 
(a) (b) 
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therefore forms square planar structures.  Using the metal as a template allows for a 
relatively straight forward synthesis procedure which can generate a small collection of 
related complexes.
[112]
  Ligands can be modified whilst retaining the geometry around the 
metal centre or the metal can be changed giving rise to a change in geometry and/or new 
optical properties.
[113]
    
-  Increasing the strength of stacking interactions: The positively charged metal is able to 
withdraw electron density from the π system of which it is coordinated leading to stronger 
interactions between the electron poor system and the G-quartets.
[113]
  The metal is also 
able to electrostatically stabilise the system by imitating the potassium and sodium cations 
that usually sit in between the G-quartet layers of the G-quadruplex structure.
[113]
      
-   Provides cationic charge: This is very important for DNA binding due to the negatively 
charged DNA backbone. 
-   Allows direct interaction with nucleic acids: Through coordinate bonding.   
- Detection: Complexes can be examined using fluorescence, redox or UV-vis 
techniques.
[113]
  
 
1.7.1  Terpyridine Based Metal Complexes 
Terpyridine (2,2':6',2''-terpyridine, tpy) is a tridentate ligand which, because of its triple 
chelation binding mode and its planar surface, is used extensively in coordination 
chemistry (Fig 1.47).
[114]
 Metals such as Cu(II), Pt(II), Zn(II) and Ru(III) can easily be 
accommodated by the ligand allowing a whole host of different metal complexes (with 
differing geometries) to be synthesised with ease.
[114]
 Tolyl-terpyridine ligand (4-(4-
methylphenyl)-2,2':6',2''-terpyridine) is another terpyridine derivative which also has 
extensive co-ordination chemistry.
[114]
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The ability of terpyridine type metal complexes to act as G-quadruplexes binders has been 
reported by Teulade-Fichou et al.
[114]
  The [Cu-ttpy][(NO3)2] complex was found to be the 
most promising candidate as it showed a strong affinity and selectivity for quadruplex 
DNA over duplex DNA (22 times more selective by fluorescent indicator displacement 
(FID) analysis).
[114]
  This can be rationalised by considering its pseudo-square pyramidal 
structure (Fig 1.48).
[114]
 The complex is able to; utilise its planar aromatic face to stabilise 
the G-quadruplex through hydrophobic interactions, centralise the position of the Cu
2+
 ion 
to mimic the naturally occurring cations that stabilise the quadruplex structure, prevent 
intercalation with duplex DNA and induce electrostatic interactions as a result of the 
highly polarised metal-ligand bonds.
[114]
    
 
 
 
 
 
        
  
Figure1.47 a. Terpyridine structure (tpy), b. Tolyl-Terpyridine structure (ttpy).
[114]
 
Figure 1.48  Square pyramidal copper(II) terpyridine structure.
[114]
 
(a) (b) 
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The effect of palladium based terpyridine complexes to stabilise G-quadruplexes have been 
investigated as a comparison to platinum.
[115]
 Platinum(II) and palladium(II) are both soft 
Lewis acids, have square planar geometries and show similar trends when binding to 
nitrogen containing chelates.
[115]
  Their difference arises from ligand exchange kinetics 
where the rate of hydrolysis, for instance, is much faster for palladium than it is for 
platinum (105 times faster).
[115]
 The kinetic instability of palladium-DNA complexes has 
prohibited the use of palladium in DNA binding drugs.
[115]
 The ability however to change 
the properties of the metal through the type of heterocylic ligands bound to it has seen an 
increase in the number of palladium complexes being synthesised for DNA targeting.
[115]
  
Both [Pd(ttpy)] and [Pd(tMebip)] (ttpy = tolyl-terpyridine, tMebip = 2,2’-(4-p-
tolylpyridine-2,6-diyl)-bis-(1-methyl-1H-benzo[d]imidazole)) complexes (Fig 1.49) have 
been found to bind more quickly to G-quadruplexes (in  less than 1 hour) and display better 
inhibition of cancer cell growth than their platinum analogues.
[115]
  They are believed to 
bind coordinatively to the base thymine (through N3) in the quadruplex loops of the DNA 
sequence (TGGGGT)4 after hydrolysis, rather than in an end stacking mode to the terminal 
G-quartet.
[115] 
 
 
 
 
Figure 1.49  Structures of a. [Pd(ttpy)Cl]
+
, b. [Pd(tMebip)]
+
, c. Molecular model showing the Pd-tMebip 
complex and its proposed interaction with the quadruplex sequence (TGGGGT)4 through thymine. 
[115]
 
(a) (b) (c) 
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There are also other substituted terpyridine ligands which have incorporated cyclic amine 
side chains in order to provide extra interactions with the DNA (Fig 1.50).
[113]
 The 
protonated amines can interact with the loops and grooves of the DNA whilst providing 
increased water solubility for the aromatic complex.
[113]
 Increasing the bulkiness of the 
complexes through addition of the side groups can also enhance the selectivity for 
quadruplex DNA over duplex DNA.
[113]
      
 
 
 
 
 
 
 
 
Di-metal terpyridine complexes (with Cu
2+
, Pt
2+
 and Zn
2+
) have been explored by Vilar et 
al (Fig. 1.51).
[20]
  They are designed to interact with the G-quartet through the stacking of 
the terpyridine analogues and also the DNA phosphate backbone through the interaction of 
the metal dipicolylamine moiety by electrostatics or direct coordination (depending on the 
metal).
[20]
  Binding experiments were conducted with the ligands alone as well as with 
those that were in complexes with the metals.
[20]
 While the di-copper and di-platinum 
complexes (Fig 1.51) were able to form strong interactions with the quadruplex DNA with 
binding constants as high as 10
6
 M
-1
 and 100 fold selectivity over duplex DNA, the ligands 
alone were not able to display comparable activity.
[20]
 This led to the conclusion that 
Figure 1.50  Platinum(II) terpyridine functionalised with amine containing ligands that 
were found to bind well to quadruplex DNA.
[113]
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metals are essential for the binding affinities seen between the aromatic polydentate 
ligands and the quadruplex DNA.
[20]
   
 
 
 
 
 
 
 
 
 
 
1.7.2  Phenanthroline Containing Metal Complexes 
Phenanthroline is another aromatic ligand that can provide a metal complex with the 
required efficient hydrophobic interactions in order to bind well to G-quadruplexes.
[116]
  
The ligand can be easily modified to create protonatable side groups which allow further 
interactions with DNA loops and grooves.
[116]
  Phenanthroline derivatives have also 
attracted attention because of their pharmacological effects in many drugs.
[116]
  The 
following two phenanthroline examples show a degree of quadruplex DNA binding.      
 
a. [Pt(phen)2][PF6]2 has been examined for its binding affinity towards a human telomeric 
DNA sequence and despite its simple design (Fig 1.52) it was able to show effective 
binding through stacking to the end face of the G-tetrad.
[117]
 It was even found to change 
the quadruplex conformation from parallel to antiparallel by being able to stabilise one 
Figure 1.51  Structures of a. Di-metallic copper(II)  complex, b. Di-metallic platinum(II) 
complex.
[20]
 
(a) (b) 
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form over another due to the position of the loops.
[117]
 The reason for its success is partially 
ascribed to its close size match to a G-quartet itself being 10.4 Å (length) which is very 
close to that of a G quartet at 10.8 Å.
[117]
 
 
b. Neidle and co-workers have developed a square planar phenanthroline based platinum 
complex that shows a high degree of G-quadruplex stabilisation and telomerase inhibition 
with a 40 fold selectivity for quadruplex DNA over duplex DNA.
[118]
  The phenanthroline 
system is modified with a cyclic amine or pyridine side arm that can interact with the loops 
of the quadruplex achieving efficient binding while the phenanthroline moiety stacks on 
top of the G-tetrad.
[118]
  The metal plays an essential part in electrostatics and mimicking 
the naturally present cations (Fig. 1.52).
[118]
      
  
 
 
 
 
 
 
 
1.7.3   Platinum Phenanthroimidazole Complexes 
Sleiman and co-workers have synthesised a platinum complex with an extended 
phenanthroimidazole ligand that increases the stacking surface area (Fig. 1.53).
[119]
  
Binding studies were conducted with both intermolecular G-quadruplex forming DNA 
(d(T4G4T4)4) and duplex DNA where the binding constant calculated for the quadruplex 
Figure 1.52  Structures of a. [Pt(Phen)2]
2+ [117]
, b. Pt
2+
 mono-substituted phenanthroline.
[118]
 
(a) (b) 
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DNA was found to be about two orders of magnitude larger than to duplex DNA, 10
7
 
versus 10
5
 M
-1
 (binding constant established from UV-vis spectroscopy).
[119]
  The high 
binding affinity for the complex to the G-quadruplex was likely to have arisen due to the 
size of the surface area of the phenanthroimidazole complex.
[119]
  Using molecular 
modelling the complex was shown to form many favourable stacking interactions with the 
bases of the terminal G-quartet along with additional stabilising hydrogen bonds between 
the ethylenediamine ligands and the sugar phosphate backbone (Fig. 1.53).
[119]
       
 
 
 
 
 
 
 
 
 
 
1.7.4  Salphen Based Metal Complexes 
Vilar and co-workers have reported the binding of nickel(II) and copper(II) salphen metal 
complexes to human telomeric DNA.
[120]
 The X-ray crystal structures of these systems 
show the metal complexes binding to the quadruplex DNA through an end stacking mode 
with the metal ion located almost in line with the other potassium ions in the central cavity 
(Fig. 1.54).
[120]
  Both complexes show antiproliferative effects in a selection of cancer cell 
lines and telomerase inhibition in a modified telomere repeat amplification protocol 
Figure 1.53  a. Structure of naphthylphenanthroimidazole ethylenediamine platinum(II), b. 
Molecular modelling prediction of complex-intermolecular quadruplex binding  showing the 
end G-quartet (brown), thymine bases (green) and the platinum complex (grey). [Reproduced 
from Ref 
119
] 
(a) (b) 
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(TRAP-LIG) assay (see page 61).
[120]
 Despite their similar structures the nickel complex 
shows better quadruplex binding than the copper analogue which can be rationalised when 
considering their X-ray crystal structures.
[120]
 The nickel(II) and copper(II) complexes both 
have butterfly (bent) like conformations and when they are bound to the quadruplex this 
bent formation is significantly reduced (Fig. 1.54).
[120]
  Despite this reduction the 
copper(II) complex displays a significant degree of bent character therefore cannot stack 
on top of the G-quartet as efficiently as the flatter nickel(II) complex; leading to the 
difference in binding abilities.
[120] 
 The nickel(II) complex is especially promising as it 
shows around a 1400 fold selectivity for telomeric quadruplex DNA over duplex DNA 
when examining their binding constants by UV-Vis spectroscopy.
[120]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.54  a. Structure of the Ni(II) salphen complex binding to a G-quartet, showing the near 
overlap of the central cavity potassium ion and the Ni(II) ion [Reproduced from Ref 
120
], b. 
Structure of Ni(II) salphen complex, c. Difference in planarity between nickel and copper 
complexes. [Reproduced from Ref 
120
] 
(a) (b) 
(c) 
copper ligand 
nickel ligand 
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1.7.5  Platinum Supramolecular squares 
Supramolecular squares are an attractive molecular design for targeting G-quadruplexes as 
they can be constructed by supramolecular self assembly which is appealing as complexes 
can be created in a single step, often in good yields also.
[121]
  The platinum supramolecular 
square shown in Fig 1.55 is an efficient G-quadruplex binder and telomerase inhibitor.
[121]
 
The reason for which is because of the high positive charge of the complex (8+), the 
arrangement of the four bipyridyl ligands and the hydrogen bonding interactions between 
the phosphates of the DNA backbone and the ethylenediamine ligands.
[121]
 The aromatic 
rings of each of the 4,4-bipyridyl ligands add to the overall binding affinity by being able 
to interact with the guanine bases in a distorted T-shape geometry.
[121]
          
 
 
 
 
 
 
 
 
 
 
1.7.6  Nickel Supramolecular Helicate 
The nickel supramolecular helicate (Fig. 1.56) is based on the design of the metallo 
supramolecular helicates synthesised by Hannon et al with the formula [M2L3]
4+
.
[11]
 Work 
conducted by Qu et al suggests that the P enantiomer of the nickel supramolecular helicate 
Figure 1.55  Structure of the supramolecular platinum square.
[121]
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is able to selectively stabilise quadruplexes formed in the telomeric region of DNA.
[122]
  
The complex was found to be 20 times more selective for G-quadruplexes over duplexes 
using UV melting experiments in a sodium rich buffer.
[122]
  Qu reports that the helicate has 
a hydrophobic surface which is similar in size to the G-quartet.
[122]
  The complex is able to 
bind by externally stacking to the end of the G-quadruplex by interacting with the two 
lateral loops.
[122]
  Circular dichroism studies on the complex have shown that it is able to 
convert an antiparallel quadruplex conformer into a hybrid conformer when conducted in a 
Na
+
 rich buffer.
[122] 
         
 
  
 
 
 
 
 
 
 
1.7.7  Substituted Salicylaldehyde Dibenzyl Semicarbazones 
Copper(II) salicylaldehyde semicarbazone complexes have recently been investigated for 
their use as G-quadruplex binders after they were found to be very cytotoxic against a 
number of cancer cell lines.
[123]
  In human leukaemia cells the complex is able to induce 
apoptosis and cause the down regulation of proteins that are used in processes such as 
translation, protein folding and transcription.
[123]
  The binding strength of the complex, 
shown in Fig. 1.57, to telomeric quadruplex DNA is more than 200 times stronger than to 
Figure 1.56  a. Structure of the nickel supramolecular helicate, b. 
crystal structure of the nickel helicate. [Reproduced from Ref 
122
] 
(a) 
(b) 
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duplex DNA.
[123]
  The binding constant obtained between the complex to the quadruplex 
DNA (10
5
 M
-1
) can be attributed to the positive charge it carries which leads to favourable 
electrostatic interactions between itself and the electron rich guanine bases.
[123]
  The square 
planar structure of the complex with its π surface area allows it to stack onto the end of a 
G-quartet.
[123]
  Circular dichroism studies found that the complex doesn't alter the structure 
of telomeric quadruplexes in the presence of K
+
 or help template their formation in cation 
free buffer.
[123]
  They are however able to recognise and bind to pre-formed quadruplexes 
which may affect the stability of the quadruplex.
[123]
  The complex is also selective for one 
type of quadruplex over another as it is 22 times more selective for telomeric quadruplexes 
over c-myc quadruplexes.
[123]
   
 
 
 
 
 
 
1.7.8  Pentacationic Manganese(III) Porphyrin 
A manganese(II) porphyrin (Fig. 1.58) has been synthesised that encompasses an aromatic 
centre and four cationic side arms, both favourable attributes for an effective G-quadruplex 
binder.
[29]
  The complex does in fact bind very well to quadruplexes and shows a 
selectivity for telomeric quadruplex DNA over duplex DNA by 4 orders of magnitude 
when measured by SPR (10
8
 versus 10
4
 M
-1
).
[29]
  The poor binding affinity of the complex 
to duplex DNA may be due to the size of the bulky cationic arms with prevents the two 
species from being very close in space.
[29]
  On the other hand the strong binding affinity of 
Figure 1.57  Structure of a copper(II) salicylaldehyde semicarbazone complex. 
 
Chapter 1: Introduction 
 
58 
 
the complex for quadruplex DNA is likely to have arisen from the stacking of the aromatic 
core over the end G-quartet and interactions between the cationic arms and the loops of the 
quadruplex DNA.
[29]
        
 
 
 
 
 
 
 
 
 
 
1.8  Experimental Monitoring of Quadruplex formation 
 
There are a multitude of techniques to study the formation of quadruplexes, a few of 
which, and the thesis sections they can be found in, are shown in Table 1.2 below:   
CD spectroscopy 
Specific CD spectra related to the 
topology of the quadruplex. Able to 
differentiate between parallel and 
antiparallel G-quadruplex structures. 
 
Chapter 3.2 
Figure 1.58  Structure of a pentacationic manganese(III) porphyrin. 
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Fluorescent intercalator 
displacement (FID) assay  
Thiazole orange binds to DNA and is 
displaced if the complex binding 
affinity for DNA is higher.  Specificity 
of drug for one type of DNA over 
another can be analysed. 
Chapter 3.4      
UV-Vis binding studies 
Shifts in MLCT bands during titrations 
indicate binding of DNA to complex.  
Possible to calculate binding constants 
from UV-vis titration data.  
Chapter 3.5 
Proton NMR 
Imino protons of quadruplex DNA can 
be examined and compared with and 
without the presence of the complex.  
Changes in symmetry of DNA or 
complex protons can indicate binding.  
Chapter 3.6 
FRET melting assay 
Labelled DNA strands that have the 
potential to fold into G-quadruplex 
structures can be analysed.  FRET only 
occurs when the ends of DNA are 
close in space, allows stability to be 
assessed.  
Chapter 3.8 
 
 
Table 1.2  Techniques used to study G-quadruplex formation and topology and the chapter of 
this thesis they are explained in detail. 
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Paving the way for the experimental monitoring of G-quadruplex structures in biological 
systems is Shankar Balasubramanian who after conducting a genome-wide study showed 
pyridostatin (Fig. 1.59), a quadruplex stabilising small molecule, was able to induce DNA  
damage in areas of the genome rich in G-quadruplex motifs.
[83]
  The DNA damage may be 
caused by pyridostatin binding to quadruplexes during transcription and replication, 
preventing the corresponding gene expression.
[124]
  This can eventually lead to DNA 
breakage brought about the activation of a DNA damage response.
[24] 
  
 
 
 
 
 
 
 
 
Further research conducted by Balasubramanian et al features a structure-specific antibody 
which is able to quantitatively visualise G-quadruplexes in human cells.
[83]
 The technique 
is particularly useful as it employs the single chain antibody clone (BG4), selected from 
over 10
10
 other antibodies due to its high affinity for G-quadruplexes.
[83]
  It is then treated 
with another antibody to amplify the fluorescence signal before adding a tertiary 
fluorochrome labelled antibody.
[83]
 Following the treatment of isolated chromosomes with 
the BG4 antibody it was found that the antibody localised at the chromosomal ends as well 
Figure 1.59  Structure of the pyridostatin. 
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as other locations within the DNA (oncogene promoter regions are a likely source).
[83]
  
(Fig 1.60) 
 
 
 
 
 
 
 
Other techniques which help probe G-quadruplex and potential binder interactions include 
TRAP and scratch wound healing assays.
[124][125]
  In the TRAP (telomere repeat 
amplification protocol) assay the ability of the quadruplex binder to inhibit telomerase in 
vitro is determined.
[125]
 A non-telomeric sequence of DNA is able to be extended by 
telomerase with telomeric repeats and then amplified by PCR producing a ladder of results 
depending on the length of telomere produced by the telomerase.
[126]
  If a complex induces 
or stabilises a G-quadruplex structure the telomerase is inhibited therefore the PCR results 
would show a reduction in telomere length with the introduction of the complex.
[126]
  The 
example TRAP assay results shown in Fig 1.61 have been produced by two ruthenium 
complexes  [Ru(bpy)2(ptpn)]
2+
 (complex 1) and [Ru(phen)2(ptpn)]
2+
 (complex 2) (also in 
Fig 1.61) where addition of higher concentrations of the complexes reduced the amount of 
telomere bands seen at higher base pair (bp) numbers.
[126]
      
Figure 1.60  Two metaphase chromosomes isolated from cervical cancer cells.  
Immunofluorescence of the BG4 antibody (seen in red) occurs both in telomeric and non-
telomeric regions of DNA. [Reproduced from Ref 
83
] 
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Scratch assays have been used to show how the mobility of cells are hindered by the 
addition of a DNA binding complex.
[127]
  In the assay cells are grown on a surface in a 
single monolayer before making a wound (scratch) on the monolayer.
[127]
  Pictures are then 
taken at regular intervals to capture the migration of cells around the wound, in principle 
mimicking cell migration during wound healing in vivo.
[127]
 
 
The proto-oncogene SRC produces a non-receptor protein that phosphorylates specific 
tyrosine residues in other proteins playing an essential role in cell motility and 
invasion.
[124]
  As with other oncogenes the protein can be over expressed leading to 
cancer.
[124]
 The promoter region of the SRC gene is a G-quadruplex rich area where the 
ability of pyridostatin (which is a selective G-quadruplex binder) was investigated to see if 
Figure 1.61  The results of a telomerase inhibition assay where the effect of the complexes on 
telomere length in the presence of telomerase was compared with telomerase + DNA (+ Control) 
and the DNA alone (- Control).  IC is the internal control primer (left) [Reproduced from Ref 
125
], 
Ruthenium complexes used in this study (right).  
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it would have an effect on the mobility of a breast cancer cell line by inhibiting the 
production of the SRC protein.
[124]
 The scratch assay results showed that after creating a 
wound across the cell plate the cells were unable to migrate back into it (Fig 1.62).
[124]
 This 
was a good indication that the mobility was being inhibited due to the binding of the 
pyridostatin and preventing the activation of the SRC gene; although not the sole 
explanation as the disruption of other cellular processes cannot be disregarded.
[124]
  The 
same experiments with another DNA binder, doxorubicin, were unable to show the same 
results as the cells were able to migrate back into the wound despite both complexes being 
able to induce similar cell damage in cell proliferation tests.
[124]
  Doxorubicin, therefore 
does not appear to target the SRC gene which infers that it is not able to bind as 
successfully to quadruplexes as pyridostatin.
[124]
   
 
 
 
 
 
 
 
 
 
 
Figure 1.62  Scratch assay conducted with the breast cancer cell line MDA-MB-231. a. 
Untreated wound at the start of the assay, b. Untreated wound after 48 h shows the 
migration of cells back into the wound, c. Treatment with pyridostatin (2 μM) shows 
very little migration back into the wound, d. Treatment with doxorubicin (100 nM) still 
sees the migration of cells back into the wound area. [Reproduced from Ref 
124
] 
(a) Untreated (0 h) (b) Untreated (48 h) 
(c) Pyridostatin (48 h) (d) Doxorubicin (48 h) (d) Doxorubicin (48 h) 
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1.9  Summary and Thesis Aims 
 
The function and binding capabilities of selected DNA structures have been reviewed in 
order to better understand the design of complexes to target them.  Structures of interest 
presented in the literature include the DNA three way junction and DNA bulges.  A three 
way junction has a hydrophobic cavity at its centre that a supramolecular iron cylinder is 
able to selectively bind to as it is the perfect size match for the cavity.
[3]
  DNA bulges, 
created by DNA mismatches, can be targeted by large intercalating aromatic systems (such 
as Bartons [Rh(bpy)2chrysi]
3+
 complex) that are too bulky to interact with DNA in its 
normal double helical structure.
[27] 
 
G-Quadruplexes may be very important DNA structures to target as they have been linked 
to processes which control transcription and replication.
[113]
  The complexes reviewed 
possess aromatic surfaces intended for the interaction with a G-quartet of a quadruplex 
which is also composed of an aromatic surface.  The nickel(II) salphen complex reported 
by Vilar et al has been found to bind to G-quadruplexes formed in the telomeric region 
selectively over duplex DNA (shows more than 1000 fold activity for quadruplex DNA 
over duplex DNA).
[120]
  The selectivity of the salphen complex and other complexes 
reported, such as the series of terpyridine complexes investigated by Teulade-Fichou et al, 
may be due to a combination of factors.
[114][120]
  These include; good overlap of π surfaces, 
cationic charge imparted by the incorporation of a metal such as platinum, square planar 
arrangement and additional side arms containing protonatable nitrogen containing groups 
which can potentially interact with the loops of the quadruplex.  Interestingly the nickel(II) 
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salphen complex had a bent rather than fully planar surface which may reflect the actual 
surface planarity of a G-quartet which may also be slightly distorted from planarity.
[120]
     
 
The work of this thesis focuses on the targeting of G-quadruplexes where a simple binder 
has been designed that has the potential to bind specifically to G-quadruplex forming 
DNA.  The design incorporates biisoquinoline which is able to create a large planar π 
surface area when coupled with metals such as platinum and palladium (which impart 
cationic charge) to create a complex that is able to bind by stacking onto the terminal G-
quartet of a G-quadruplex structure.  It is hoped that by attempting to synthesise a complex 
that has an excellent size and shape match for a G-quartet, enhanced selectivity will be 
obtained.  The interactions of the complex with both duplex and quadruplex forming DNA 
will be investigated using; circular dichroism where conformation changes of the 
quadruplex can be monitored and the presence of induced signals linked to binding modes, 
fluorescent indicator displacements to determine selectivity using thiazole orange, UV-vis 
spectroscopy to determine binding constants, NMR spectroscopy to monitor changes in the 
quadruplex spectrum as complex is added, FRET melting experiments to monitor whether 
complex binding is able to increase the stability of the complex and gel electrophoresis 
which can help determine the selectivity when all relevant types of DNA are present.  The 
ability of the binder to interact with RNA quadruplexes will also be investigated along with 
cytotoxic assays on selected cancer cell lines.    
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Chapter 2: Design, Synthesis and Characterisation of 3,3-Biisoquinoline 
Metal Complexes 
2.1  Introduction 
 
The majority of research into G-quadruplex binders involves the synthesis of organic 
compounds such as porphyrins and acridine based structures.  Despite showing good G4 
binding abilities their synthesis is often not simple and they don't all show very good 
selectivity.[1] Introducing metals into complexes used to target G-quadruplexes can help 
improve binding in many ways as it helps strengthen electrostatic interactions, mimics 
cations already present in the quadruplex structure and enables the relatively easy synthesis 
of multiple complexes where the metal imparts structural deviations between each 
complex.  Terpyridine, salphen and phenanthroline metal complexes show a good affinity 
for G-quadruplexes however are not designed to maximise G-quartet coverage therefore 
stacking opportunities are missed.[1][2][3] As discussed with the three way junction binder, 
the iron supramolecular helicate, an excellent size match is essential for efficient binding 
between a complex and a specific DNA structure.  It is therefore pertinent to explore 
whether a G-quadruplex binder that can be created with an excellent size match for end 
stacking will have the most efficient binding affinity.  
 
This chapter focuses on the methodology explored whilst finding a suitable ligand to use in 
metal complexes which undergo efficient G-quadruplex binding.  The synthesis of 
biisoquinoline, the ligand of choice, and the biisoquinoline complexes of the platinum, 
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palladium, rhenium and rhodium analogues will be discussed explaining the design and 
methodology behind each complex.        
 
 
2.2 Molecular Design of G-Quadruplex End Stacking Biisoquinoline 
Complexes 
 
The isoquinoline structure is found in many medicinal products.[4] An example of this is 
berberine which is a natural alkaloid and is able to bind to telomeric parallel quadruplexes 
in a 2:1 fashion (Fig. 2.1).[4]  When examined by FRET melting experiments with 
quadruplex forming DNA, berberine derivatives were found to increase the melting 
temperature of the DNA by up to 25 °C with binding constants calculated at 106 M-1.[5]  
When the same FRET melting experiments were repeated with excess duplex present in 
the solution (50 times more duplex than quadruplex DNA) the melting temperature was 
similar to the quadruplex DNA only solution.  This indicates that the compound prefers to 
bind to G-quadruplex forming DNA over duplex DNA.  This is because if the compound 
that was bound to the quadruplex favoured binding to the duplex DNA instead the melting 
temperature would decrease as the quadruplex is no longer stabilised by compound.[5]  
 
Berberine and its interaction with G-quadruplexes has been investigated by X-ray 
crystallography where it was found to stack side by side onto a G-quartet at the 3'-end and 
5'-end of the quadruplex (Fig. 2.1).[4] Interestingly at the 3'-end of the intramolecular 
quadruplex the G-quartet is bent with an angle of 13.9° with the two sets of guanine pairs 
arranged in a coplanar way (slightly funnel shaped).[4]  The two berberine compounds 
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which bind to the 3'-end are also bent having an angle of 19.7° in order to efficiently stack 
onto the also bent G-tetrad.[4]   
 
 
 
 
 
 
   
 
 
 
When isoquinoline is coupled with itself to form biisoquinoline and then complexed with 
platinum it creates a square planar complex that has the potential to be an excellent size 
match for a G-quartet (Fig. 2.2).[6]  The complex also benefits from a large aromatic 
surface for efficient stacking and a metal cation to enhance electrostatic interactions, hence 
the investigation of this complex and its derivatives.     
 
 
 
 
 
 
Figure 2.1  a. Structure of berberine , b. Crystal structure of the Ber/h-Tel23  adduct 
showing the binding of two berberine molecules to both the 3'-end and 5'-end of a G-
quadruplex. [Reproduced from Ref 4] 
10.8 Å 
10.8 Å 
Figure 2.2  a. Structure and size of [Pt(ibiq)]2+, b. Structure and size of G-quartet.[6][7] 
(a) 
(a) (b) 
(b) 
13.5 Å 
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2.2.1  Isoquinoline Building-Blocks 
The isoquinoline building-block (3-chloroisoquinoline), required to make biisoquinoline, 
can be synthesised in three steps starting from the readily available and inexpensive 
homophthalic acid (Scheme 2.1).[8]    
 
 
 
 
Step a: The first step of the reaction involves the formation of an ammonium carboxylate 
salt.  Carboxylic acids do not undergo the same nucleophilic substitution reactions that 
occur with acid chlorides and esters (unless a dehydrating agent is used such as 
dicyclohexylcarbodimide - DCC).[9]  Instead the strong base, NH4OH , will undergo an 
acid-base reaction with the carboxylic acid (Scheme 2.2).[9]  In the second step the 
intermediate is converted to an amide, when heated to 200 °C, by dehydration (Scheme 
2.2).[9]  The amide generated can then react in the same way (however this time 
intramoleculary) with the other carboxylic acid moiety.   
 
 
 
 
 
Scheme 2.1  Synthesis of 3-chloroisoquinoline under the following conditions: a NH4OH, 1,2-
dichlorobenzene, 200ºC; b PhP(O)Cl2, 160ºC; c Sn0, HOAc/HCl, 60ºC. 
 
Scheme 2.2  Two step formation of amide between carboxylic acid and ammonia. (1) acid-base 
reaction, (2) dehydration of intermediate.     
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Step b: This is followed by a chlorodehydroxylation step with phenylphosphonic 
dichloride.  The chloride ions are able to partake in nucleophilic addition reactions 
involving the carbonyl groups (Scheme 2.3).  The hydrolysis products from the reaction 
include phenylphosphonic acid and its salts which are water soluble therefore easy to 
isolate from the chlorodehydroxylation product.[10]  
 
 
 
 
Step c: The third step from Scheme 2.1 involves the removal of the 1-chloro substituent 
using tin powder in a reaction mixture with hydrochloric acid.   The tin is able to 
regioselectively reduce 1,3-dichloroisoquinoline which can be rationalised when 
considering the aromaticity of the compound when the charge is delocalised.[11]  Structure 
a in Fig. 2.3 is important because this is the only delocalised form that doesn’t disrupt the 
Scheme 2.3  Reaction scheme showing the mechanism of chlorodehydroxylation using 
phenylphosphonic dichloride.     
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aromaticity of the benzene ring.[11]  This leaves C1 as the most electron deficient therefore 
the position of attack for nucleophiles.  C3 is also a possibility for nucleophilic attack but 
to achieve this charged state aromaticity of the benzene ring has to be interrupted (structure 
b).  
 
 
 
 
 
 
 
2.2.2  Metal Catalysed Homocoupling   
The 3-chloroisoquinoline building-block can then be used in a homocoupling reaction 
which sees the evolution of 3,3-biisoquinoline.  There are a plethora of methods available 
in the literature that can be used for such coupling reactions.  Three different metals are 
described and how they are used to catalyse the homocoupling of aryl halides.  
 
Copper  
Ullmann-type coupling is a copper catalysed condensation reaction which enables the 
formation of important carbon-carbon or carbon-heteroatom bonds in organic synthesis.[12] 
Despite its past success in generating synthetic targets, its use is restricted due to the harsh 
reaction conditions required to conduct the condensation reactions; often needing polar 
solvents with high boiling points such as dimethylformamide or nitrobenzene (230°C).[12] 
(b) 
(a) 
Figure 2.3 Charged structures of isoquinoline rationalising likely places of nucleophilic 
attack. 
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The reaction is also less favourable because it requires stoichiometric amounts of copper 
reagents, has only a limited range of substrates and is low yielding.[12] 
  
The proposed reaction scheme for the Ullmann reaction would involve the oxidative 
addition of 3-chloroisoquinoline to the copper and the removal of the coupled product by 
reductive elimination, shown below in Scheme 2.4.[13]         
 
  
 
 
 
 
 
 
 
Palladium 
Palladium can also potentially be used in the homocoupling of isoquinolines in Ullmann 
type reactions.[14]  One particular synthesis of interest in the literature describes the 
synthesis of homocoupled aryl halides using the palladium complex Pd(OAc)2 in the 
presence of homogenous reductant, hydroquinone.[14] The synthesis is attractive because it 
operates under relatively mild conditions (basic, 50°C) and can be used to successfully 
couple electron rich and electron deficient aromatic bromides and iodides.[14]  Chlorides 
couple less successfully and generally produce low yields (in some instances no reaction 
occurs).[14]    
Scheme 2.4 Proposed Ullmann reaction scheme for the formation of biaryls.[12][13]  
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The suggested mechanism for this catalytic cycle is shown in Fig. 2.4 where under basic 
conditions the Pd species is able to eliminate benzoquinone generating an anionic aryl 
palladium species.[14]  A halogenated aryl group (Ar-I) can then react with the palladium 
species with the loss of I- to produce the biarylpalladium species.[14]  Reductive elimination 
will then see the reformation of the Pd0L2 catalyst and the coupled biaryl product.
[14]        
 
    
 
 
 
 
 
 
 
 
 
Despite the success of palladium cross coupling reactions the palladium complexes 
required can be expensive.[15]  This is because they are required in equimolar quantities to 
the starting material in some reactions whilst in others, despite using a catalytic amount, 
the palladium cannot be used repeatedly.[15][16]       
 
Nickel 
Using a nickel catalysed reaction in the homocoupling of aryl halides is an attractive 
alternative as only mild conditions are required for it to proceed, other functional side 
Figure 2.4 Catalytic cycle of aryl homocoupling using palladium in an Ullmann type reaction with 
the addition of hydroquinone.[14]  
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groups such as ketones and aldehydes do not interfere in the coupling of the halides and 
nickel catalysts are relatively cheap and readily available when compared to their 
palladium analogues.[17] The reaction also produces the product in a relatively good yield 
and is dependent on the choice of nickel complex, solvents and additional reagents such as 
triphenyphosphine, iodide or bromide.[18]  
 
The preparation of the reactive nickel(0) reagent occurs in situ (Ni0 is air sensitive) from a 
mixture of nickel(II) hexahydrate, triphenylphosphine and zinc in DMF.[18] During this 
setup the reduction of NiII to Ni0 occurs through the activated zinc.[18]  The solution turns 
from blue/green to deep red/brown indicating the formation of the active reagent.[18]  At 
this point the aryl halide can be added which, as it forms the biaryl product, transforms the 
solution back to its initial NiII colour blue/green.[18] The bidentate ligand is then easily 
removed with a weak solution of ammonia.        
 
The proposed reaction scheme for the nickel catalysed reaction is shown in Scheme 2.5 
where the first step is the oxidative addition of the aryl halide to Ni(0).[19] This is followed 
by its metathesis to a diarylnickel(II) complex and corresponding nickel halide.[19]  In the 
third step reductive elimination produces the desired biaryl and the initial Ni(0) species.[19] 
 
 
 
 
 
Scheme 2.5 Proposed nickel mediated biaryl formation reaction.[19]  
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This type of synthesis has also been used in order to produce 2,2':6',2"6",2"'-
quarterpyridine (Fig. 2.5) which chelates strongly to the nickel therefore has to be 
precipitated out in its complex form before using potassium cyanide to remove the metal, 
liberating the ligand. [18][20]  
 
 
 
 
 
 
Nickel was chosen as the catalyst of choice for the homocoupling of 3-chloroisoquinoline 
because of its advantages in availability, feasibility and expense. The reaction scheme, 
Scheme 2.6, shows the formation of the homocoupled product, 3,3-biisoquinoline, using 
the nickel template.  
 
 
 
Following synthesis, 3,3-biisoquinoline will be complexed with platinum and then 
palladium in a square planar geometry to compare how each metal alters the complexes 
ability to interact with DNA.  The octahedral structure of a rhenium complex with one 
Figure 2.5  Structure of 2,2':6',2"6",2"'- quarterpyridine synthesised in a nickel homocoupling reaction. 
[19]  
Scheme 2.6  Synthesis of 3,3-biisoquinoline using a nickel based homocoupling reaction.  
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biiosoquinoline ligand will be also be synthesised in order to compare how geometry 
affects DNA binding and finally a rhodium analogue will be explored in order to explore 
how the lower charge of Rh(I) (also Re(I)) will effect DNA binding.  
 
2.3  3,3-Biisoquinoline Synthesis and Characterisation  
 
2.3.1  Isoquinoline-1,3-dione (1)   
Homophthalic acid was used as the starting material in the production of the required 
building block 3-chloroisoquinoline according to a literature procedure.[8][21] The first step 
in this synthesis was to convert the acid into isoquinoline-1,3-dione. (Scheme 2.7) 
Homophthalic acid was dissolved in excess ammonium hydroxide which was then 
removed in vacuo leaving the ammonium carboxylate salt. The salt was suspended in 1,2-
dichlorobenzene and heated to 200°C to allow the dehydration of the product to form the 
amide.  The product obtained was sufficiently pure to continue to the next stage of the 
reaction in an 88 % yield. 
 
 
 
 
 
 
Electron ionisation mass spectrometry data produced a molecular ion peak consistent with 
the product formation.  The 1H-NMR spectrum (Fig. 2.6) was assigned with the use of 2D 
COSY (see Appendix 1.1 for COSY, NOESY and mass spectrometry data).  In order to 
Scheme 2.7  Synthesis of isoquinoline 1,3-dione. 
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characterise fully the spectrum NOESY was also acquired to differentiate between protons 
H2 and H5 (as only H2 would exhibit the long range coupling with H1).   
 
 
2.3.2  1,3-Dichloroisoquinoline (2)   
The second stage of the building block synthesis involved the chlorodehydroxylation of 1 
(isoquinoline 1,3-dione) using phenylphosphonic dichloride carried out according to a 
literature procedure[8] (Scheme 2.8). Following this reaction, after a three hour reflux, the 
solution was treated with both THF and water.  The unwanted hydrolysis products are 
water soluble therefore were easily removed during the extraction process.  The extracted 
product was purified using column chromatography to give a final yield of 59 %.    
 
 
Figure 2.6  1H-NMR spectrum (300 MHz, d6-DMSO, 298 K) of isoquinoline 1,3-dione.  
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The molecular ion peak corresponding to [H + (C9H5Cl2N)]
+ was found when analysing 
the compound by electron ionisation mass spectrometry and elemental analysis confirms 
the composition.  The 1H-NMR spectrum was fully assigned (Fig. 2.7), with the help of 2D 
COSY spectra (Appendix 1.2), and shows the emergence of a fully aromatic system with 
all protons within the range 7.88 - 8.38 ppm and the disappearence of sp3 and NH protons.  
 
 
 
Scheme 2.8  Synthesis of 1,3-dichloroisoquinoline. 
Figure 2.7  1H-NMR spectrum (300 MHz, d6-DMSO, 298 K) of 1,3-dichloroisoquinoline.  
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2.3.2  3-Chloroisoquinoline (3) 
In the final transformation from 1,3-dichloroisoquinoline to 3-chloroisoquinoline (Scheme 
2.9), tin was used to selectively remove the chloride through nucleophilic attack at the 
chloride position nearest H5 (position most prone to nucleophilic attack due to resonance 
stabilisation - see 2.2.1).  At the end of the reaction the tin(II) chloride generated was 
neutralised using ammonium hydroxide causing the precipitation of SnO or SnO.H2O.
[22]      
 
Following the reaction and work up a waxy orange product was produced which was 
purified using column chromatography on silica before using in the coupling reaction.  The 
yield of compound 3 at the end of the reaction was 10 %.  The lack of product may have 
been due to its difficult isolation at the end of the reaction from the Sn precipitates.  When 
followed by TLC the full conversion of the dichloro compound to the monochloro was 
achieved before ending the experiment (Rf values in CH2Cl2, compound 2: 0.8, compound 
3: 0.5). 
 
 
 
 
 
 
Mass analysis using electron ionisation produced a molecular ion peak that corresponded 
with the product.  The 1H-NMR spectrum (Fig. 2.8) shows a new proton environment, 
formed from the selective removal a one chloride group, slightly further downfield to the 
other aromatic protons as it is adjacent to the more electronegative nitrogen.  Full 
Scheme 2.9  Synthesis of 3-chloroisoquinoline. 
 Chapter 2: Design, Synthesis and Characterisation of 3,3-Biisoquinoline Metal Complexes 
 
88 
 
identification of each of the proton peaks was achieved from the analysis of a 2D COSY 
spectrum. (Appendix 1.3)        
 
 
2.3.4  3,3-Biisoquinoline (ibiq) (4) 
The nickel homocoupling reaction described in Subchapter 2.2.2 was used to couple two 3-
chloroisoquinoline units together to create the required bidentate ligand to complex with 
the desired metal. (Scheme 2.10)   
 
Figure 2.8  1H-NMR spectrum (300 MHz, MeOD, 298 K) of 3-chloroisoquinoline. 
Scheme 2.10  Synthesis of 3,3-biisoquinoline. 
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Before starting the reaction the zinc acting as the reducing agent was activated by washing 
with dilute HCl, water, ethanol, acetone and diethyl ether before drying under vacuum.[23] 
Once thoroughly dry it was used to reduce the Ni(II) complex in situ, in a solution 
containing DMF and triphenylphosphine under argon, to Ni(0).    Only once the solution 
had turned from green to brick red could the 3-chloroisoquinoline be added to the reaction 
mixture to start the coupling process.  The reaction mixture was heated to 70°C for 4 hours 
and was kept air free for the duration.  After the 4 hours the reaction was allowed to cool 
before pouring into a 7% solution of ammonium hydroxide.  The aim of this was to 
dissociate any newly formed bidentate ligand from the nickel into solution to be extracted 
whilst substituting it with NH3 ligands.  The blue aqueous solution formed as a result of 
this nickel complex formation could be seen in the water layer after extraction had taken 
place.   
 
The biisoquinoline product isolated was heavily contaminated with the side product 
triphenylphosphine oxide (from triphenylphosphine oxidation) and excess DMF which 
were removed following extensive washing with water to remove the DMF and multiple 
column chromatography silica columns in diethyl ether to remove the triphenylphosphine 
oxide.  The yield from this reaction was 10% and despite it being very low the nickel 
reaction using NiCl2.6H2O was the only synthesis procedure that yielded the coupled 
product.  Biaryl synthesis using bis-triphenylphosphine palladium chloride and another 
using NiBr2(PPh3)2 yielded no product.
[19][24]  The main problem with the homocoupling 
reactions is the relative unreactivity of the heteroaryl chlorides when compared with their 
bromide and iodide counterparts.[25]  This is due to the aryl (Ar) C-Cl bond strength (Ar-Cl 
= 96 kcal mol-1, Ar-Br = 81 kcal mol-1 and Ar-I = 65 kcal mol-1), which makes it harder for 
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the chloride to bind to the nickel centre during the oxidative addition step.[25]  They are 
however the most attainable aryl halides as they are inexpensive and widely available.[25]    
 
The electron ionisation mass spectrometry analysis identified the molecular ion peak.  The 
1H-NMR spectrum shown in Fig. 2.9 in MeOD shows the new position of H1 further 
downfield after the coupling process when compared to its position in 3-chloroisoquinoline 
due to the larger area of aromaticity.  Both 2D COSY and NOESY were used to accurately 
assign all protons in the system (Appendix 1.4) thus confirming synthesis of the desired 
product.    
 
 
 
 
 
 
Fig 2.9  1H-NMR spectrum (300 MHz, MeOD, 298 K) of 3,3-biisoquinoline. 
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2.4  Synthesis and Characterisation of Palladium, Platinum, Rhenium and 
Rhodium Biisoquinoline Complexes 
 
2.4.1  [Pd(ibiq)2][BF4]2 (5) 
The starting material used for the palladium complex was tetrakis(acetonitrile)
palladium(II) tetrafluoroborate which was simply reacted with the newly formed 3,3-
biisoquinoline ligand in a 2:1 ratio by stirring overnight in acetonitrile (Scheme 2.11).  The 
product of the reaction was then washed with methanol and diethyl ether to remove the 
starting materials leaving pure [Pd(ibiq)2][BF4]2 in a 50% yield which was soluble in both 
acetonitrile and dimethyl sulfoxide.   
 
 
 
The mass spectrum produced using electrospray ionisation showed peaks at 653 and 309 
m/z corresponding to the species [Pd(C18H12N2)2Cl]
+ and [Pd(C18H12N2)2]
2+ respectively 
(Appendix 1.5).  1H-NMR spectroscopy showed the presence of the proton peaks seen in 
the 3,3-biisoquinoline spectrum (Fig. 2.10) and to confirm the synthesis of the compound 
Scheme 2.11  Synthesis of [Pd(ibiq)2][BF4]2. 
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complexed to the palladium both the ligand and palladium product were run in CD3CN to 
compare the positions of the proton peaks H1 and H6.         
 
        
 
 
There is a shift further downfield for the protons in the ligand bound to the palladium as 
the palladium withdraws electron density from the aromatic system.  This will increase the 
stacking ability of the complex for electron rich aromatic rings helping to form stronger 
interactions with other aromatic surfaces.   
 
The crystal structure of the palladium biisoquinoline complex was probed by single crystal 
X-ray diffraction (results provided by Dr Louise Male, University of Birmingham).  The 
results revealed a bowed structure similar to the literature structure seen for the platinum 
Figure 2.10  1H-NMR spectrum (300 MHz, CD3CN , 298 K) of [Pd(ibiq)2][BF4]2 and comparison 
with 3,3-biisoquinoline (ibiq) in the same solvent. 
ibiq  
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analogue of the complex (Fig. 2.11).[6]  The similarity of the two complexes implies that 
they will have similar stacking interactions with the DNA.  A slipped stack structure is 
formed by the palladium complex in the crystal with overlaid biisoquinoline units (Fig. 
2.12).  This has been reported for the platinum complex in the literature.[6]  
 
 
 
 
 
 
 
 
Examination of the selected bond lengths in Table 2.1 shows there is a slight difference in 
the N-Pd bond lengths from the nitrogen atoms in the same biisoquinoline unit (0.003 Å).  
This difference is greater than the platinum complex (0.001 Å) indicating that the 
palladium complex may be slightly more distorted from planarity.[6][26][27] To investigate 
any distortion from planarity further the angles between the two opposing isoquinolyl 
groups were considered.  For a truly planar surface this would be 0° however it is known 
that both systems are bowed therefore the extent of this angle will be linked with the 
degree of distortion.  The angle between the isoquinolyl groups in the platinum complex is 
Fig 2.11  a. The structure of Pd(ibiq)2 with ellipsoids drawn at the 50 % probability level. Benzene 
solvent has been omitted for clarity. The Pd complex is located on inversion centre such that only half 
the molecule is crystallographically unique. Symmetry transformation used to generate equivalent 
atoms: $1: 1-x, -y, 1-z. b. Side view showing the bowed conformation of the complex. 
(a) (b) 
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26° whereas in the palladium complex it is 24° (angles between planes, see page 99, Fig. 
2.16 for further images).[6] Despite this each isoquinolyl group within each ligand is almost 
planar for both complexes.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.2  [Pt(ibiq)Cl2] (6) 
The synthesis of [Pt(ibiq)Cl2] was similar to the synthesis of [Pt(bpy)Cl2] where one 
equivalent of bipyridine was heated under reflux in water with platinum 
tetrachloroplatinate and a small amount of HCl for 1.5 hours (Scheme 2.12).[28]  Achieving 
the same type of complex with biisoquinoline instead of bipyridine required the use of a 
50:50 mixture of water and acetonitrile as an alternative to 100% water to aid the 
Metal Pd-N1(ibiq) Pd-N2(ibiq) N1-Pd-N2 N1-Pd-N2' 
Pd 2.033(13) 2.036(14) 79.6(6) 100.4(6) 
Fig 2.12  Slipped stack structure of [Pd(ibiq)2]2+. 
Table 2.1 Selected bond lengths (Å) and bond angles (deg) from the crystal structure of [Pd(ibiq)2][BF4]2.  
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dissolution of the biisoquinoline ligand, as reported in the literature.[6]  Once the reaction 
starts the product is quickly formed as a yellow solid that starts to precipitate out of the 
solution.  The presence of HCl in the reaction is particularly important as a concentrated 
solution will favour the formation of the red version of the complex whereas when less is 
used the yellow version of the complex is synthesised.[28]  The complexes both exhibit the 
same chemical structure and differ only in the arrangement of molecules within the 
crystal.[28] The formation of the yellow form was optimised in the experiment as its 
production was more reliable than the red form which often reverted back to the yellow 
form in solvents such as chloroform and dichloromethane.[28]  It was also important not to 
leave the reaction for longer periods of time as it led to the formation of the doubly 
substituted platinum complex [Pt(ibiq)2]
2+.        
 
 
 
Once synthesised, the yellow filamentous needles were washed with chloroform, 
acetonitrile, methanol and diethyl ether producing the final product in a 26% yield.  
Disappointingly the complex was only sparingly soluble in dimethyl sulfoxide and 
insoluble in all other solvents which hindered its use in the binding experiments. 
 
 
Scheme 2.12  Synthesis of [Pt(ibiq)Cl2]. 
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Electrospray ionisation mass spectrometry was able to confirm the synthesis of the 
platinum complex by the observation of a m/z peak at 545 corresponding to 
[Na(Pt(C18H12N2)2Cl2)]
+ (Appendix 1.6).  The proton NMR (Fig. 2.13) showed a pattern of 
peaks similar to the biisoquinoline ligand alone however this time they were shifted much 
further downfield, particularly H6.  The dramatic shift of proton H6 arises because it points 
directly in the field of the chloride ligand.  This downfield shift is well known in other 
metal polypyridyl complexes such as [Ru(tpy)(HL)Cl][PF6] where HL is 6-phenyl-2,2’-
bipyridine.[29]  The quality of the spectrum is poor due to the poor solubility of complex.  
 
 
2.4.3  [Pt(ibiq)2][PF6]2 (7) 
The synthesis of [Pt(ibiq)2][PF6]2 was also carried out simply by heating under reflux 
potassium tetrachloroplatinate and 3,3-biisoquinoline in a 50:50 mixture of acetonitrile and 
water overnight (Scheme 2.13).  After 12 h the hot solution was filtered to remove any 
[Pt(ibiq)Cl2] that may have formed during the reaction and unreacted ligand.  The product 
Fig 2.13  1H-NMR spectrum (300 MHz, d6-DMSO, 298 K) of [Pt(ibiq)Cl2].  
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was precipitated out by treating the refluxed solution with a methanolic solution of 
NH4PF6.  When NaBF4 was used instead the resulting product was poorly soluble in both 
CH3CN and DMSO therefore only the PF6 counter ion was used.  Careful washing with 
methanol and diethyl ether resulted in the pure product being obtained in a 27% yield.   
 
 
Mass analysis using ESI gave molecular ion peaks at 353 and 742 m/z corresponding to 
[Pt(C18H12N2)2]
2+ and [Cl(Pt(C18H12N2)2)]
+ respectively (Appendix 1.7).  The 1H-NMR 
spectrum (Fig. 2.14) showed only the biisoquinoline peak symmetry but with slight shifts 
in ppm allowing the differentiation of the platinum complex from the unbound ligand.       
Scheme 2.13  Synthesis of [Pt(ibiq)2][PF6]2. 
Figure 2.14  1H-NMR spectrum (300 MHz, CD3CN, 298 K) of [Pt(ibiq)2][PF6]2. 
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Unfortunately, during these experiments only small crystals of [Pt(ibiq)2][PF6]2 were 
produced that could not be used in further single crystal x-ray diffraction studies. [6]  The 
complex is known to exist in a bowed conformation in a similar way that bipyridine 
platinum complexes exist.[6][30]  The figure below, reported in the literature, (Fig. 2.15) 
shows the crystal structure and also the side on view showing its bowed nature.[6]  Selected 
bond lengths and angles are also displayed in Table 2.2.     
 
 
 
 
 
 
 
 
 
 
 
 
Metal Pt-N1(ibiq) Pt-N2(ibiq) N1-Pt-N2 N1-Pt-N2' 
Pt 2.012(4) 2.011(4) 79.4(2) 100.6(2) 
 
 
Figure 2.15  ORTEP drawings of [Pt(ibiq)2][PF6]2 showing the (a) top and (b) side view of the 
crystal. Thermal ellipsoids are depicted at the 50% probability level. [Reproduced from Ref 6] 
Table 2.2 Selected bond lengths (Å) and bond angles (deg) from the crystal structure of [Pt(ibiq)2][PF6]2.[6] 
 
(a) 
(b) 
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The palladium and platinum structures when overlaid show very little difference in 
planarity or size, both have a bowed structure (Fig. 2.16).  
 
 
 
 
 
 
 
 
 
 
 
 
2.4.4  [Re(CO)3(ibiq)(Py)][CF3SO3] (8)  
Pentacarbonylchlororhenium(I) was used as the starting point for incorporation of the 
biisoquinoline ligand into an octahedral arrangement.  The reaction was carried out in three 
parts (Scheme 2.14) involving first the addition of the bidentate ligand replacing two of the 
carbonyl groups.  The next part involved exchanging the chloride group for acetonitrile 
using silver trifluoromethanesulfonate which was done to facilitate the exchange of that 
ligand in the next step of the reaction.  Acetonitrile ligands are displaced more easily by 
other σ-donor ligands making them in general more labile for ligand substitution 
reactions.[31] In the final step of the reaction the actonitrile group was displaced by pyridine 
to give the product in a 50% yield. 
Figure 2.16  Superimposed crystal structures of [Pt(ibiq)2][PF6]2 (pink) and 
[Pd(ibiq)2][BF4]2 (blue). 
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The mass spectrum of the final product conducted using electrospray ionisation showed a 
peak at a m/z of 606 corresponding with the molecular ion [Re(C12H18N2)(CO)3(C5H5N)]
+.  
The H-NMR spectrum (Fig. 2.17) accounts for all of the protons in the 3,3-biisoquinoline 
unit and the pyridine group in the correct integrations and was assigned fully with the use 
of 2D COSY and NOESY spectra (Appendix 1.8).  The downfield shift of proton H6 when 
bound to the rhenium is consistent with other rhenium complexes in the literature.[32]  In 
the complex fac-[(4,4'-bpy)ReI(CO)3(dppz)]
+, proton H6 of the dppz ligand shifts 5 ppm 
downfield when compared to the free ligand and in another complex containing 
phenanthroline a 6 ppm shift downfield can be seen.[32][33]  
 
       
Scheme 2.14  Synthesis of [Re(CO)3(ibiq)(Py)][CF3SO3]. 
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Crystals of the rhenium complex were obtained through slow diffusion of benzene into a 
solution of the complex in methanol.  The single crystal x-ray structure determined 
confirms the structure of the rhenium complex (Fig. 2.18). 
 
The rhenium metal centre sits in an octahedral arrangement which is six-coordinate.  The 
two biisoquinoline Re-N bonds are similar lengths 2.162 and 2.169 Å (shows similar 
values to bipyridine in the literature[34]) whereas the Re-N bond originating from the 
pyridine ligand is slightly larger at 2.208 Å indicating the bidentate ligand is slightly more 
strongly bound than the monodentate ligand.  The N1-C9 and N2-C10 bond lengths are the 
same length at 1.386 Å and the torsion angle between the two isoquinolyl unts is 9.6° 
Figure 2.17  1H-NMR spectrum (300 MHz, MeOD, 298 K) of [Re(CO)3(ibiq)(Py)][CF3SO3]. 
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indicating that a small amount of twisting is occurring therefore the biisoquinoline unit is 
slightly distorted from planarity.  The three carbonyl Re-C bonds are all similar lengths 
1.917 - 1.929 Å.  A table of selected bond lengths and angles for the complex is shown in 
Table 2.3.    
 
Metal Re-N(ibiq) Re-N(pyr) 
N(ibiq)-Re-
N(ibiq) 
N1-C9-C10 N2-C10-C9 
Re 2.162(2) 
2.169(2) 
2.208(2) 75.85(8) 115.3(2) 115.2(2) 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 2.3 Selected bond lengths (Å) and bond angles (deg) from the crystal structure of 
[Re(CO)3(ibiq)(Py)][CF3SO3]. 
 
Figure 2.18  The structure of [Re(CO)3(ibiq)(Py)][CF3SO3] with ellipsoids drawn at the 50 % probability 
level. Benzene solvent has been omitted for clarity.  
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 2.4.5  [Rh(COD)(ibiq)]Cl2 (9)  
A cyclooctadiene rhodium chloride dimer was used as the starting material where the 
chloride ligand was exchanged for 3,3-biisoquinoline.[35]  The reaction required very little 
preparation or reaction time producing the singly substituted complex, 
[Rh(COD)(ibiq)][PF6] in a 72% yield, after only 15 minutes vigorous stirring with 
potassium hexafluorophosphate in dichloromethane at room temperature (Scheme 2.15).  
Reactions carried out at higher temperatures, with longer time scales and with different 
stoichiometries did not produce the doubly substituted complex.  The rhodium 
hexaflourophosphate salt produced in the reaction was later converted to its chloride form 
using Dowex which made the complex water soluble.   
 
 
The molecular ion peak corresponding to [Rh(C12H18N2)(C8H12)]
+ was observed at a m/z of 
467 following electrospray ionisation mass spectrometry (Appendix 1.9).  The 1H-NMR 
spectrum (Fig. 2.19) shows the presence of both the COD and biisoquinoline groups with 
the latter when compared with the ligand alone and also with the other metal complexes, 
being seen further upfield (less charge on metal centre therefore less electron 
withdrawing).     
Scheme 2.15  Synthesis of [Rh(COD)(ibiq)][PF6]. 
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2.5   UV-Visible Absorbance Characteristics - Complexes 4 - 9 
  
The absorbance spectrum of 3,3-biisoquinoline (4) shows very strong π-π* ligand 
transitions in the UV region at  250 nm with further lower energy peaks at 304 and 324 nm 
which may be due to n-π* transitions from the lone pairs on the nitrogen atoms.  This 
strong π-π* transition is seen in all of the other complexes 5-9 between 251-263 nm.  In the 
rhenium complex, 8, UV transitions can be seen as low as 217 nm attributed to π-π* 
transitions from the pyridine ligand.   
 
Figure 2.19  1H-NMR spectrum (300 MHz, CD3CN, 298 K) of [Rh(COD)(ibiq)][PF6]. 
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Ligands with a higher degree of delocalisation such as biisoquinoline have a smaller 
energy gap between their bonding and anti-bonding orbital's causing absorptions to be seen 
at longer wavelengths; less energy is required to excite an electron.  Pyridine has less of an 
aromatic surface for delocalisation to occur across, therefore exhibits higher energy 
transitions.[36]  
 
Further charge transfer bands are seen between 370 - 452 nm in the metal containing 
complexes.  As these bands do not appear in the biisoquinoline only absorbance spectrum, 
it is likely that they are due to interactions between the metal centre and the ligands, 
especially for complexes 5 and 7 where there are no other ligands apart from 
biisoquinoline present.  The bands seen at 370 nm and 382 nm for [Pd(ibiq)2]
2+ and 
[Pt(ibiq)2]
2+ respectively may originate from MLCT transitions because the metal centre 
for each is in a relatively low oxidation state and the biisoquinoline ligand has low lying π* 
orbitals.   
 
MLCT bands have been observed in similar complexes containing bipyridine ligands, such 
as [Ru(bpy)3]
2+.[37]  The UV-vis spectrum for the ruthenium bipyridine complex shows 
absorbance peaks at both 452 nm and 243 nm which originate from MLCT transitions.[37]  
The most intense peak, seen at 286 nm, is the result of ligand centred π-π* transitions.[37][38]  
The platinum bipyridine complex [Pt(bpy)(dppm)]2+ also exhibits MLCT transitions, 
which can be found at 334 nm and 320 nm.[39]   
 
The extinction coefficient for each of the transitions and the wavelengths they occur at can 
be seen Table 2.4 for all synthesised complexes.     
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2.6   Conclusions 
 
The molecular design proposed fulfils the necessities for a G-quadruplex binder in that the 
palladium and platinum complexes have a planar aromatic surface for stacking and 
efficient burial of hydrophobic surfaces and a metal centre providing electrostatic 
interactions by withdrawing electron density from the aromatic ligands, mimicking the 
monovalent cation that usually sits in the central channel of the quadruplex structure.    
 
After considering the possible synthetic routes for the homocoupling of 3-
chloroisoquinoline, the catalytic cycle involving nickel was chosen not only because of the 
availability and price of the nickel complex, but also the feasibility of the reaction 
(relatively mild conditions).   
 
The synthesis of the ligand 3,3-biisoquinoline and the palladium, platinum, rhenium and 
rhodium complexes incorporating this ligand have been described.  Despite the relatively 
Complex UV-Vis Transitions / λmax(nm) (εmax/dm3 mol-1 cm-1) 
4a 250 (30,100), 304 (60,600), 324 (17,600) 
5b 251 (95,600), 305 (31,600), 328 (27,500), 370 (16,400) 
6c 263 (39,300), 308 (29,700), 360 (11,200), 380 (15,300) 
7b 262 (72,400), 335 (19,300), 382 (13,000) 
8a 217 (43,500), 256 (46,300), 303 (33,300), 354 (11,900), 374 (13,800) 
9d 219 (33,400), 260 (37,400), 315 (22,000), 364 (8,400), 452 (1,100) 
Table 2.4  UV-vis transitions and extinction coefficients occurring in complexes 4-9 under 
the following conditions, a. MeOH, b. 15% DMSO:85% H2O, c. DMSO, d. H2O.    
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low yields of the products, enough of each was attained to carry out the necessary 
characterisations and subsequent binding experiments discussed in the next chapter.  
 
The anions for the palladium and platinum complexes differ because of differences in 
solubility.  This may have an effect on the binding and cell studies however both anions 
are non-coordinating and if they were to interact it would most likely be through fluorine 
which both anions contain.      
  
In Chapter 3 the ability, of the complexes synthesised, to bind different structures of DNA 
will be assessed using fluorescent indicator displacements, circular dichroism, linear 
dichroism, UV-vis titrations, H-NMR, gel electrophoresis and FRET melting. 
 
2.7   Experimental 
 
General Methods 
All characterisation techniques took place within the University of Birmingham.  NMR 
spectra were recorded in CDCl3, CD3CN, CD3OD and d6-DMSO.  1D 
1H NMR and COSY 
spectra were recorded on Bruker AV(III)300 and AV(III)400 instruments operating at 300 
MHz and 400 MHz respectively.  13C NMR and HSQC spectra were recorded on a Bruker 
AV(III)400 instrument operating at 100 MHz (see appendix for spectra).  Electrospray 
ionisation was performed on a Waters LCT Time of Flight Spectrometer, electron 
impact mass spectrometry on a VG ZabSpec mass spectrometer and elemental analysis on 
a CE  Instrument  EA1110.  A  Varian  Cary  5000  UV‐Vis spectrometer was used to 
obtain UV-Vis spectra for the complexes and infrared spectra were recorded on a Perkin 
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Elmer Spectrum 100 FT-IR spectrometer.  The single crystal X-ray structures were 
obtained by Dr Louise Male (University of Birmingham crystallographer) and carried out 
on an Agilent SuperNovadiffractometer using an Atlas detector. The data collections were 
driven and processed and absorption corrections were applied using CrysAlisPro.[40] 
 
The compounds and solvents used were obtained from Fisher, Sigma Aldrich, Scientific 
Laboratory Supplies and Acros organics.  All the solvents were of a standard grade and 
were used without further purification.  Silica gel was used for the chromatographic 
separation of products using columns run under gravity.   
 
 
Isoquinoline-1,3-dione (1) [8][21] 
Molecular weight = 160.15 gmol-1 
Molecular Formula = C9H7O2N 
 
Homophthalic acid (15.0 g, 0.08 mol) was dissolved in concentrated (28 %) NH4OH (100 
ml) and then was evaporated to dryness under vacuo.  This part of the procedure was 
repeated with additional NH4OH (50 ml).  1, 2-dichlorobenzene (70 ml) was added to the 
resulting orange residue and heated with stirring at 200°C for 2 h without a condenser 
making sure the residue dissolved.  The concentrated mixture was allowed to cool to room 
temperature, diluted with methanol (300 ml), and allowed to stand overnight.  The 
precipitate was collected by filtration, washed with methanol, and dried under reduced 
pressure to leave tan shards. 11.28 g, 88% yield. 
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1H NMR (300 MHz, d6-DMSO): δ 11.29 (s, 1H, NH), 8.01 (d, 1H, J = 6.0, H5), 7.64 (t, 1H, 
J = 6.0, H3), 7.45 (t, 1H, J = 6, H4), 7.38 (d, 1H, J = 6.0, H2), 4.03 (s, 2H, H1).  
13C NMR (100 MHz, d6-DMSO): δ 170.9, 165.3, 136.6, 133.4, 127.8, 127.4, 127.1, 124.9, 
35.9. 
Elemental analysis.  Calculated for C9H7O2N; C, 67.1; N, 8.7; H, 4.4.  Found: C, 67.1; N, 
8.5; H, 4.1.   
Mass analysis (EI, +ve): m/z = 161 [H(C9H7O2N)]
+ . 
IR (Solid): ν = 3163 (m), 3061 (m), 2885 (m), 1673 (vs), 1608 (s), 1583 (w), 1462 (m), 
1336 (w), 1367 (m), 1282 (s), 1136 (m), 1031 (w), 926 (w), 877 (m), 736 (s) cm-1. 
 
 
1,3-Dichloroisoquinoline (2) [8] 
Molecular weight = 198.05 gmol-1 
Molecular Formula = C9H5Cl2N 
 
Phenylphosphonic dichloride (19.0 ml, 0.13mol) was added to (1) isoquinoline-1,3-dione 
(8.86 g, 0.06 mol) and heated under reflux (160 °C) for 3 hours.  
The reaction was left to cool to room temperature and then left to stand overnight.  
The brownish yellow solid formed was collected by filtration, and re-dissolved in 
tetrahydrofuran (250 ml), treated with water (70 ml), and then the solution was 
concentrated under vacuo to remove the tetrahydrofuran.  
The aqueous material remaining was neutralized with concentrated NH4OH (28 %) before 
being extracted with ethyl acetate (3 × 150ml). The ethyl acetate phases were combined, 
washed with water, brine, dried over Na2SO4 and reduced under vacuo to form a yellow 
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powdery solid. This was then purified by column chromatography (silica gel, CH2Cl2, Rf 
0.8) to give an off white solid, 6.46g, 59% yield. 
 
1H NMR (300 MHz, d6-DMSO): δ 8.36 (d, 1H, J = 8.7, H5), 8.24 (s, 1H, H1), 8.15 (d, 1H, J 
= 8.4, H2), 8.03 ( t, 1H, J = 8.1, H3), 7.92 (t, 1H, J = 8.4, H4). 
13C NMR (100 MHz, d6-DMSO): δ203.7, 145.4, 132.1, 128.7, 126.6, 126.3, 119.8, 100.4, 
60.8. 
Elemental analysis:  Calculated for C9H7Cl2N; C, 54.6; N, 7.1; H, 2.5.  Found: C, 55.1; N, 
7.1; H, 2.3.   
Mass analysis (EI, +ve): m/z = 199 [H(C9H5Cl2N)]
+ . 
IR (Solid): ν = 3082 (w), 3060 (w), 1616 (m), 1575 (m), 1552 (m), 1486 (m), 1395 (w), 
1295 (s), 1252 (s), 1151 (w), 1094 (s), 982 (s), 839 (s), 755 (m), 745 (s), 706 (s) cm-1. 
 
 
3-Chloroisoquinoline (3) [8] 
Molecular weight = 163.61 gmol-1 
Molecular Formula = C9H6ClN 
 
1,3-Dichloroisoquinoline (2) (7.68 g, 0.04 mol from multiple batches) was suspended in 
glacial acetic acid (42.1 ml) and concentrated HCl (14.9 ml).  It was then treated with tin 
powder (13.9 g, 0.12 mol) and stirred and heated at reflux (55°C) for 3 hours. The mixture 
was cooled to room temperature and the precipitated tin salts were removed by filtration 
through celite. The filtrate was basified to pH 9 with concentrated NH4OH and then 
extracted with ethyl acetate (5 × 150 ml). The organic extracts were combined, washed 
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with saturated NaHCO3 solution, dried over Na2SO4, and concentrated in vacuo.  The waxy 
yellow residue produced was purified by column chromatography (silica gel, CH2Cl2, Rf 
0.5) to give a pale yellow solid, 0.63 g, 10 % yield. 
 
1H NMR (300 MHz, MeOD): δ 9.12 (s, 1H, H6), 8.14 (d, 1H, J = 8.4, H5), 7.92 (d, 1H, J = 
8.4, H2), 7.92 (s, 1H, H1), 7.83 (t, 1H, J = 8.1, H3), 7.71 (t, 1H, J = 8.4, H4). 
13C NMR (100 MHz, MeOD): δ 153.8 (CH6) , 133.0 (CH3), 129.2 (CH4), 129.0 (CH5), 127.0 
(CH2), 121.5 (CH1). 
Mass analysis (EI, +ve): m/z = 163 [C9H6ClN]
+. 
IR (Solid): ν = 3075 (w), 3052 (w), 1626 (m), 1584 (w), 1572 (m), 1485 (m), 1426 (m), 
1390 (w), 1334 (m), 1273 (m), 1197 (w), 1138 (w), 1064 (s), 1011 (w), 944 (s), 884 (vs), 
855 (s), 738 (vs) cm-1. 
 
 
3,3-Biisoquinoline (4) 
Molecular weight = 256.30 gmol-1 
Molecular Formula = C18H12N2 
 
Operating under an argon atmosphere [NiCl2.6H2O] (278 mg, 1.17mmol), PPh3 (1.23 g, 
4.68 mmol) and zinc dust washed with dilute HCl, H2O, EtOH and Et2O (82 mg, 1.24 
mmol) were added to a schlenk tube.  DMF (13 ml) was then added by syringe into the 
sealed vessel.  The brick red solution that formed was left to stir at 70°C for an hour before 
adding a degassed solution of 3-chloroisoquinoline, 3, (0.19 g, 1.17 mmol) in DMF (6.5 
ml).  The mixture was then left to heat at 70°C for 4 h.  After heating, the mixture was 
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allowed to cool to room temperature before pouring onto a 7 % ammonium hydroxide 
solution (19 ml) – a small amount of concentrated (28 %) ammonium hydroxide was added 
to ensure all the ligand had been removed from the metal.  The product was then extracted 
in dichloromethane and diethyl ether (2:1, 3 x 65 ml) before removing the solvent from the 
organic layer in vacuo.  The yellow-orange oil that remained was diluted with 
dichloromethane (40 ml) and washed with water (4 x 13 ml) and brine (26 ml) before 
drying over MgSO4 and reducing in vacuo to an off white solid.   This was purified by 
column chromatography (silica gel, CH2Cl2 to remove un-reacted compound 3 Rf 0.5, 
followed by ethyl acetate to elute the coupled product Rf 0.2) to give a pale yellow solid.  
This was followed by another column to remove any traces of triphenylphosphine oxide 
(silica gel, diethyl ether) which again left a pale yellow solid, 0.059 g, 10 % yield.   
 
1H NMR (300 MHz, MeOD): δ 9.40 (s, 2H, H6), 8.85 (s, 2H, H1), 8.17 (d, 2H, J = 8.1, H5), 
8.09 (d, 2H, J = 8.1, H2), 7.84 (t, 2H, J = 6.9, H3), 7.73 (t, 2H, J = 6.9, H4).  
Mass analysis (EI, +ve): m/z = 256 [C12H18N2]
+. 
IR (Solid): ν = 3048 (w), 2973 (w), 1620 (m), 1575 (m), 1553 (m), 1487 (m), 1433 (m), 
1387 (w), 1338 (w), 1295 (m), 1253 (m), 1190 (m), 1140 (w), 1026 (w), 983 (m), 940 (m), 
872 (m), 818 (w), 775 (m), 745 (s), 706 (m) cm-1. 
UV‐Vis (MeOH) λmax [nm] (εmax/dm3 mol‐1 cm‐1): 213 (30200), 250 (60600), 304 
(23200), 324 (17600), 351 (3100). 
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[Pd(i-biq)2](BF4)2 (5) 
Molecular weight = 792.63 gmol-1 
Molecular Formula = PdC36H24N4B2F8 
 
 
 
A solution of 3,3-biisoquinoline, 4, (9.5 mg, 0.037 mmol) in acetonitrile (6 ml) was added 
to a schlenk tube and placed under an argon atmosphere.  
Tetrakis(acetonitrile)palladium(II) tetrafluoroborate (8.5 mg, 0.019 mmol) was then added 
to the mixture and left to stir overnight.  The solution was then filtered and the filtrate 
reduced in vacuo to a yellow solid.  This was then washed with chloroform (5 ml), 
methanol (5 ml) and diethyl ether (5 ml) and left to dry under vacuum.  7.6 mg, 50 % yield. 
 
1H NMR (300 MHz, CD3CN): δ 9.30 (s, 4H, H6), 8.79 (s, 4H, H1), 8.23 (d, 4H, J = 8.1, 
H5), 8.08 (d, 4H, J = 8.1, H2), 7.93 (t, 4H, J = 7.2, H3), 7.77 (t, 4H, J = 7.5, H4). 
1H NMR (300 MHz, DMSO): δ 9.97 (s, 4H, H6), 9.40 (s, 4H, H1), 8.64 (d, 4H, J = 8.1, H5), 
8.35 (d, 4H, J = 8.1, H2), 8.25 (t, 4H, J = 6.9, H3), 8.06 (t, 4H, J = 7.5, H4). 
13C NMR (100 MHz, DMSO): δ158.6 (CH6), 135.5 (CH3), 130.7 (CH4), 130.3 (CH5), 127.5 
(CH2), 121.1 (CH1). 
Mass analysis (ESI, +ve): m/z = 309 [Pd(C12H18N2)2]
2+, 637 [F + (Pd(C12H18N2)2)]
+. 
IR (Solid): ν =3612 (vw), 3058 (w), 1631 (m), 1602 (w), 1495 (m), 1441 (w), 1392 (m), 
1355 (w), 1328 (w), 1289 (w), 1210 (w), 1013 (vs), 972 (s), 905 (s), 751 (s) cm-1. 
UV‐Vis (15 % DMSO : 85 % H2O) λmax [nm] (εmax/dm3 mol‐1 cm‐1): 251 (95600), 305 
(31600), 328 (27500), 370 (16400). 
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[Pt(i-biq)Cl2 (6) [6] 
Molecular weight = 521.00 gmol-1 
Molecular Formula = PtC18H12N2Cl2 
 
 
Potassium tetrachloroplatinate (13.0 mg, 0.03 mmol) was dissolved in water (2.2 ml) 
before adding 2 M HCl (0.1 ml) and then a suspension of 3,3-biisoquinoline (8.0 mg,  0.03 
mmol) in acetonitrile (2.2 ml).  The mixture was heated under reflux for 1.5 h during 
which time a yellow solid precipitated.  The solution was left to cool to room temperature 
before filtering, washing with acetonitrile and then drying under vacuum.  4.0 mg, 26 % 
yield. 
 
1H NMR (300 MHz, d6-DMSO): δ 10.26 (s, 2H, H6), 9.21 (s, 2H, H1), 8.50 (d, 2H, J = 8.4, 
H5), 8.15 (m, 4H, H2 and 3), 7.91 (t, 2H, J = 8.1, H4).  
Mass analysis (ESI, +ve): m/z = 545 [Na(Pt(C18H12N2)Cl2)]
+ 
IR (Solid): ν = 3092 (w), 3054 (w), 3027 (w), 1629 (w), 1602 (w), 1496 (m), 1438 (w), 
1389 (m), 1355 (m), 1290 (w), 1150 (w), 1048 (m), 1018 (m), 961 (m), 904 (m), 884 (m), 
743 (s) cm-1. 
UV‐Vis (DMSO) λmax [nm] (εmax/dm3 mol‐1 cm‐1): 263 (39300), 308 (29700), 360 
(11200), 380 (15300). 
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[Pt(i-biq)2][PF6]2 (7) [6] 
Molecular weight = 997.09 gmol-1 
Molecular Formula = PtC36H24N4P2F12 
 
 
 
Potassium tetrachloroplatinate (4.5 mg, 0.01mmol) was dissolved in water (5 ml) before 
adding a suspension of 3,3-biisoquinoline (5.5 mg, 0.02 mmol) in acetonitrile (5 ml).  The 
mixture was heated under reflux overnight producing a yellow solution.  The solution was 
hot filtered before adding a methanolic solution of NH4PF6.  An off white solid 
precipitated immediately which was collected, washed with chloroform, methanol and 
diethyl ether before leaving to dry under vacuum.  2.7 mg, 27 % yield. 
 
1H NMR (300 MHz, CD3CN): δ 9.68 (s, 4H, H6), 9.05 (s, 4H, H1), 8.48 (d, 4H, J = 8.1, 
H5), 8.33 (d, 4H, J = 8.4, H2), 8.20 (t, 4H, J = 7.5, H3), 8.03 (t, 4H, J = 8.1, H4).  
Mass analysis (ESI, +ve): m/z = 353 [Pt(C18H12N2)2]
2+, 742 [Cl + (Pt(C18H12N2)2)]
+. 
IR (Solid): ν = 3649 (vw), 3069 (w), 1622 (m), 1575 (w), 1552 (w), 1488 (m), 1392 (m), 
1357 (w), 1294 (m), 1253 (w), 1210 (w), 1155 (w), 1013 (vs), 909 (s), 983 (s), 924 (m), 
755 (s) cm-1. 
UV‐Vis (15 % DMSO : 85 % H2O) λmax [nm] (εmax/dm3 mol‐1 cm‐1): 262 (72400), 335 
(19300), 382 (13000). 
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[Re(i-biq)(CO)3Py][CF3SO3] (8) 
Molecular weight = 757.73 gmol-1 
Molecular Formula = C27H17N3ReO6F3S 
 
 
 
Part 1 
3,3-biisoquinoline (4) (8.0 mg, 0.031 mmol) and pentacarbonylchlororhenium(I) (5.4 mg, 
0.015 mmol) were put under an argon atmosphere before being suspended in toluene (5 
ml).  The solution was heated at 120°C for 4 hours and then left to cool to room 
temperature before filtering and collecting the yellow solid formed.   
Part 2 
[Re(i-biq)(CO)3Cl] (from part 1) (11.0 mg, 0.019 mmol) and AgO3SCF3 (5.0 mg, 0.019 
mmol) were put under an argon atmosphere before dissolving in CH3CN (15 ml).  The 
reaction mixture was left to reflux in the dark for 16 h before cooling to room temperature.  
The solution was then filtered and the filtrate reduced in vacuo to leave a yellow residue 
which was then directly used in the next step of the reaction. 
 
Part 3 
The residue of [Re(i-biq)(CO)3CH3CN][CF3SO3] from part 2 was heated under reflux in 
pyridine (4 ml) for 4 h.  The yellow oil produced after reducing the solution in vacuo was 
precipitated out using diethyl ether.  A beige solid was collected.  6.6 mg, 50 % yield.  
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1H NMR (300 MHz, MeOD):δ 10.12 (s, 2H, H6), 9.14 (s, 2H, H1), 8.50-8.45 (m, 4H, H5, 1", 
5"), 8.21 (d, 2H, J = 8.1, H2), 8.08 (t, 2H, J = 6.9, H3), 7.97 (t, 2H, J = 6.9, H4), 7.84 (t, 1H, 
J = 7.8, H3"), 7.28 (t, 2H, J = 6.3, H2", 4"). 
13C NMR (100 MHz, MeOD): δ 158.8 (CH6), 153.3 (CH5 or H1"/5"), 141.1 (CH3"), 135.8 (CH3), 
132.0 (CH4), 130.0 (CH5 or H1"/5"), 129.0 (CH2), 127.9 (CH3"), 122.8 (CH1). 
Mass analysis (ESI, +ve): m/z = 606 [Re(C12H18N2)(CO)3(C5H5N)]
+ 
IR (Solid): ν = 3068 (w), 2022 (s), 1898 (vs), 1628 (m), 1602 (m), 1488 (m), 1446 (m), 
1391 (m), 1358 (w), 1272 (m), 1256 (s), 1218 (m), 1139 (m), 1067 (m), 1028 (s), 902 (m), 
750 (s) cm-1. 
UV‐Vis (MeOH) λmax [nm] (εmax/dm3 mol‐1 cm‐1): 217 (43500), 256 (46300), 303 
(33300), 354 (11900), 374 (13800). 
 
 
[Rh(ibiq)(COD)][PF6] (9) (COD = Cycloocta-
1,5-diene) 
Molecular weight = 671.24 gmol-1 
Molecular Formula = C29H33N2RhPF6 
 
 
 
[Rh2Cl2(COD)2] (2.56 mg, 0.005 mmol) in dichloromethane (3 ml) and potassium 
hexafluorophopshate (2.56 mg) in water (3 ml) were placed in the reaction vessel before 
adding ibiq (10 mg, 0.04 mmol) and vigorously stirring for 15 min.  After this time the 
orange dichloromethane layer was extracted from the solution and washed with more water 
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(3× 2 ml).  The washed solution was then reduced to ~ 1 ml with nitrogen gas before 
adding ethanol (0.3 ml) followed by slowly adding another (0.6 ml) of ethanol to fully 
precipiate out the product.  The product was then filtered, washed with diethyl ether and 
left to air dry to leave an orange powder, 4.8 mg,  72 % yield. 
 
1H NMR (300 MHz, CD3CN): δ 8.83 (s, 2H, H6), 8.58 (s, 2H, H1), 8.21 (d, 2H, J = 8.1, 
H5), 8.14 (d, 2H, J = 9.0 H2), 8.00 (t, 2H, J = 7.2, H3), 7.85 (t, 2H, J = 6.9, H4), 4.84 - 4.76 
(m, 4H, HA), 2.68 - 2.59 (m, 4H, HB), 2.29 - 2.20 (m, 4H, Hc)  
Mass analysis (ESI, +ve): m/z = 467 [Rh(C12H18N2)(C8H12)]
+ 
IR (Solid): ν = 3647 (w), 3271 (br m), 3011 (m), 2946 (m), 2913 (m), 2881 (m), 2838 (m), 
2167 (w), 1976 (w), 1626 (m), 1598 (m), 1494 (m), 1434 (w), 1390 (m), 1352 (m), 1304 
(w), 1212 (w), 1078 (w), 1045 (w), 1011 (m), 980 (m), 911 (m), 755 (s) cm-1. 
UV‐Vis (H2O) λmax [nm] (εmax/dm3 mol‐1 cm‐1): 219 (33400), 260 (37400), 315 (22000), 
364 (8400), 452 (1100). 
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Chapter 3: DNA Binding Studies 
3.1  Introduction 
 
The binding properties of the complexes [Pd(ibiq)2][BF4]2, [Pt(ibiq)2][PF6]2 and 
[Re(CO)3(py)(ibiq)][CF3SO3] with both duplex and G-quadruplex type DNA will be 
explored in this chapter using a variety of spectroscopic techniques.  In order for a complex 
to be a good potential binder for a G-quadruplex it needs to specifically target this structure 
over the more commonly found duplex form.  The square planar complexes have ligands 
that should be too large to fit between a base pair in a double helical structure; instead they 
should be the right size and shape to stack on top of a G-quartet.  
 
The binding studies with the complex [Pt(ibiq)Cl2] were limited due to its poor solubility 
in DMSO and water, whereas [Pd(ibiq)2][BF4]2 and [Pt(ibiq)2][PF6]2 experiments required 
15 % DMSO solutions, [Re(CO)3(py)(ibiq)][CF3SO3] 15 % methanolic solutions and 
[Rh(COD)(ibiq)]Cl2 was fully soluble in water.  Different solvent systems were used due 
to the varying solubility of the four compounds; no one solvent could dissolve all of the 
complexes.  Despite the majority of complexes requiring additional solvents to be fully 
soluble, the final percentage of these solvents in the experimental DNA binding solutions 
did not exceed 2 %. 
 
3.1.1  Types of DNA Investigated in Binding Studies 
Four types of DNA will be used in the binding experiments in order to assess how selective 
the complexes are for one type of DNA sequence or structure over another.  The types of 
DNA to be used are ct-DNA, htelo quadruplex forming DNA, c-myc quadruplex forming 
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DNA and ds26 (a self-complimentary duplex forming sequence); each of which will be 
discussed in detail. 
 
ct-DNA 
Calf thymus DNA (ct-DNA) is composed of a varying selection of bases and therefore 
DNA sequences, consisting of mainly double but also single stranded regions.  The 
concentration of ct-DNA is measured in bases determined by UV spectroscopy as strand 
concentration cannot be calculated.  The ability of the complexes to bind to duplex DNA 
will be assessed using ct-DNA in stability assessment, circular dichroism, linear dichroism 
and UV-vis titration experiments. 
 
Htelo DNA 
Human telomeric DNA is made up of a repeat base sequence of TTA-GGG which has been 
identified as a G-quadruplex forming region due to it being guanine rich.  Htelo is a 22 
base sequence composed of the bases; 5’-A-GGG-TTA-GGG-TTA-GGG-TTA-GGG-
3’, which mimics the DNA sequence found at the telomeric ends.[1]  Under the appropriate 
salt conditions the sequence is able to take the form of either an antiparallel or antiparallel 
hybrid G-quadruplex structure (Fig. 3.1), monitored using circular dichrosim.  The ability 
of the complexes to stabilise, bind or even induce a G-quadruplex structure in this region 
of DNA can be investigated using circular dichroism, UV-vis titrations, 
1
H-NMR, FRET 
melting and fluorescent indicator displacement experiments.   
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C-myc DNA 
Sequences found in oncogene promoter regions of DNA are guanine rich and have the 
potential to fold into G-quadruplexes.
[1]
  The c-myc sequence is made up of 22 bases taken 
from part of the oncogene promoter region; 5’-TGA-GGG-TGG-GTA-GGG-TGG-
GTA-A-3’.  Parallel G-quadruplex structures (Fig. 3.2) are formed from the c-myc 
sequence when placed in the same conditions as the htelo DNA sequence.  It can therefore 
be used as a direct comparison with the htelo DNA to look at selectivity and hence binding 
modes.  The loops of the quadruplex differ in each case and may give more clues towards 
how the complex is interacting with the quadruplex.  C-myc DNA will be used in circular 
dichroism, UV-vis titration and fluorescence indicator experiments.  
 
 
 
 
 
 
 
Figure 3.1  a. Antiparallel G-quadruplex, b. Antiparallel hybrid G-quadruplex. [Reproduced from Ref 
1
] 
Figure 3.2  Parallel G-quadruplex. [Reproduced from Ref 
1
] 
(a) (b) 
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ds26 
A 26 base self-complimentary sequence used in similar experiments in the literature, 5’-
CAA-TCG-GAT-CGA-ATT-CGA-TCC-GAT-TG-3’, was used as a comparison to the 
guanine rich quadruplex forming sequences.
[2]  
The number of binding sites for this strand 
and also the quadruplex DNA has been evaluated with the dye thiazole orange during 
fluorescent indicator displacement experiments, allowing a direct comparison between the 
two types of  DNA.  The duplex forming ds26 sequence is also used as a competitor in the 
FRET melting and PAGE experiments.   
 
Using the results from the binding experiments and also the crystal structures recorded for 
complexes 5, 7 and 8, the possible modes of binding to each type of DNA will be explored.  
The influence of cations on DNA structure in solution will also be examined for G-
quadruplex forming sequences whose structure can change depending on the type of cation 
present.   
 
3.1.2  Stability of Complexes 5, 7, 8, 9 
Before starting the binding experiments the stability of each of the complexes was assessed 
using UV-vis spectroscopy to observe the change in absorbance over time (Fig. 3.3).  The 
most stable of the complexes would show no difference in their λmax throughout the 
duration of the experiment.  Of the four complexes, when tested alone in solution, 
[Re(CO)3(py)(ibiq)][CF3SO3] (8) was the most stable and showed only a 0.2 % decrease in 
absorbance intensity over 12 hours.  [Pt(ibiq)2][PF6]2 (7) was the next stable with a loss of 
intensity of only 8 % over the same duration of time.  The palladium (5) and rhodium (9) 
complexes both showed much higher losses of absorbance, 16 % and 31 % respectively.   
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Complex stability was further investigated in the presence of calf thymus DNA (ct-DNA) 
where the stability of all but one of the complexes improved upon the addition of ct-DNA 
(Fig. 3.3).  The palladium complex showed a decrease of 4 % in absorbance compared 
with the previous 16 %.  The same was true for the rhodium complex absorbance which in 
the presence of the ct-DNA decreased 7 % instead of 31 %.  The platinum complex (7) was 
relatively stable in solution alone however the stability did increase when ct-DNA was 
added from an absorption loss of 8 % to 7 %.  The rhenium complex appeared to 
destabilise upon adding the DNA differing by 4 % which may have been the result of 
experimental error. 
 
Since the biisoquinoline ligands should be too large to intercalate, the complexes may be 
binding to the grooves of the DNA through electrostatic interactions provided by the metal 
centres withdrawing electron density from the aromatic ligand structure.  Coordinative 
binding is another possible binding mode for complexes 5 and 7 as their complex and 
complex+DNA spectra at 0 h do not match (Fig. 3.3 - c and d).  The band which is 
suspected to be attributed to MLCT has been red shifted.  The complexes which show the 
greatest UV-vis stabilisation are more likely to have bound more favourably to the ct-
DNA.  Once bound it is possible that they are protected from the effects of solvent 
degradation by the DNA.  Complex 8 is already quite stable in solution therefore the 
presence of DNA changes the stability very little making it harder to determine whether the 
two species are interacting in solution.  It is hoped that the complexes will act in a similar 
(or better) way in the presence of G-quadruplex forming DNA.   Complexes which interact 
through end stacking with a G-quadruplex may be shielded from the effects of solvent 
degradation by the quadruplex loops.  However, for this study, only ct-DNA was examined 
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which demonstrates that complexes 5, 7 and 9 are potentially interacting with duplex DNA 
because their absorption loss decreases upon the addition of ct-DNA.   It is also worth 
noting that ct-DNA is not solely made up of duplex sequences and therefore may have the 
ability to fold into quadruplexes and other structures in its single stranded regions.  The 
stability seen in the complexes may arise from binding to other secondary structures rather 
than duplex type DNA alone.      
 
 
 
 
 
 
 
 
 
 
Figure 3.3  a. Normalised UV-Vis stability studies of complexes 5 and 7 at room temperature (10 uM, 15 % DMSO: 
H2O) and the same complexes in the presence of ct-DNA in a 6:1 ratio DNA:complex (DNA buffer contains 6.7 mM 
NaCl and 0.33 mM Na(CH2)2AsO2.3H2O, 2.1 % DMSO: H2O).  b. Normalised UV-Vis stability studies of complexes 
8 and 9 at room temperature (15% MeOH:H2O and H2O only respectively) and in the presence of DNA in a 6:1 ratio 
DNA:complex (DNA buffer contains 6.7 mM NaCl and 0.33 mM Na(CH2)2AsO2.3H2O, 2.1 % MeOH: H2O and H2O 
only respectively) λmax = 329 nm for [Pd(ibiq)2][BF4]2, 378 nm for [Pt(ibiq)2][PF6]2, 376 nm for 
[Re(CO)3(py)(ibiq)][CF3SO3] and 312 nm for [Rh(ibiq)COD][Cl], c. Comparison of Pd complex and Pd complex+ct-
DNA spectra at 0 h, d. Comparison of Pt complex and Pt complex+ct-DNA spectra at 0 h. 
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3.2  Circular Dichroism with complexes 5, 7, 8 and 9 
 
Circular dichroism (CD) is a spectroscopic technique that can be used to probe the 
conformation of different types of DNA.  The observed spectrum obtained from an 
experiment is generated by measuring the difference in absorbance between left (Al) and 
right (Ar) circularly polarised light giving a CD signal expressed in degrees which is 
known as the ellipticity, θ.[3] 
 
Circularly polarised light arises from superposition of oscillating horizontal and vertical 
polarised light (both linear).
[4]
  The size of electric field vector remains constant but rotates 
in the form of a helix about the propagation direction (Fig. 3.4).
[4]
 Whether left or right 
circularly polarised light is produced depends on whether the vector forms a left or right 
handed helix.  The magnitude vector will be perpendicular to the electric field at any point 
in time and space.
[4]
 
 
 
 
 
 
 
 
 
 
Figure 3.4  Left-circularly polarized light that is propagating in z-direction. The rotating electric field 
vector is represented by the small arrows. [Reproduced from Ref 
5
] 
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Only molecules which are chiral can produce a CD spectrum.  Non-chiral molecules can 
only be seen when they are interacting with the chiral molecule producing induced circular 
dichroism (ICD).  Chiral molecules have non-superimposable mirror images and they do 
not have a plane of reflection therefore interact differently with left and right circularly 
polarised light.
[4]
  The extinction coefficients for each type of circularly polarised light will 
be different and this difference is plotted against wavelength to give a CD spectrum.
[4] 
 
The relationship between left and right circularly polarised light is shown in the two 
equations that follow using the signal expressed in degrees (top) and molar extinction 
coefficients (bottom): 
CD = Al - Ar [θ] 
Δε = εl - εr [M
-1 
cm
-1
] 
 
Chiral sugar units make up the sugar phosphate backbone in DNA.  The DNA chirality is 
helical and produces a CD signal.  The characteristic spectrum obtained for each sequence 
of DNA will be explained in the following subchapters; 3.2.1, 3.2.2, 3.2.3 and 3.2.4.  CD is 
a highly sensitive method that allows conformational transitions between complex nucleic 
acid arrangements to be followed during different experimental conditions.
[6]
  Therefore 
quadruplex forming DNA will give a different spectrum to duplex DNA.  Parallel and 
antiparallel quadruplex differentiation can also be achieved.
[6]
 To assess whether the small 
percentage of solvent used in the experiments had any effect on the CD spectroscopy of the 
DNA, control experiments were carried out.  The titrations were carried out normally 
except omitting the complex from the solvent solution.  The controls showed that the small 
amount of solvent had no effect on the DNA (see appendix section 5 for DMSO controls).       
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3.2.1  ct-DNA and its Characteristic CD Spectrum 
The characteristic CD signal for this type of DNA can be seen in Fig. 3.5 between 200 - 
300 nm.  The bands produced in this region are fairly weak and arise from the transitions 
of purine and pyrimidine bases which are in a weakly chiral environment because of the 
base pairs being perpendicular to the double helix.
[3]
 
 
 
 
 
 
 
 
 
 
In the following titration experiments the concentration of ct-DNA is kept constant whilst 
an increasing amount of complex is added in order to see how it affects the observed CD 
spectrum.  Any changes to the region 200 - 300 nm may indicate conformational changes 
in the DNA.  If the complexes do bind to the DNA they may acquire some induced 
chirality from the environment causing the appearance of new CD bands, an effect called 
induced circular dichroism (ICD).  Any new or changing CD bands can provide insight 
into how the complex is binding to the DNA.  Alternatively, binding could induce chirality 
in the complex if it gets distorted.   
 
 
Figure 3.5  Characteristic CD spectrum of ct-DNA (B-DNA conformation) [300 μM, 1cm pathlength cuvette] 
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3.2.1.1  CD Studies and Binding Constant Determination of 5, 7, 8 and 9 
[Pd(ibiq)2][BF4]2 - (5) - (see p176 for UV-vis) 
The palladium complex was titrated into a solution of ct-DNA whilst monitoring and 
recording a CD spectrum after every addition of the complex.  The complex generates very 
intense ICD bands in the MLCT region of the spectrum at 388 nm and 367 nm indicating 
that binding is occurring between the two species (Fig. 3.6).  The peaks corresponding to 
the B-DNA configuration have not moved however they are now much more intense with 
the addition of the complex indicating complex-DNA interactions are present.  
 
 
 
 
[Pt(ibiq)2][PF6]2 - (7) (see p178 for UV-vis) 
The CD spectrum for the square planar platinum complex is similar to that shown by the 
palladium complex which is as expected due to the similarity between the two complexes.  
There are however more transitions occurring in the CD spectrum for the platinum 
complex (Fig. 3.7).  The two complexes (5 and 7) both have isosbestic points, at 238 nm 
and 262 nm (Pd complex ) and at 242 nm and 265 nm (Pt complex), that arise at relatively 
Figure 3.6  a. CD spectrum showing the titration of [Pd(ibiq)2][BF4]2 in increasing concentrations 
to 300 μM ct-DNA (20 mM NaCl, 1 mM Na(CH2)2AsO2.3H2O, pH 6.8), 1 mm pathlength 
cuvette.  Ratio of DNA:complex shown in the legend (right), b. ICD versus concentration of 
complex at selected λmax. 
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low complex concentrations due to the unbound and bound species.  It appears as though 
further isodichroic points at 297 nm and 317 nm can be seen in the platinum complex CD 
spectrum when the DNA:complex ratio rises above 8:1.  This however is most likely due to 
the background noise of the CD experiment.
[7][8]
    
 
 
 
 
 
The mode of binding cannot be determined from the CD spectra alone as groove binding 
and direct metal base interactions are both possible ways in which the complexes can bind 
to the ct-DNA.  Both the platinum and palladium complexes have a bowed type crystal 
structure which is likely to put strain on the metal-nitrogen bonds (Fig. 3.8).  This could be 
relieved when a ligand is lost from the metal centre and the metal binds instead to either 
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Figure 3.7  a. CD spectrum showing the titration of [Pt(ibiq)2][PF6]2 in increasing concentrations to 
300 uM ct-DNA (20 mM NaCl, 1 mM Na(CH2)2AsO2.3H2O, pH 6.8) with a magnification of the 
region containing the isosbestic points at 297 nm and 317 nm, 1mm pathlength cuvette.  Ratio of 
DNA:complex shown in the legend (right), b. ICD versus concentration of complex at selected λmax. 
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DNA bases (one or two), water or chloride.  Intercalation should be prevented due to the 
large size of the ligand.   
 
 
 
 
[Re(CO)3(py)(ibiq)][CF3SO3] - (8) 
In this complex the 3,3-biisoquinoline ligand is no longer in a square planar environment 
and instead is part of an octahedral arrangement.  The same titration experiment was 
conducted with the rhenium complex and ct-DNA to give the spectrum in Fig. 3.9.  
   
 
 
 
 
 
Figure 3.8  Bowed crystal structures of [Pt(ibiq)2][PF6]2 (pink) and [Pd(ibiq)2][BF4]2 (blue) overlaid . 
Figure 3.9  a. CD spectrum showing the titration of [Re(CO)3(py)(ibiq)][CF3SO3] in 
increasing concentrations to 300 uM ct-DNA (20 mM NaCl, 1 mM Na(CH2)2AsO2.3H2O, pH 
6.8), 1 mm pathlength cuvette.  Ratio of DNA:complex shown in the legend (right), b. UV-vis 
spectrum of  the [Re(CO)3(py)(ibiq)][CF3SO3]. 
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The spectra gave no evidence for an interaction of the complex with the ct-DNA as no 
induced circular dichroism peaks or changes in intensity of the DNA peaks could be seen.  
It seems in the octahedral arrangement the complex cannot groove bind or interact directly 
with the bases as it is most likely sterically hindered by the other ligands in the complex.  
Despite this lack of interaction the complex may have a preference for other types of DNA 
structure which may provide it with a degree of selectivity.   
 
[Rh(COD)(ibiq)]Cl2 - (9) 
The CD spectrum obtained from the titration of the rhodium complex (9) into a ct-DNA 
solution clearly shows ICD peaks formed due the interaction between the two species (Fig. 
3.10).  The two ICD peaks at 344 nm and 386 nm may be due to MLCT transitions 
however the origin of the band at 262 nm is unclear as it could have been induced by the 
ligand or be the result of a change in DNA conformation. 
 
 
 
Figure 3.10  a. CD spectrum showing the titration of [Rh(COD)(ibiq)]Cl2 in increasing 
concentrations to 300 μM ct-DNA (20 mM NaCl, 1 mM Na(CH2)2AsO2.3H2O, pH 6.8).  Ratio of 
DNA:complex shown in the legend (right). 1 cm pathlength cuvette, b. UV-vis spectrum of 
[Rh(COD)(ibiq)]Cl2, c. ICD versus concentration of DNA at selected λmax. 
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A negative band can be seen at 297 nm, the knowledge of which when combined with the 
emergence of a band at 262 nm and the disappearance of the band at 272 nm suggests a B 
→  Z conformational DNA transition.  B to Z DNA transitions are usually associated with 
charge quenching and occurs through the groove or backbone.  The phosphate groups are 
located closer in space in the Z conformation causing the destabilisation of the structure 
through negative repulsion (see Figure 3.11 for Z-DNA CD spectrum).
[9]
  Cations can 
shield the negative charges between the phosphate groups stabilising the structure.
[9]
  A 
complex in the literature with this effect is [Co(NH3)6]
3+
 which was studied by CD using 
poly[d(GC)] DNA.
[10]
    
 
 
 

 
 
 
 
Binding Constant Determination 
The data sets used for each of the binding constant determinations throughout the rest of 
this sub-chapter were reproducible, however the method of analysis was not therefore the 
binding constant results can only be given as estimates of binding. 
 
The palladium complex ICD spectrum (Fig. 3.12 - a) shows the presence of one potential 
binding mode at low complex concentrations and another for higher complex 
Figure 3.11  CD representation of B, A and Z forms of DNA [Reproduced from Ref 
11
] 
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concentrations when comparing the peaks at 250 nm, 273 nm and 388 nm which all follow 
the same trend.  It is possible that the low concentration measurements may not fit with the 
other data due to the small signal to noise ratio.  The platinum complex shows ICD bands 
at 254 nm, 277 nm, 305 nm, 335 nm, 378 nm and 397 nm, which can be seen in Fig. 3.12 - 
b.  Both ICD bands at 254 nm and 277 nm follow a similar trend to the palladium complex 
however the band at 397 nm shows more of a linear relationship at both low and high 
complex concentrations.    
 
 
The calculation of binding constants was attempted using the intrinsic method described by 
Rodger and Norden.
[12] 
 Generally the ICD signal is proportional to the number of complex 
molecules that bind to the DNA (if there is only one binding mode) therefore cb= αr where 
cb is the concentration of complex bound, α is the proportionality constant and r is the ICD 
response.
[12]
  This relationship allows the equilibrium binding constant (K) to be calculated 
using the following equation where cf is the free ligand concentration, S is the number of 
unfilled binding sites, c is [complex]tot and d is [DNA]/n (n = binding site size in bases).  A 
Scatchard plot can be used to calculate the binding constant when binding is complete.
[12] 
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Figure 3.12  ICD of selected λmax shown in the legend to the right of each chart in nm.  
a. Palladium complex ICD comparison, b. Platinum complex ICD comparison. 
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From the graphs presented in Fig. 3.12 the total concentration of complex bound to DNA 
cannot be read from the graph as the binding curve is incomplete.  The intrinsic method 
uses the difference between two different complex concentrations to calculate α and n 
which can then be used in a Scatchard plot to calculate K.
[12]
  The equation used to plot the 
data for the intrinsic method is shown below (where the intercept = α and the gradient = 
[DNA]/nα and k and j represent all pairs of data points, Cm = [DNA] and L = [complex]): 
 
    
      
 
     
 
  
  
 
    
 
  
 
    
 
  
     
  
 
The results of the analysis for the palladium complex for both low concentration binding 
and higher complex concentrations are shown in Fig. 3.13.  Using the intrinsic method 
described, no reliable results could be obtained from the two graphs.  There are not enough 
data points for each of the graphs to be conclusive of a linear relationship between x and y.  
The plots also contain outlier points which further hinder the determination of the binding 
constant from the analysed data.  When analysing the data as a whole and not splitting 
between high and low concentrations a random scatter of points emerged.  The results 
abstracted from the intrinsic platinum complex graph also showed only a random scatter of 
points that could not be analysed any further, at any of the ICD wavelengths selected.  An 
explanation for this could be that there are two modes of binding which are occupied at the 
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same time therefore each particular binding mode constant cannot be calculated.  This may 
also be a possibility for the palladium complex.   
 
 
 
A plot of the rhodium complex ICD bands against concentration is shown in Fig. 3.14, 
where similar binding curves can be seen for the four ICD bands. 
  
 
 
 
 
 
 
 
Similar analysis using the intrinsic method for each λmax yielded a random distribution of 
points therefore it is possible that the binding mode is not the same for all 
concentrations.
[12] 
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Figure 3.13  Palladium complex: a. Intrinsic method used for concentrations 0 μM to 9.3 μM, b. Intrinsic 
method used for concentrations 14.0 μM to 70.0 μM. Calculated for ICD at λ277. 
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Figure 3.14  Rhodium complex ICD vs. concentration for selected λmax. 
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3.2.2  ds26-DNA and its Characteristic CD Spectrum 
This self complementary strand was chosen as a duplex type DNA control as it has a 
known sequence unlike the ct-DNA and it will also be used in FRET melting experiments 
as a competitor.  The reason for this is because it has a melting temperature that is around 
70°C which is higher than the labelled telomeric sequence (around 50°C) therefore the 
duplex will not unwind when the quadruplexes unfold (remains a competitor and is not 
single stranded).
[2]
 It also does not affect the quadruplex forming DNA when the ligand 
investigated is omitted.   
 
The CD spectrum generated for the ligand binding to ds26 will allow comparisons to be 
drawn between this system and that of the ct-DNA.  A characteristic CD spectrum for the 
self-complementary ds26 oligo is shown in Fig. 3.15. 
 
 
 
 
 
 
 
 
 
3.2.2.1  CD Study and Binding Constant Determination of 7 
The platinum complex (7) previously tested with ct-DNA was unable to provide a binding 
constant due to the possible presence of more than one binding mode.  In order to rule out 
Figure 3.15  Characteristic CD spectrum of ds26 (B-DNA conformation) [300 μM] per base. 
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possible binding modes that may occur in various parts of the ct-DNA the same experiment 
was conducted with ds26 which has a defined structure.  The resulting spectrum can be 
seen in Fig. 3.16 where very clear ICD peaks can be seen at 397 nm, 332 nm and 306 nm; 
interestingly, the ICD is proportional to the concentration of the complex added (Fig. 3.17 
- a).  
 
 
 
 
 
 
 
 
 
The intrinsic method combined with a Scatchard plot was used to calculate a binding 
constant for the ICD observed at λ397 nm.  The first four points at the beginning of the 
titration were omitted due to the signal to noise ratio at such low concentrations of 
complex.  The resulting binding constant calculated from the Scatchard plot was in the 
region of 10
5
 M
-1
 (Fig. 3.17 - b) with a value of n (6.25 bases or 3.13 base pairs).  
 
Figure 3.16  CD spectrum showing the titration of [Pt(ibiq)2][PF6]2 in increasing concentrations to 
300 μM (per base) ds26 (20 mM NaCl, 1 mM Na(CH2)2AsO2.3H2O, pH 6.8).  Ratio of 
DNA:complex shown in the legend (right). 
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3.2.3  Htelo DNA and its Characteristic CD Spectrum 
The guanine rich strand of DNA that mimics the DNA found in the telomeric region of 
DNA, htelo, can exist in three different conformations depending on the type of cation 
present in the solution.  Potassium and sodium cations are the correct size to be able to 
coordinate to the hole between the G-tetrads held in place by electrostatic interactions with 
eight O6 atoms lining the two planes of G-tetrads.
[1]
  The sodium cations generally sit in 
the central cavity of the quartet while the potassium cations sit between the quartet 
layers.
[1]
  The three types of structure seen using circular dichroism are shown in Fig. 3.18.  
Before measuring the CD response of the DNA in each cation condition, the DNA was 
annealed and left to cool slowly to room temperature before placing in a fridge overnight.  
The DNA preparation ensures that any quadruplexes formed have originated from the 
specific experimental conditions; the most thermodynamically stable structure would form 
during the slow cool and would not deteriorate overnight.  
 
When in a potassium rich solution, a characteristic antiparallel hybrid spectrum is seen 
where the major peak observed at 295 nm originates from its antiparallel character and the 
smaller side peak at 265 nm represents its parallel nature (Fig. 3.18).  There is also a small 
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Figure 3.17  a. ICD plotted versus concentration for the [Pt(ibiq)2]
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nm, b. Platinum complex intrinsic plot produced from ICD generated with ds26 at λ397 for complex 
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amount of unfolded DNA represented by the peak at 253 nm.  In a sodium rich solution a 
solely antiparallel conformation is found as now only a peak at 295 nm can be seen, the 
shoulder of the hybrid is no longer present (Fig. 3.18).  In the third condition both 
potassium and sodium ions were omitted to see whether the quadruplex would fold in the 
absence of cations.  There is now a new more defined peak at 253 nm which is due to the 
unfolded htelo DNA strand, however despite the lack of any cations there is still evidence 
of the quadruplex formation with the peak at 295 nm demonstrating the stability of the G-
quadruplex structure (Fig. 3.18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2 
0 
2 
4 
6 
8 
10 
225 245 265 285 305 325 
C
D
 /
 m
d
e
g
 
Wavelength / nm 
-10 
-5 
0 
5 
10 
225 245 265 285 305 325 
C
D
 /
 m
d
e
g
 
Wavelength / nm 
-2 
-1 
0 
1 
2 
3 
4 
5 
225 245 265 285 305 325 
C
D
 /
 m
d
e
g
 
Wavelength / nm 
K
+
 rich buffer 
Na
+
 rich buffer 
No added metal ion buffer 
Figure 3.18  Characteristic CD spectra generated from a telomeric strand of DNA in a buffer which is K
+
 rich, 
Na
+
 rich and another without cations present. K
+
 rich buffer: 3 μM htelo in 100 mM KCl, 10 mM Tris-HCl pH 
7.4, Na
+
 rich: 3 μM htelo DNA in 100 mM NaCl , 10 mM Tris-HCl pH 7.4, No metal ion buffer: 3 μM htelo 
in 10 mM Tris-HCl pH 7.4. Quadruplex structures where formed shown to the right. [Reproduced from Ref 
1
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All three conditions were used in the titration experiments conducted to investigate 
whether the initial conformation of the quadruplex in solution affected any potential 
binding of the platinum, palladium and rhenium complexes (5, 7 and 8). 
 
3.2.3.1  CD Studies and Binding Constant Determination of 5, 7 and 8 
The circular dichroism experiment using htelo was conducted in the same way as the CD 
titrations with ct-DNA.  The concentration, however, of DNA is recorded per strand rather 
than per base so as to give an indication of how many complex molecules bind per strand 
or quadruplex.  In all of the following CD experiments the concentration of DNA (per 
strand) used was 3 μM. 
 
[Pd(ibiq)2][BF4]2 - (5) 
The binding of the palladium complex to the telomeric DNA was examined in K
+
, Na
+
 and 
no added metal ion solutions.  An attempt was also made to determine a binding constant 
for each cation condition using the intrinsic method combined with a Scatchard plot (where 
the Scatchard plot could not be used alone) in order to compare results with those obtained 
for the duplex forms of DNA.     
 
K
+
 Buffer 
When the titration is carried out in the potassium rich buffer (Fig. 3.19 - a) the addition of 
the complex to the telomeric DNA sees an ICD peak emerge at 388 nm indicating that 
binding is occurring between the two species as the complex alone showed no CD 
response.  A peak also arises at 272 nm however its origin is unclear as it could be another 
ICD band from the complex masking the DNA peaks, or a change in conformation from an 
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antiparallel hybrid to a parallel quadruplex.  The complex has had an effect on the DNA 
because the peak corresponding to the unfolded DNA strand is no longer present at 253 
nm, therefore the complex is either promoting the formation of the antiparallel hybrid (the 
response of which is hidden by the intense ICD peaks) or forming the parallel quadruplex 
conformer.  The existence of a constant shoulder at 295 nm indicates that the former is 
occurring.  
 
 
 
 
 
 
 
 
 
Examination of the ICD peaks for this system (Fig. 3.19 - b) shows that at low complex 
concentrations a different binding mode may be occurring as the ICD at each wavelength is 
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Figure 3.19  a. CD spectrum showing the titration of [Pd(ibiq)2][BF4]2 in increasing concentrations to 3 μM 
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not directionally proportional to the concentration.  The higher concentration levelling off 
of the graph could be explained by the possible complete binding of the complex to the 
DNA followed by the precipitation of the DNA/complex as the concentration further 
increases (results in the ICD intensity decreasing).  Despite this the Scatchard plot alone 
was not able to yield a satisfactory relationship between ICD and concentration.  Reading 
from the ICD chart the point of complete binding occurs at a complex concentration of ~12 
μM indicating a 4:1 complex:DNA binding mode (DNA concentration 3 μM).  This 
however would only be the case if all the complex added was in a bound state with the 
DNA.  The high ratio of complex observed may be a result of the square planar nature of 
the complex which may stack upon itself whilst bound to the quadruplex.   
 
A binding constant in the region of 2.3 × 10
6
 M
-1
 was calculated for the titration using the 
ratios of complex:DNA; 1:1, 2:1, 3:1, 4:1 and 5:1 (Fig. 3.19 - c).  The lower and higher 
ratios did not fit with the data and yielded randomly scattered points.  An error could not 
be calculated as the three repeats of the experiment did not yield decipherable data when 
examined by both the Scatchard and intrinsic methods.  The value of n when converted to 
bases becomes 5.5 which correlates closely with the four guanines which are part of the top 
face of a G-quadruplex.     
 
Na
+
 Buffer 
When the titration was then conducted in a sodium rich buffer the same ICD peaks 
appeared upon increasing concentrations of the complex (Fig. 3.20 - a).  The peak at 388 
nm is likely to have arisen from MLCT interactions and the peak at 272 nm shows the 
same behaviour as that of the potassium rich buffer.  Again it is not possible to conclude 
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whether the peak at 272 nm is due to an overlapping complex ICD peak or a change of 
conformation from antiparallel to parallel. 
 
A plot of ICD against concentration for the peaks at 388 nm and 272 nm shows that as 
complex concentration increases above 12 μM no change in the ICD signal occurs.  This 
indicates that at this concentration the complex has saturated the DNA (Fig. 3.20 - b).  The 
complex appears to bind in a similar way to both conformations of quadruplex resulting in 
the same final CD spectrum for both. 
 
Using the ICD at λmax 388 nm the intrinsic and Scatchard methods were used to try to 
calculate a binding constant for the palladium complex binding htelo DNA in a sodium 
rich buffer.  Despite using the same ratios as the potassium rich buffer experiment omitting 
the lowest and highest complex concentrations no result could be obtained from the 
intrinsic method as only a random scatter of points originated from the calculations.  The 
binding of the complex to the two different quadruplex conformations therefore may be 
more different than first predicted from the matching CD spectra.  
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Figure 3.20  a. CD spectrum showing the titration of [Pd(ibiq)2][BF4]2 in increasing concentrations to 3 
μM (per strand) htelo (100 mM NaCl, 10 mM Tris-HCl, pH 7.4).  Ratio of DNA:complex shown in the 
legend (right).  b. ICD plotted versus concentration for the palladium complex at λmax 388 and 272 nm. 
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No Added Metal Ions Present in the Buffer 
Finally in order to see the effect on quadruplex formation without the electrostatic 
stabilisation of the cations the titration was carried out in 10 mM Tris-HCl buffer alone, 
without any additional cations.  The initial spectrum, before the addition of any complex, 
shows the presence of mainly unfolded htelo DNA but also antiparallel quadruplex 
formation.  Addition of the complex saw the decrease of the peak at 253 nm representing 
the unfolded DNA strand and the appearance of a peak at 388 nm due to ICD (Fig. 3.21 - 
a).  A rapidly rising peak is also seen at 272 nm, the same peak seen in both the K
+
 and 
Na
+
 buffer conditions, that is likely to be an ICD peak overshadowing the DNA 
quadruplex conformational response. 
 
An ICD comparison between the three λmax 388 nm, 272 nm and 250 nm shows a linear 
increase to ~12 μM followed by a slight decrease in intensity as the concentration of 
complex increases further and the DNA begins to precipitate out of the solution (Fig. 3.21 
- b).   
 
Despite the intrinsic method yielding a straight line, after attempting to calculate a binding 
constant, when its result was used to calculate the binding constant using a Scatchard plot 
no linear relationship could be established (the Scatchard plot alone also yielded no 
useable results).  Examining the CD spectra it appears that the shape of the quadruplex 
peak formed when no metal ions are present matches that of the peak formed in the sodium 
rich buffer which may be why both sets of results fail to produce a binding constant.    
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[Pt(ibiq)2][PF6]2 - (7) 
K
+
 Buffer 
When the titration is carried out in a potassium rich buffer the initial antiparallel hybrid CD 
peak of the DNA becomes dominated by the ICD peaks of the complex at relatively low 
concentrations of complex (Fig. 3.22 - a).  The presence of the ICD peaks at 388 nm and 
276 nm indicate that the complex is binding to the DNA.  
 
When the ICD is plotted against the concentration for the peaks at 395 nm and 276 nm it is 
observed that they do not follow the same trend (Fig. 3.21 – b).  The ICD at 276 nm peaks 
at 19 μM before starting to descend as the concentration increases further whereas the ICD 
at 395 nm continues to increase and only begins to start levelling off as the concentration 
of complex increases giving an approximate binding ratio of 10:1 (complex:DNA).  Such a 
high binding ratio could be rationalised by the ability of the platinum complex to stack 
upon itself as with every titration addition the complex isn't solely binding to the DNA.  
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Figure 3.21  a. CD spectrum showing the titration of [Pd(ibiq)2][BF4]2 in increasing concentrations to 3 μM 
(per strand) htelo (10 mM Tris-HCl, pH 7.4).  Ratio of DNA:complex shown in the legend (right).  b. ICD 
plotted versus concentration for the palladium complex at λmax 388, 272 and 250 nm. 
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The ICD at 395 nm was chosen to calculate the binding constant as this alone is due to the 
complex binding however no linear relationship could be attained using the data. 
 
 
 
Na
+
 Buffer 
The sodium rich buffer with the initial antiparallel quadruplex conformer generated similar 
ICD peaks, as seen with the potassium rich buffer, at 395 nm and 272 nm (Fig. 3.23).  A 
plot of the ICD versus the concentration gave the same result as the potassium buffer 
therefore once again no binding constant could be calculated. 
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Figure 3.23  a. CD spectrum showing the titration of [Pt(ibiq)2][PF6]2 in increasing concentrations to 3 μM 
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Figure 3.22  a. CD spectrum showing the titration of [Pt(ibiq)2][PF6]2 in increasing concentrations 
to 3 μM (per strand) htelo (100 mM KCl, 10 mM Tris-HCl, pH 7.4).  Ratio of DNA:complex 
shown in the legend (right).  b. ICD plotted versus concentration for the platinum complex at λmax 
395 and 276 nm. 
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No Added Metal Ions Present in the Buffer 
In the absence of both potassium and sodium there is a definite transformation of the DNA 
as before the addition of any complex the majority of the telomeric DNA is unfolded 
however the peak corresponding to the unfolded strand is no longer apparent when the 
complex is added (Fig. 3.24).  This indicates that the complex is changing the 
conformation of the DNA; the actual structure formed however is still hidden by intense 
ICD peaks that form in the same region.  The ICD peaks have been compared at 395 nm 
and 272 nm against the concentration giving a similar result to the other two buffer 
conditions.  The only difference is that the ICD at 272 nm does not start to decrease at very 
high concentrations of complex.  
 
 
 
For the htelo DNA strand it appears that the ICD peaks generated by both the palladium 
and platinum complexes remain the same for all types of buffer used.  The majority of the 
titrations yielded no binding constant which indicates that there is no single binding mode 
in operation.
[12] 
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Evidence in the literature has shown that the potassium cation is preferred due to the 
relative energies of hydration therefore under cellular conditions it is most likely that the 
telomeric DNA adopts the quadruplex conformation observed in the potassium cation 
solution.
[13]
 It is also worth noting computational analysis results (using cation positions 
suggested by the crystal structure) reported by Jiande Gu and Jerzy Leszczynskiof suggest 
that the G-tetrads have a slightly distorted structure when optimising the bond distances 
between the potassium cation and the O6 atom from the guanine bases (Fig. 3.25).
[13]
  The 
slightly distorted nature of the platinum and palladium complex may make them an ideal 
fit for the top of a G-tetrad and may be how the complexes are binding to the telomeric 
DNA indicated by the strong ICD peaks in titration experiments. 
 
 
 
 
 
 
[Re(CO)3(py)(ibiq)][CF3SO3] - (8) 
K
+ 
Buffer and No Metal Ion Buffer 
The rhenium complex did not show any interaction with the telomeric DNA as seen in Fig. 
3.26, just as it showed no interaction with the ct-DNA.  The titration carried out in 
potassium rich buffer shows the antiparallel hybrid quadruplex which doesn't change upon 
titration of the complex.  When the titration is carried out without the potassium (or 
sodium) the mostly unfolded htelo DNA remains in its unfolded state.     
Figure 3.25 Side view of a slightly distorted G-tetrad and a potassium cation in its optimal position 
between O6 atoms of the guanine bases. [Reproduced from Ref 
13
] 
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3.2.4  C-myc DNA and its Characteristic CD Spectrum 
Another example of a guanine rich DNA sequence that has the potential to fold into a G-
quadruplex is found in the promoter region of the c-myc gene.  The base sequence differs 
to that found in the telomeric region and as a consequence has different loops that link the 
G-quartet layers resulting in the formation of a parallel conformer.  When the structure of 
the G-quadruplex formed from the c-myc DNA strand was investigated in different cation 
buffers, the structure remained the same for all three conditions (K
+
 rich, Na
+
 rich and no 
metal cations present) imposed upon the DNA. 
 
The characteristic CD spectrum of a parallel G-quadruplex is shown in Fig. 3.27 where a 
peak can be seen at 265 nm.  The spectrum differs from that of the anitparallel response 
because all of the guanines are now in an anti position about the glycosidic bond where in 
the antiparallel quadruplex both syn and anti guanine conformations were present. 
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Figure 3.26 a. CD spectrum showing the titration of [Re(CO)3(py)(ibiq)][CF3SO3] in increasing 
concentrations to 3 μM (per strand) htelo (100 mM KCl, 10 mM Tris-HCl, pH 7.4).    b. CD 
spectrum showing the titration of [Re(CO)3(py)(ibiq)][CF3SO3] in increasing concentrations to 3 
μM (per strand) htelo (10 mM Tris-HCl, pH 7.4).  For both ratio of DNA:complex shown in the 
legend (right). 
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3.2.4.1  CD Studies and Binding Constant Determination of 5 and 7  
[Pd(ibiq)2][BF4]2 - 5 
K
+
, Na
+
 and No Cation Buffer Comparison 
The CD spectra for c-myc DNA differ much more between the different buffer conditions 
than for the telomeric DNA.  In the K
+ 
rich buffer a very small ICD peak can be seen at 
374 nm, and at 265 nm there is a small decrease in intensity of the DNA peak (Fig. 3.28).  
Potential binding isn't as evident in this system which may be because of the different 
DNA structure formed by the c-myc DNA strand which is preventing the palladium 
complex from binding and inducing the same extent of circular dichroism.  
 
An ICD peak at 380 nm is present at a slightly higher intensity (compared with the 
potassium buffer) when the titration is carried out in the sodium rich buffer however this 
can only be noticed at very high concentrations of complex.   
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Figure 3.27 CD spectrum of c-myc alone after annealing and leaving overnight forming a parallel G-
quadruplex conformer (3 μM (per strand) htelo in 100 mM KCl, 10 mMTris-HCl, pH 7.4).     
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The buffer without the potassium or sodium cation influence sees a CD spectrum which is 
more similar to those seen with the telomeric DNA with an ICD peak at 374 nm which red 
shifts at higher concentrations to 382 nm (Fig. 3.28).  The other peak seen at 265 nm 
intensifies as the complex concentration increases and also shifts as the ICD of the 
complex begins to hide the DNA peak.  A binding constant couldn’t be calculated as the 
intrinsic method yielded only a random scatter of points. 
 
The apparent binding in the absence of the cations indicates the importance they have on 
ligand quadruplex binding in the c-myc system.  It is possible that the interaction between 
the palladium complex and the quadruplex DNA is not an end stacking one and the 
palladium is instead interacting with the quadruplex loops.  The antiparallel loops maybe 
more accessible hence why binding is seen with the antiparallel hybrids and not the parallel 
conformer.  A possible way the palladium complex could bind to the DNA bases is through 
coordinative bonding which may occur after the loss of one of the biisoquinoline ligands.  
Work reported by Teulade-Fichou has shown through mass spectrometry studies that 
palladium terpyridine chloride complexes predominantly interact with G-quadruplexes by 
direct co-ordination to the bases after hydrolysation.
[14]
  Binding to the terminal G-quartets 
(N7 position) is hindered due to the stacking of the aromatic ligand and the presence of 
Hoogsteen hydrogen bonding therefore it is postulated that the complexes co-ordinate to 
the thymine bases linking the G-quartets.
[14]
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Figure 3.28  a. CD spectrum showing the titration of [Pd(ibiq)2][BF4]2 in increasing concentrations to 3 μM 
(per strand) cmyc (100 mM KCl, 10 mM Tris-HCl, pH 7.4) and the corresponding ICD versus 
concentration.  b. CD spectrum showing the titration of [Pd(ibiq)2][BF4]2 in increasing concentrations to 3 
μM (per strand) cmyc (100 mM NaCl, 10 mM Tris-HCl, pH 7.4) and the corresponding ICD versus 
concentration, c. CD spectrum showing the titration of [Pd(ibiq)2][BF4]2 in increasing concentrations to 3 
μM (per strand) cmyc (10 mM Tris-HCl, pH 7.4).  pH 7.4) and the corresponding  ICD versus concentration. 
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[Pt(ibiq)2][PF6]2 - 7 
K
+
, Na
+
 and No Cation Buffer Comparison 
The CD spectra produced from the platinum complex titrations were unexpectedly very 
different from those obtained for the palladium complex despite the complexes being very 
similar in structure.  In the potassium rich buffer where the palladium complex showed 
very little interaction with the c-myc DNA, the platinum complex produced many ICD 
peaks of high intensity, with both negative and positive peaks, at 405 nm, 353 nm and 300 
nm (Fig. 3.29 - a).  The DNA peak at 265 nm shifts to 260 nm before it loses intensity 
indicating that the structure of the DNA has changed. The negative ICD band at 300 nm is 
more unusual and hasn’t been seen in any of the DNA-complex systems so far therefore its 
origin cannot be explained. 
 
The CD spectrum obtained from the titration carried out in the sodium rich buffer doesn’t 
contain any of the negative peaks that the complex produced when carrying out the 
titration in the potassium rich buffer.  The DNA peak in this spectrum increases in intensity 
until it reaches the ratio 0.17:1 where the λmax shifts from 265 nm to 268 nm and the 
intensity of the peak begins to decrease (Fig. 3.29 - b).  The ICD peak at 396 nm follows 
the same trend with a red shift of 2 nm.  It appears that when subjected to high 
concentrations of the complex in Na
+
 rich buffer a new binding event occurs which causes 
the differences observed in the CD spectrum. 
 
The CD spectrum of the titration carried out without either of the cations is particularly 
interesting as the whole CD signal reverses helicity (Fig. 3.29 - c).  The final titration sees 
the CD trace as almost a mirror image of its former self at lower concentrations.  The 
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presence of more than one binding mode is even more apparent for this system as the 
intensity of the ICD peak at 396 nm increases up to a ratio of 0.25:1 (DNA:complex) 
before the peak shifts to 400 nm and decreases in intensity.  At the ratio of 0.14:1, as the 
peak begins to descend into the negative region of the spectrum, a new peak can be seen 
emerging at 392 nm.   
 
Attempts at recording a binding constant using a Scatchard plot with and without the 
intrinsic method were unsuccessful and no results could be obtained for any of the CD 
experiments carried out with c-myc DNA.  
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Figure 3.29  a. CD spectrum showing the titration of [Pt(ibiq)2][PF6]2 in increasing concentrations to 3 μM 
(per strand) cmyc (100 mM KCl, 10 mM Tris-HCl, pH 7.4) and the corresponding  ICD versus 
concentration   b. CD spectrum showing the titration of [Pt(ibiq)2][PF6]2 in increasing concentrations to 3 
μM (per strand) cmyc (100 mM NaCl, 10 mM Tris-HCl, pH 7.4) and the corresponding  ICD versus 
concentration. 
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Both the palladium and platinum complex CD plots show that binding is occurring 
between the complexes and the htelo DNA with all spectra showing the same type of 
response to the binding event(s).  This could be because of binding to the loops and/or end 
stacking to the antiparallel hybrid quadruplex structure (see Fig. 3.30 for the different 
quadruplex structures all with differing loops).  
 
With the c-myc DNA it is more apparent that different binding modes are occurring for 
each complex and the ability of the complex to end stack determines the CD response seen.  
The palladium complex shows very little induced chirality with the c-myc DNA when 
cations are present as the CD spectrum changes very little therefore it seems that it is no 
longer to bind to the DNA loops or the G-quartet surface whilst in the parallel 
conformation.  It is possible that the main binding mode of the palladium complex is 
through direct metal-base binding which occurs after the loss of one of the biisoquinoline 
ligands.  When the accessibility of the loops is restricted, binding does not occur.  The 
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Figure 3.29 continued  c. CD spectrum showing the titration of [Pt(ibiq)2][PF6]2 in increasing 
concentrations to 3 μM (per strand) cmyc (10 mM Tris-HCl, pH 7.4) and the corresponding  ICD versus 
concentration .           
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platinum complex on the other hand appears to be end stacking as the loop size has not 
affected its binding ability. 
 
 
 
 
 
 
 
3.2.5  Comparison of Binding Constants calculated from CD data 
As most of the CD spectra produced were not able to produce a linear intrinsic relationship 
very few binding constants could be calculated.  The spectra that did produce a linear 
relationship after applying the intrinsic method hinted that duplex DNA binding constants 
were around 10
5
 M
-1 
and htelo binding constants around 10
6 
M
-1
.   
 
3.3   Linear Dichroism  
 
Linear dichroism or LD is the result of the difference in the absorbance of light linearly 
polarised parallel and perpendicular to an orientation axis at a specific wavelength.
[15]
  It 
can be used to probe DNA conformations and drug-DNA interactions (DNA length 
permitting, >250 base pairs, as it has to be long enough to be oriented).
[4][15]
 
 
LD(λ) = Apar(λ) - Aper(λ) 
 
Figure 3.30  Possible loops that can form in a G-quadruplex structure. 
[Reproduced from Ref 
1
] 
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The LD signal is measured using a couette cell which orients the sample by viscous 
drag.
[16]
  This method of orienting the sample is called flow orientation and is 
advantageous for biological molecules such as DNA as they need to be hydrated.
[16]
  The 
viscous drag is created when the DNA in solution is flowed between the narrow walls of 
the couette in a gap between a cylindrical cell that rotates and causes alignment within 
another which remains stationary (Fig. 3.31).
[16]
 The two perpendicular beams will interact 
with the oriented DNA producing an LD spectrum.
[16] 
 
 
 
 
 
 
 
 
 
 
Both positive and negative signals can be produced, the former occurring if the transition 
moment is aligned so that it is more parallel than perpendicular to the orientation axis and 
the latter if the same moment is less parallel and more perpendicular to the orientation 
axis.
[16]
 
 
Generally DNA binding molecules on their own are too small to exhibit a LD signal as 
they cannot be oriented.  They can however contribute to the LD spectrum when they 
Figure 3.31  Representation of the process which occurs when DNA is placed in a couette and rotated, 
causing the DNA to align thus allowing a LD signal to be produced when subjected to plane polarised 
light. [Reproduced from Ref 
16
]  
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become oriented through binding to the DNA in a regular arrangement.  Induced linear 
dichroism (ILD) peaks produced from ligand-DNA binding events can help deduce the 
type of binding occurring as the spectrum is a direct result of how the ligand is orientated 
with respect to the DNA.        
 
3.4.1  ct-DNA and its Characteristic LD Spectrum 
The LD spectrum produced from ct-DNA alone is shown in Fig. 3.32.  The negative signal 
at 255 nm arises because of the orientation of the DNA bases with respect to the helix axis.  
The DNA bases are perpendicular to the helix axis (also the transitions of the bases) 
therefore the transition moment of the bases is more perpendicular then parallel to the 
orientation axis hence giving a negative response (LD = Apar- Aper) .
[15][16]
 
 
 
 
 
 
 
 
 
 
In the following titration experiments the concentration of ct-DNA is kept constant whilst 
an increasing amount of the complex is added in order to see how it affects the observed 
LD spectrum.  Control titrations carried out using a solution of 65% acetonitrile without 
the complex showed no effect on the DNA.  Changes in intensity to the region 200 - 300 
Figure 3.32  LD spectrum of ct-DNA (B-DNA) [300 μM]. 
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nm may indicate kinking or coiling of the DNA.  LD peaks that form at longer 
wavelengths are due to ligand binding and will be oriented in a particular way to the DNA 
helix. 
 
LD studies using the htelo and c-myc strands of DNA cannot be used as they are not long 
enough to orient therefore the results reported are for the complexes interaction with ct-
DNA only.  Solvents such as DMSO could not be used in the couette (because of its 
construction) therefore the complexes had to be dissolved in acetonitrile (unable to 
dissolve the complexes in other solvents).  Despite the platinum complexes solubility in 
acetonitrile, when diluted with water the complex was quick to precipitate out even at the 
highest percentage of acetonitrile permissible for use in the couette.  This lack of solubility 
prevented the examination of the platinum complex (7) using LD.   
 
3.2.1.1  LD Studies of 5 and 8 
The biisoquinoline complexes used in the LD studies show no peaks in the LD spectrum 
alone as the complexes are too small to be oriented by the couette cell.  Any ILD peaks 
therefore must be a result of the complex interacting with the oriented ct-DNA.     
 
[Pd(ibiq)2][BF4]2 - 5 
When the palladium complex is titrated into the ct-DNA solution there is an initial 
decrease in the intensity of the LD band corresponding to the DNA at 255 nm which then 
remains constant up to a ratio of 8:1 (DNA:complex) with no corresponding ILD peaks.  
At this stage the LD spectrum provides no evidence to indicate that regular complex 
binding is occurring (Fig. 3.33).  The complex may be binding but in a random way 
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causing the sum of many different orientations that do not result in a LD peak.  As the 
complex concentration increases from a DNA:complex ratio of 6:1 (44.3 μM) to 3:1 (88.3 
μM) an ILD peak is seen at 350 nm and the DNA LD peak at 255 increases in intensity.  
This indicates that at high concentrations of complex a binding event occurs which is 
regular enough to produce a peak in the spectrum.  The negative sign of the ILD peak 
produced suggests that the complex is binding by intercalation (binding perpendicularly to 
the helix orientation) if the absorption transition moment is polarised in the plane of the 
ligands.  The increase in intensity of the DNA LD peak is also consistent with this because 
the result of intercalation is the lengthening or stiffening of the DNA as it becomes more 
orientated.
[17]
  A possible explanation for this may be the insertion of an isoquinolyl unit, 
occurring at high complex concentrations.  This however does not rule out coordination.  
  
 
 
 
 
 
 
 
 
 
[Re(CO)3(py)(ibiq)][CF3SO3] - 8 
As with the CD analysis of the rhenium complex very little is seen in the LD spectrum 
(Fig. 3.34).  There is a slight decrease in the intensity of the DNA peak at 256 nm when the 
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Figure 3.33  a. LD spectrum of 300 μM ct-DNA (B-DNA) in 20 mM NaCl and 1 mM 
Na(CH2)2AsO2.3H2O (pH 6.8) with the addition of increasing concentrations of [Pd(ibiq)2][BF4]2. 
Legend to the right shows the ct-DNA:complex ratios.  b. ILD pattern generated from the complex 
titration.  
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first titration of complex occurs (40:1, DNA:complex) however as more and more complex 
is added the intensity remains the same suggesting that the initial small decrease in 
intensity may be due to the solvent effect.  The complex also failed to induce any LD peaks 
suggesting that the complex does not bind to B-DNA.    
 
 
 
 
 
 
 
 
 
3.4   Fluorescent Indicator Displacements with complexes 5 and 7 
 
The G-quadruplex fluorescent indicator displacement protocol used by Marie-Paule 
Teulade-Fichou et al 
[18]
 is a quick and convenient way to assess the binding affinity of a 
ligand towards G-quadruplexes.  The selectivity of the ligand for quadruplex over duplex 
DNA can also be investigated.  The assay is monitored by the loss of fluorescence caused 
by the displacement of the dye thiazole orange by the ligand which occurs if the ligand has 
a stronger binding affinity to the DNA than the dye.  Following the titration experiment the 
concentration at which the total fluorescence has decreased by 50% can then be calculated 
giving a corresponding DC50 value.  
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Figure 3.34  LD spectrum of 300 μM ct-DNA (B-DNA) in 20 mM NaCl and 1 mM 
Na(CH2)2AsO2.3H2O (pH 6.8) with the addition of increasing concentrations of 
[Re(CO)3(py)(ibiq)][CF3SO3]. Legend to the right shows the ct-DNA:complex ratios. 
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Thiazole orange (Fig. 3.35) was chosen as the dye of choice because of its highly 
fluorescent nature when bound to DNA compared with its lack of fluorescence in solution.  
It has a binding affinity of 2 to 3 × 10
6
 M
-1
 with both quadruplex and duplex DNA 
showing no selectivity for one structure over the other.
[18]
  TO binds in an intercalative 
fashion to duplex DNA between base pairs whereas with G-quadruplexes it binds to a 
tetrad in a single site manner with the loops helping to play a part in its structural 
accommodation.
[19][20]
  Htelo and c-myc quadruplex forming DNA strands were used to 
investigate how well the complex displaced the TO from a quadruplex structure and ds26 
was used as the duplex comparison (ds12 and ds17 previously investigated by Teulade-
Fichou demonstrating that duplex sequence length does not affect binding).
[18] 
 
 
 
 
 
 
 
 
 
The number of thiazole orange dye molecules that can bind to each type of DNA 
investigated has also been reported by Teulade-Fichou using a combination of mass 
spectrometry and fluorescent titration techniques.
[19]
 The mass spectrum corresponding to 
Fluorescent Non Fluorescent Non Fluorescent 
Thiazole 
orange 
Thiazole 
orange 
Figure 3.35  Above. Structure of the dye thiazole orange, Below. A schematic of how the ligand 
tested alters the fluorescence of the solution to indicate binding. 
Thiazole  
orange 
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the telomeric DNA system is shown in Fig. 3.36 where the predominant DNA+TO peak is 
that of the 1:1 ratio.
[18]
  Using the same techniques the ratio of TO and ds26 was found to 
be 2:1.
[18]
  To achieve competitive displacement by the ligands the experimental ratios of 
TO:DNA were 2:1 for the telomeric DNA (also c-myc DNA) and 3:1 for the ds26 DNA.
[18]
 
 
 
 
 
 
 
 
 
 
The experiment can potentially provide information on the selectivity of the ibiq 
complexes for quadruplex over duplex DNA and also for one type of G-quadruplex 
structure over another.  This is determined by the amount of complex that is required to 
reduce the fluorescence intensity of thiazole orange which is read after every titration (TO 
absorbs light at 501 nm and emits at 550 nm).  The thiazole displacement can be calculated 
by working out the area of the initial emission curve (510 nm - 750 nm) with the DNA and 
TO only and taking away the fluorescence area of the curve after each time the complex is 
added.  A DC50 value is read from the resulting chart which is the concentration at which 
the TO fluorescence has reduced by 50 %.  Terpyridine and salphen complexes in the 
literature reported by Vilar et al have DC50 values ranging from 0.17 μM to > 2.5 
μM.[14][21] Complexes that can be considered as 'good binders' must have a DC50 value that 
Figure 3.36  ESI-MS proﬁle of the association of TO with htelo DNA obtained with 5 mM of 
DNA and 10 mM of TO, in 150 mM ammonium acetate, 15% MeOH. [Reproduced from Ref 
18
] 
 Chapter 3: DNA Binding Studies 
 
 
167 
 
does not exceed the 0.5 μM 'threshold' that has been established for this type of analysis.[22] 
The FID experiments were carried out in potassium rich buffer only as this most resembled 
physiological conditions.  Solvent controls showed no decrease in fluorescence when 
titrated alone into a TO-DNA solution.     
 
3.4.1  Titrations with htelo 
When the palladium complex was titrated into the TO-DNA solution there was a 
significant decrease in the fluorescence on recording the emission spectrum.  With 
subsequent additions of the complex the fluorescence decreased further and the 50 % 
displacement mark was reached at low levels of complex.  The same was true of the 
platinum complex which had a very similar effect when titrated into the fluorescent 
mixture.  In Fig. 3.37 the decrease in fluorescence can be seen for the two complex 
titrations along with a comparison of the two complexes after calculating the percentage 
displacement after each addition of complex using the following equation (where FA is the 
fluorescence area and FA0 is the fluorescence area of bound TO without added complex): 
 
% Displacement = 100 - [(FA-FA0) × 100] 
 
Both complexes displace the TO initially to similar extents however as the concentration of 
the complexes increase the platinum complex is able to displace slightly more of the dye 
before reaching an equilibrium.  The overall difference between the complexes is very 
much as to be expected after considering the CD results where both complexes showed 
similar spectra upon binding to the htelo DNA. 
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3.4.2  Titrations with c-myc 
When the same titrations were carried out using the c-myc DNA strand more of a 
difference was noted between the palladium and platinum complex, and the decrease in 
fluorescence of the TO-DNA (Fig. 3.38).  The platinum complex showed a similar result to 
the htelo DNA titration where at low concentrations of complex the fluorescence 
significantly decreased.  This was not true for the palladium complex which was unable to 
displace the TO at such low concentrations indicating that the binding affinity of the 
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Figure 3.37  a. Emission spectrum for the palladium complex when titrated into 0.25 μM htelo 
DNA solution containing  100 mM KCl / 10 mM Na cacodylate + 0.5 μM TO, b. Emission 
spectrum for the platinum complex when titrated into 0.25 μM htelo DNA solution containing  
100 mM KCl / 10 mM Na cacodylate + 0.5 μM TO. c. Percentage TO displacement comparison.  
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palladium complex towards the c-myc DNA quadruplex is less than that between the same 
type of DNA and the platinum complex.  The CD spectra for the palladium complex with 
the c-myc DNA also showed a lack of interaction when compared with htelo DNA.  The 
platinum complex on the other hand showed a strong yet different response (negative ICD 
peaks were now present) showing that there was a good interaction between itself and the 
c-myc DNA which is consistent with the FID data produced. 
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Figure 3.38  a. Emission spectrum for the palladium complex when titrated into 0.25 μM cmyc DNA 
solution containing  100 mM KCl / 10 mM Na cacodylate 0.5 μM TO, b. Emission spectrum for the 
platinum complex when titrated into 0.25 μM cmyc DNA solution containing  100 mM KCl / 10 mM 
Na Cacodylate 0.5 μM TO, c. Percentage TO displacement comparison. 
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3.4.3  Titrations with ds26 
When the titrations were carried out with duplex DNA the emission signal decreased very 
little upon increasing amounts of complex (Fig. 3.39 and 3.40).  Both of the complexes 
exhibited similar behaviour with much complex needed to reach the 50 % displacement 
concentration (the palladium complex failed to reach displacement concentration).  The 
lack of displacement of the TO by the two complexes suggests they bind much more 
weakly to duplex DNA than the TO.  However another explanation could be that the 
complex is binding to the duplex DNA without displacing the TO.  The lack of binding is 
not reflective of the CD analysis of the complexes with B-DNA where very strong ICD 
signals are seen indicating the occurrence of binding events.  After consideration of both 
sets of results it appears that the complexes will bind to duplex DNA if there are no 
competitors, as evidenced by the CD response.  The binding affinity however is not high 
enough to be able displace another binder, like TO, leading to the lack of displacement 
seen in the FID experiments.  
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Figure 3.39  a. Emission spectrum for the palladium complex when titrated into 0.25 μM ds26 DNA 
solution containing  100 mM KCl / 10 mM Na cacodylate 0.75 μM TO, b. Emission spectrum for 
the platinum complex when titrated into 0.25 μM ds26 DNA solution containing  100 mM KCl / 10 
mM Na Cacodylate 0.75 μM TO. 
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3.4.4  Comparison of DC50 Values 
The DC50 values (concentration at which TO fluorescence has reduced by 50 %) calculated 
for both complexes with htelo, c-myc and ds26 DNA are shown in Table 3.1.  With htelo 
DNA both complexes are just around the '0.5 μM threshold' therefore can be considered as 
good binders.  Results for c-myc DNA show much more of a difference between the two 
complexes with the palladium complex displaying a DC50 value twice the required 
threshold and the platinum complex showing the lowest displacement concentration seen 
in the FID experiments conducted.  More importantly with regards to selectivity, the DC50 
values calculated for the ds26 DNA are quite high indicating that the complexes are more 
selective for quadruplex DNA over duplex DNA based on this analysis. 
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Figure 3.40  % TO displacement comparison for the palladium and platinum complexes with ds26 
DNA. 
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 DC50 / μM 
htelo c-myc ds26 
[Pd(ibiq)2][BF4]2 0.57 ± 0.12 1.03 ± 0.49 6.25 ± 0.45
* 
[Pt(ibiq)2[PF6]2 0.55 ± 0.14 0.31 ±0.10 2.47 ± 0.48 
 
The selectivity of the complexes for one type of DNA over another have been calculated in 
The selectivity of the complexes for one type of DNA over another have been calculated in 
Table 3.2.  The greatest difference in selectivity, 11 fold, is seen for the palladium complex 
when comparing the DC50 values of the complex with htelo and ds26 DNA.  The palladium 
complex is also more selective for c-myc DNA over ds26 and also shows selectivity 
between different types of quadruplexes (preferring htelo over c-myc).  The platinum 
complex is also more selective towards quadruplex DNA over duplex with its highest 
degree of selectivity occurring for c-myc DNA over ds26 DNA.    
 Selectivity [DC50(A)/DC50(B)] 
ds26/htelo ds26/c-myc htelo/c-myc c-myc/htelo 
[Pd(ibiq)2][BF4]2 10.96 ± 2.44 6.07 ± 2.92 - 1.81 ± 0.94 
[Pt(ibiq)2[PF6]2 4.49 ± 1.44 7.97 ± 3.00 1.77 ± 0.73 - 
 
 
The combination of the CD and FID results suggest that the complexes bind by stacking on 
top of the G-quartet displacing the TO and lowering the fluorescence.  In the case of the 
palladium complex with the c-myc DNA, displacement of the TO requires higher complex 
concentrations indicating that it doesn't stack as well on the c-myc quadruplex or the 
complex is binding to a different site.      
 
Table 3.1  DC50 values calculated for palladium and platinum FID complex titrations with htelo, cmyc and 
ds26 DNA. 
* 
estimated value as result extrapolated due to 50 % displacement mark not being reached.  
Table 3.2  Selectivity comparison between the different types of DNA investigated.  
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3.5  UV-Vis Absorption Spectroscopy Titrations (Complexes 5 and 7) 
 
Ultraviolet-visible absorption spectroscopy titrations are used to investigate how the 
complexes bind to the DNA by analysing the degree of hypochromicity and measuring red 
shifts.  The presence of both these factors is linked to DNA binding by intercalation, direct 
metal-base binding and end stacking.
[23]
   The red shift can be the result of a π* orbital from 
the ligand coupling with a π orbital from the DNA bases (an energy decrease is associated 
with the π - π* transition causing a peak shift to a longer wavelength) or a change of 
polarity of environment.
[23]
  The stronger the interaction between orbitals the greater the 
hypochromicity and red shift will be.
[24]
  Hypochromic effects without the additional red 
shift may be attributed to non-covalent DNA loop (groove) or backbone binding.
[14]
  The 
UV-vis spectrum may also show hyperchromicity which is linked to electrostatic binding 
(external contact - DNA backbone) or the denaturing (melting) of the DNA where the 
DNA bases are more flexible and less shielded from absorbing light.
[25]
  The titration can 
be used to calculate binding constants on the assumption that the binding between the 
complex and the DNA is 1:1. 
 
During each experiment the complex UV-vis spectrum is measured first and then 
monitored whilst DNA is titrated into the solution.  A blank titration is also carried out at 
the same time in order to remove any DNA peaks that absorb in the same region as the 
complex.  The solvent control used in the blank titration showed no effect on the DNA.  
All titrations were carried out in potassium rich buffer to best match physiological 
conditions.   
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3.5.1  [Pd(ibiq)2][BF4]2- Titrations with htelo, c-myc and ct-DNA 
When the htelo DNA was added to the palladium complex solution the absorbance at 252 
nm, due to ligand π-π* transitions, decreased significantly (43%).  A red shift of 5 nm was 
observed in the presumed MLCT region (at 368 nm) only, which begins to appear at a 1:1 
ratio of complex:DNA (Fig. 3.41 - a).  The same response occurred when c-myc DNA 
instead was added to the palladium complex solution.  The absorbance peak at 250 nm 
showed a similar degree of hypochromicity (41 %) and the only red shift (6 nm) was 
observed in the MLCT region when a new peak emerges at a complex:DNA of 1:1 (Fig. 
3.41 - b).  The emergence of the new peak in the MLCT region with both types of DNA 
creates an isosbestic point at 371 nm indicating that interconversion is occurring between 
two species.  Considerable hypochromicity and large red shifts can be indicative of both an 
end stacking and direct coordination binding mode.
[15]
  The change in the coordination 
sphere may be due to the loss of a ligand from the palladium centre caused by the bond 
strain of the bowed structure.  This result, however, is surprising for the c-myc DNA 
interaction because in the CD experiments no ICD peaks relating to binding were seen.  
Therefore the response could be due to end stacking as it was presumed that the parallel 
loops wouldn't be as accessible for the [Pd(ibiq)]
2+ 
to bind to.  
 
When examining the interaction of the palladium complex with ct-DNA a hypochromic 
effect was again observed (43 %) with the same magnitude of red shift occurring (6 nm) in 
the MLCT region (Fig. 3.42).  It is suspected therefore that the palladium complex again 
loses a ligand and binds  in a coordinative manner to the duplex DNA bases.   
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Figure 3.41  a. UV-Vis titration of htelo DNA into 7 μM [Pd(ibiq)2]
2+
 solution, ratio of complex:htelo 
DNA shown in the legend and binding curve plotting Cf versus r. b.UV-Vis titration of cmyc DNA into 
7 μM [Pd(ibiq)2]
2+
 solution, ratio of complex:c-myc DNA shown in the legend and binding curve 
plotting Cf versus r. 
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3.5.2  [Pt(ibiq)2][PF6]2 - Titrations with htelo, c-myc and ct-DNA 
The absorbance spectrum for the platinum complex with htelo DNA also displays 
considerable hypochromicity (48 %) with a loss of absorbance of 15 % after the first 
addition of DNA at 262 nm (Fig. 3.43 - a).  The initial titration of DNA also induces an 
immediate red shift (10 nm) of the MLCT band (380 nm).  These changes that occur in the 
absorbance spectrum after so little addition of the htelo DNA again indicate that end 
stacking and/or direct coordination are the possible binding modes between the complex 
and the DNA.  End stacking was thought to be the most probable binding mode as the 
platinum demonstrates slower coordination rates than palladium however the extent of 
bowing in the structure may lead to a coordination route.  Further to this upon increasing 
amounts of htelo DNA the new red shifted peak at 390 nm increases in absorbance.  
Despite the apparent conversion of one species to another no isosbestic point could be 
located as the initial conversion is not a gradual one.  This is indicated by the sudden red 
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Figure 3.42  Left. UV-Vis titration of ct-DNA into 7 μM palladium solution, ratio of complex:ct-DNA 
shown in the legend, Right (top) - Scatchard plot for binding constant calculation, Right (bottom) - UV-
vis stability solutions showing the red shift of the ct-DNA + Pd complex solution compared with the 
complex solution alone, both at 0 h. 
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shift after adding DNA.  Titrations conducted with c-myc DNA show hypochromic 
changes of 46 % at 262 nm and a red shift of 12 nm in the MLCT region (381 nm - 393 
nm) (Fig. 3.43 – b).  An isosbestic point can be seen in this system at 388 nm.  All of these 
observations indicate that the DNA is most likely binding to the complex in an end 
stacking mode. 
 
Finally the interaction of the platinum complex with ct-DNA was investigated.  The UV-
vis spectrum shows the greatest degree of hypochromism of all the DNA-complex systems 
with a 54 % loss in absorbance (Fig. 3.43 - c).  A red shift of 10 nm is seen in the MLCT 
region at a complex:DNA ratio of 1:1 which is very similar to the red shift seen with the 
quadruplex forming DNA.  Both of these effects are consistent with direct coordination of 
the platinum to DNA bases unless the ligand is intercalating between the base pairs 
instead.  Each type of DNA differs by the ratio of complex:DNA at which the red shift 
occurs, for the quadruplex systems this is 60:1 (htelo) and 6:1 (c-myc).  Hence the 
interconversion between the two species (bound and unbound) occurs at lower DNA 
concentrations for htelo and c-myc, and a higher concentration for ct-DNA.   
 
In a hypothesised competitive system, if both types of DNA (quadruplex and duplex) were 
present, the results indicate that the complex would stack onto the quadruplex DNA at low 
loading concentrations.  This would generate the new species which causes the red shift 
before the complex could coordinatively bind to the ct-DNA (which has a red shift that 
occurs at high complex loading concentrations).        
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Figure 3.43 a. UV-Vis titration of htelo DNA into 7 μM [Pt(ibiq)2]
2+
 solution, ratio of complex:htelo 
DNA shown in the legend and binding curve plotting Cf versus r. b. UV-Vis titration of cmyc DNA 
into 7 μM platinum solution, ratio of complex:c-myc DNA shown in the legend and binding curve 
plotting Cf versus r, c. UV-Vis titration of ct-DNA into 7 μM platinum solution, ratio of complex:ct-
DNA shown in the legend and Scratchard plot to calculate the binding constant. 
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3.5.3  Binding Constant Comparison 
Absorption was measured at 268 nm in each system in order to make a direct comparison 
between them.  The MLCT region would have been the preferred choice to calculate a 
binding constant however the platinum complex titrations in this region are comprised of 
overlapping shifts which make it difficult to calculate. Two methods have been used to 
calculate the binding constant, one for the ct-DNA whose base sequence hence strand 
concentration is unknown and one for the quadruplex DNA (htelo and c-myc) which have 
defined sequences with accurately measured strand concentrations.  Both methods have 
been reported in the literature
[23]
, most relevantly in work published by Shankar 
Balasubramanian.
[26] 
 
Method 1: 
The method used for ct-DNA systems uses the equation below
[23][26]
: 
 
[DNA] / (εa - εf) = [DNA] / (εb - εf) + [Kb (εb - εf)]
-1
 
 
In this equation [DNA] is measured in bases, εa is the observed absorbance/[complex], εf is 
the extinction coefficient for the free complex and εb is the extinction coefficient for the 
complex in its fully bound form.  Plotting [DNA]/(εa - εf) versus [DNA] gives the intercept 
as [Kb (εb- εf)]
-1
.  Binding constant determination for the palladium complex binding to ct-
DNA can be found in Fig. 3.42 and for the platinum complex Fig. 3.43 - c (pages 176 and 
178). 
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Method 2: 
A one site binding isotherm has been used to determine quadruplex DNA binding 
constants
[26]
: 
r = BmaxCf/Kd+Cf 
 
The above equation can be used after calculating Cf (concentration of free ligand) which is 
determined from Cf = (1 - α) × C, where C is the [complex]tot and α is the fraction of 
complex that is bound to the DNA {α = (Af - A) / (Af - Ab)}, Af = absorbance of free 
complex and Ab = absorbance of fully bund complex. The binding function r (where r = 
Cb/[DNA] and Cb = C - Cf) is then plotted against [Cf] and analysed by nonlinear 
regression using Sigmaplot version 10.  Graphical results for the palladium complex with 
htelo and c-myc DNA and the platinum complex with htelo and c-myc DNA can be found 
in Fig. 3.41 - a, 3.41 - b, 3.43 - a and 3.43 - b respectively (pages 175 and 178). All the 
quadruplex DNA data fit the one site binding isotherm. 
 
Results: 
The binding results for the complex and DNA systems tested using UV-vis spectroscopy 
are shown in Table 3.3.  The ratios of affinity for the palladium complex and the platinum 
complex to htelo and cmyc are approximately the same but reversed.  It appears that all 
three types of DNA bind well to the platinum complex which again is suggested in the CD 
results where an intense spectrum is generated in each titration.   
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DNA Type 
Intrinsic binding constant / M
-1
 
[Pd(ibiq)2][BF4]2 [Pt(ibiq)2][PF6]2 
ct-DNA (3.0 ± 2.0) × 10
5
 (1.0 ± 0.5) × 10
6
 
htelo (2.5 ± 1.0) × 10
6
 (1.8 ± 0.4) × 10
6
 
c-myc (4.0 ± 1.9) × 10
5
 (9.7 ± 6.0) × 10
6
 
 
 
3.6  
1
H-NMR Experiments with Complex 7 
Work in collaboration with H. Guiset-Miserachs, Dr. D. Donghi and Prof. R. Sigel of 
the University of Zürich - Experiments run by Dr. D. Donghi and samples prepared by 
Hannah Pritchard. 
 
Proton NMR spectroscopy is environment sensitive and the presence of binding can be 
accurately monitored by studying the movement and symmetry of peaks.  Two types of 
analysis were conducted using an AV700 MHz spectrometer that was equipped with a TXI 
z-gradient CryoProbe which was able to detect a reagent concentration of 100 μM. The 
experiments were conducted in the NMR facility of the Chemistry Department at the 
University of Zurich.  The platinum complex was chosen for the NMR experiments as it 
showed the best binding potential in the previous DNA binding experiments.  Htelo DNA 
was used to assess the complex-quadruplex binding interaction.      
 
3.6.1  1D 
1
H-NMR 
The first type of analysis discussed is simply 1D 
1
H-NMR spectroscopy which with the use 
of the AV700 MHz spectrometer could produce well resolved NMR spectra requiring very 
Table 3.3 Summary of binding constants calculated using a 1:1 binding isotherm for htelo and cmyc 
DNA and Scatchard plot for ct-DNA, uncertainty calculated from average of three.  
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little amounts of DNA.  The concentration of htelo DNA and the platinum complex were 
kept constant at 100 μM for all experiments (in 85 % H2O, 15 % d6-DMSO, 50 mM KCl) 
to make sure that any changes to the NMR spectrum were not due to concentration effects. 
 
The platinum complex 
1
H-NMR is shown at the bottom of Fig. 3.44 - d, the spectrum 
above this (c) is the htelo DNA alone.  In this spectrum imino proton peaks can be seen 
between 10 ppm and 12 ppm which result from the exchange of protons within the 
terminal G-quartets.  Well defined imino peaks indicate a unique structure has been 
adopted whereas poorly defined peaks are the result of multiple quadruplex structures; the 
latter appears to be the case for this system.
[27]
  Imino proton exchange within this region 
occurs due to the more distorted or flexible nature of the end quartets in the quadruplex 
structure; the other imino protons from inner quartets exchange much more slowly.
[27][28]
 
 
Spectrum b in Fig. 3.44 shows the htelo DNA and complex in a 1:1 mixture where new 
peaks have appeared on the very edge of the imino proton region around 12.8 ppm.  Most 
of the undefined imino proton peaks that were present in the DNA spectrum only, have 
remained in the same place.  The new set of peaks between 8 - 10 ppm are hard to 
distinguish as they appear too low for imino protons.  The complex peaks are no longer 
present at the same chemical shifts when mixed with the DNA and are also very difficult to 
locate on the 1:1 spectrum.  The addition of one equivalent of complex has generated a 
further mix of quadruplex structures one of which may be that of the complex bound to the 
DNA.  
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In the top spectrum a two equivalents of complex have been added causing the initial 
imino sequence seen in the DNA only spectrum to disappear leaving a more defined set of 
proton peaks between 10.5 - 12.8 ppm.  The peaks between 8.0 - 10.5 ppm have remained 
constant and therefore may be a combination of complex and other DNA protons.  The 
shift of imino protons is a good indication that the complex is interacting with the htelo 
DNA through an end stacking binding mode.   
 
 
 
 
 
 
Figure 3.44  1D
1
H-NMR spectra where the concentration of each species is 100 μM (200 μM for 2 
equiv of Pt complex), in 15 % d6-DMSO, 85 % H2O, 50 mM KCl : a. Htelo DNA:platinum complex 
(1:2), b. Htelo DNA:platinum complex (1:1), c. Htelo DNA alone, d. Platinum complex alone. 
(d) 
(b) 
(c) 
(a) 
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The same NMR experiments were then conducted in D2O in order to remove the imino 
protons from the spectra (due to their fast exchange rates) so an attempt could be made to 
identify the complex peaks.  The resulting spectra can be seen in Fig. 3.45 where by 
superimposing the red spectrum (DNA+complex+H2O+d6-DMSO) over the blue spectrum 
(DNA+complex+D2O+d6-DMSO) the imino protons could be identified.  The peaks that 
remain could have come from both the complex and the other non imino protons of the 
DNA.   
 
The symmetry of the complex peaks alone could not be matched anywhere on the spectrum 
when in the DNA mixture.  This indicates the complex is bound to the DNA because if the 
complex wasn't properly bound and just spinning on the top of the quadruplex the 
symmetry of the complex would appear exactly the same.  Along with the change in 
symmetry there is a definite chemical shift further indicating that binding has taken place.  
 
 
 
 
 
Figure 3.45  Overlaid spectra of blue - DNA:complex (1:2) in D2O and red - DNA:complex (1:2) 
H2O. 
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3.6.2  DOSY 
Diffusion-ordered spectroscopy (DOSY) can be used to separate NMR responses of 
different compounds by their diffusion coefficient which depends on the size and shape of 
the molecule, temperature and viscosity of the solution.  The technique can also assess 
aggregate formation and the degree of solvation around the molecule in question.
[28]
  The 
diffusion coefficient (if shape of the molecule is spherical) can be described by the Stokes-
Einstein equation where D (diffusion coefficient) is linked to KB - Boltzmann constant, T - 
temperature, η - viscosity and r - radius of the molecule.[29] 
 
Stokes-Einstein Equation: D = KBT/6πηr 
 
The translational diffusion of the molecules is measured using pulsed magnetic field 
gradient NMR (PFG-NMR) spectroscopy where the usage of a gradient allows molecules 
to be labelled depending on their location in the sample tube.
[29]
 Larger molecules will 
diffuse slowly giving a stronger signal as more nuclei will remain in place that can refocus 
whereas smaller molecules diffuse quickly and become out of range therefore cannot 
refocus.
[29] 
 An example of a diffusion decay curve is shown in Fig. 3.46 which generated a 
diffusion coefficient of 2.787 × 10
-10
 m
2
/s.  This was plotted by the Bruker NMR software 
using the equation below where I - intensity observed, I0 - unattenuated signal intensity, D 
- diffusion coefficient, g - gradient strength, δ - gradient length, Δ - diffusion time and γ - 
gyromagnetic ratio.
[29]
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DOSY spectra were generated for three systems htelo only; (100 μM), htelo (100 μM) + 
platinum complex (100 μM) and platinum complex only (100 μM).  All the experiments 
were conducted in 85 % H2O / 15 % d6-DMSO at 25 °C.  In Fig. 3.47 the three DOSY 
spectra have been overlaid to show how the diffusion coefficient has changed between 
each system.  The purple trace shows the complex alone displaying the greatest rate of 
diffusion through the solution as it is the smallest system of the three examined.  The peak 
centred around 4.75 ppm is due to the DMSO which couldn't be reduced or eliminated 
from the spectra.  The system in green is that of the DNA alone which diffuses at a slower 
rate due to its larger size.  Finally the blue DOSY spectrum represents a mixture of the 
DNA and platinum complex together where only one molecule has been identified as only 
one diffusion coefficient is shown.  If the complex wasn't bound to the DNA it would be 
Figure 3.46 Diffusion decay curve for Platinum complex 7 (100 μM) in a 85% H2O, 15% d6-DMSO 
solution. 
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free to diffuse at a faster rate through the solution producing another set of correlation 
spots on the spectrum.  The absence of any additional spots displaying a different diffusion 
coefficient and the additional spots produced at the diffusion coefficient recorded indicates 
that the complex has bound to the DNA.   
 
 
 
 
The diffusion coefficient estimate for each system is displayed in Table 3.4 which has been 
used to calculate the corresponding radii using the Stokes-Einstein equation.  The viscosity 
of this system containing 85 % H2O and 15 % d6-DMSO has been previously reported by 
Figure. 3.47  Overlaid DOSY spectra for purple - platinum complex 7 (100 μM) in a 85% H2O, 15% 
d6-DMSO solution, green - htelo DNA (100 μM) in a 85% H2O, 15% d6-DMSO solution, blue - 
Pt:DNA (2:1) (100 μM DNA, 200 μM Pt complex) in a 85% H2O, 15% d6-DMSO solution. 
Pt:DNA 
(2:1) 
DNA alone 
Pt complex 
alone 
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Sacco and Matteoli as 0.429 mPa/s at 25°C (obtained from plotting reported ratios versus 
viscosity to obtain a result for 15 % d6-DMSO).
[30]
 
System Studied 
Diffusion Coefficient 
Estimate (m
2
/s) 
Radius (nm) 
Pt complex(7) 2.8 × 10
-10 
1.8 
htelo DNA 1.6 × 10
-10 
3.3 
htelo DNA + Pt complex 
(7)  (1:2)  
1.3 × 10
-10 
3.9 
 
 
 
When the complex is bound to the DNA there appears to be an increase in molecule radius 
when compared with the DNA alone.  The longest reported dimension of the platinum 
complex alone from its crystal structure is 1.35 nm (diameter) which does not correspond 
with the estimated experimental radius of 1.82 nm therefore diameter of 3.64 nm.
[31]
  A 
strong possibility to account for this is the aggregation of the complex in solution.  The 
complex has been designed to effectively stack on a flat planar surface therefore it may be 
stacking on top of itself giving the appearance of a larger molecule in solution hence a 
larger radius.  It appears though that when binding to the DNA it may no longer be in its 
aggregated form as the additional length of radius (from DNA alone to DNA with 
complex) corresponds more closely with the single molecule binding only.  The high 
concentration of DNA and complex in this experiment may be the cause of the aggregation 
(100 μM DNA, 200 μM [Pt(ibiq)2]
2+
); the CD experiments required much lower 
concentrations (3 μM DNA) therefore would be less likely to exhibit this effect.  
Table. 3.4  Summary of diffusion coefficients and radii estimates calculated using the following 
constants: KB = 1.380 × 10
-23
 J K
-1
, T = 298 K, η = 4.29 × 10
-4
 Pa s, π = 3.14. 
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3.7   Gel Electrophoresis Studies 
 
The sugar phosphate backbone of DNA is negatively charged therefore during an 
electrophoresis experiment the DNA will migrate through the gel matrix towards a 
positively charged electrode.  The speed by which the DNA fragments move through the 
gel depends upon their size; with smaller fragments moving rapidly through the gel and 
larger fragments moving more slowly.
[32]
  Overall DNA charge and conformation can also 
affect how quickly the molecule moves through the gel.  Two types of gel electrophoresis 
experiment have been used to examine how the complexes bind to different types of DNA: 
 
- Agarose gel electrophoresis is used with larger molecules such as plasmid DNA (pBR322 
double stranded circular DNA) to investigate the duplex binding ability of the complexes.  
The technique offers a large separation range but with limited resolution of the DNA. 
 
- Polyacrylamide gel electrophoresis (PAGE) is used for smaller sequences of DNA (22 
base htelo sequences) and gives a better resolution of the DNA molecules, however it only 
has a small range of separation. 
 
3.7.1  Agarose Gel Electrophoresis with Complexes 5 and 7 using Plasmid DNA 
In order to probe the interaction between duplex DNA and biisoquinoline complexes 5 and 
7 a double stranded supercoiled DNA plasmid was used.  The supercoiling nature of DNA 
has been observed in living cells and is particularly important in processes that require 
DNA duplex unwinding such as transcription.
[33]
 The negative supercoiled (under wound) 
DNA in the c-myc promoter region for example enables the formation of G-
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quadruplexes.
[34]
  The closed circular DNA structure is useful for the study of DNA-
complex interactions because the plasmid will take on a different form depending on how 
the complex interacts with the DNA.   
 
For complexes that aren't able to break the sugar phosphate DNA backbone the plasmid 
will remain in the supercoiled form and any complex binding will be observed by the 
slower migration of the supercoiled band through the gel.
[35]
  When the complex is able to 
cause DNA cleavage of one strand, the supercoiled form relaxes into a nicked circular 
open form which travels more slowly through the gel; cleavage of both strands leads to the 
linear form which if present can be found between the supercoiled and nicked circular 
forms.
[35]
  This is shown schematically in Fig. 3.48. 
 
The experiment is set up so that the agarose gel contains a selection of wells to which are 
added different ratio's of complex to pBR322 DNA. Once loaded, an electric field is 
applied which causes the negatively charged DNA to move towards the positive electrode 
(Fig. 3.48). The extent to which the DNA moves depends upon its supercoiled or nicked 
circular structure and its charge.  The supercoiled structure is more compact therefore will 
have a different migration speed to the larger nicked circular structure . 
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The forms of the DNA are visualised in the gel using ethidium bromide which binds to 
DNA through an intercalative mode.  This fluorescent stain can be easily detected by UV 
light thus allowing the position of the DNA in the gel to be seen.   
 
Complex binding to the negatively supercoiled DNA can cause changes in the rate that the  
DNA migrates across the gel.  The effectiveness of the complex-DNA interaction can be 
investigated by treating the DNA with different ratios of complex and observing any 
change to the position of the supercoiled band when compared with a control.  The 
negatively supercoiled DNA is underwound so if the complex increases the positive 
supercoiling then the extent of negative supercoiling is decreased.  Intercalators, for 
example, positively supercoil because the site they bind at is effectively unwound.  This 
causes a stiffening of the DNA when taking up the slack of underwinding.   
 
The following experiments were conducted to assess whether the biisoquinoline complexes 
would display any significant unwinding behaviour or other binding activity with duplex 
DNA.  The plasmid has no telomeres (as circular) and tetrads are not expected to form in 
Circular plasmid 
Figure 3.48  Pictorial example of a gel electrophoresis experiment indicating the direction of 
migration of the DNA and the location of the nicked circular and supercoiled plasmid after 
visualising using ethidium bromide and UV light.   
Linear plasmid 
Supercoiled plasmid + 
- 
 Chapter 3: DNA Binding Studies 
 
 
192 
 
any promoter regions therefore this experiment is probing intercalation or other duplex 
binding modes   Different ratios of complex to DNA were loaded onto a 1% agarose gel 
before applying an electric potential.  After running the gel the DNA was visualised using 
ethidium bromide and UV light to assess the extent of complex-DNA interaction.   
 
[Pd(ibiq)2][BF4]2 - 5 
The pBR322 plasmid DNA was treated with the palladium complex in DNA:complex 
ratios from 40:1 to 2:1.  Due to the insolubility of the complex in water alone a small 
percentage of DMSO was required to completely dissolve it.  Controls using both DMSO 
and water were used to make sure that the addition of the DMSO had no effect on the 
unwinding of the DNA.  Before the gel was loaded with the samples, the DNA and 
complex mixtures were left at room temperature for 2 hours.    
      
Very little change can be seen from the UV visualised agarose gel at the end of the 
experiment (Fig. 3.49).  A small amount of movement of the supercoiled band (sc) starts to 
occur at a ratio of 5:1 indicating that there is a small amount of binding to the supercoiled 
structure slowing the rate of migration through the gel.  The separation between the 
supercoiled (sc) and open circular (oc) bands is reduced at high loading indicating some 
DNA unwinding but this is a small effect and cannot be readily quantified from this 
experiment.  There is little evidence for a strong interaction with this plasmid DNA which 
in order for it to be a selective quadruplex binder shows good promise.  The result 
contrasts with the CD data where the strong ICD peaks produced for a linear genomic ct-
DNA suggest there is a more significant interaction between the complex and the DNA.   
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[Pt(ibiq)2][PF6]2 - 7 
As with the palladium complex the platinum complex required a small amount of DMSO 
to fully dissolve the complex in H2O.  The gel electrophoresis results show that there is a 
gradual reduction in the migration rate of the supercoiled band as the concentration of the 
platinum complex increases (Fig. 3.50).  Even at the lowest concentration addition of the 
complex there is an immediate shift of the supercoiled band when compared with the 
control in lanes 1 and 13.  This indicates that either the complex is binding to the 
supercoiled DNA and unwinding it or binding and retarding its movement.  The circular 
band can also be seen to migrate more slowly through the gel on the addition of the 
- 
Figure 3.49  Agarose gel electrophoresis (1% agarose) showing the migration of the supercoiled and 
nicked circular forms of the DNA plasmid when an electric potential is applied.  pBR322 was treated 
with the complex and then left at 20°C for 2 hours before the gel was run.  Control lanes without 
complex 1-DMSO, 2-H2O, 14- H2O, lanes 3-13, DNA:complex ratios, 2:1, 3:1, 4:1, 5:1, 6:1, 8:1, 
10:1, 15:1, 20:1, 30:1, 40:1. 
+ 
1          2         3          4         5         6          7         8         9        10       11       12       13      14   
+ 
Complex 
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complex.  At a DNA:complex ratio of 8:1, the supercoiled band becomes more strained 
and can no longer be seen.   It appears to have been wound into the circular form however 
this movement could again be due to band retardation.  The increase in concentration of 
complex from 6:1 to 2:1 sees the further retardation of the circular band and the 
appearance of a new band in between the original two.  It is likely that the charge on the 
open circular plasmid is quenched through the binding of many positively charged 
complexes, retarding its movement through the gel.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is no surprise that the platinum complex has shown that it is able to bind to duplex DNA 
in the gel electrophoresis experiments as in all other experiments, regardless of the type of 
DNA, the complex has produced results that indicate significant binding.   
- 
Figure 3.50  Agarose gel electrophoresis (1% agarose) showing the migration of the supercoiled and 
nicked circular forms of the DNA plasmid when an electric potential is applied.  pBR322 was treated 
with the complex and then left at 20°C for 2 hours before the gel was run.  Control lanes without 
complex 1-DMSO, 13-H2O, lanes 2-12, DNA:complex ratios, 2:1, 3:1, 4:1, 5:1, 6:1, 8:1, 10:1, 15:1, 
20:1, 30:1, 40:1. 
+ 
1          2            3          4           5           6           7           8           9          10         11         12       13    
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3.7.2  Non-denaturing PAGE with Complexes 5 and 7 using htelo and c-myc DNA 
Work in collaboration with H. Guiset-Miserachs, Dr. D. Donghi and Prof. R. Sigel of 
the University of Zürich - Experiments conducted by Hannah Pritchard  
 
Polyacrylamide gel electrophoresis works very much in the same way that agarose gel 
electrophoresis does but is suited to smaller DNA fragments because of the smaller pore 
size created by the gel forming process.
[36]
 
 
The visualisation of DNA in the gel can be achieved using many techniques.  In the 
experiments with the ibiq complexes UV light alone was used to locate the DNA bands 
however a more widely used way to visualise the DNA involves radiolabelling specific 
fragments of DNA  and recording an autoradiogram.
[37]
  Radioactive labelling is useful as 
very small quantities of DNA can be used as the technique is highly sensitive.
[37]
  Another 
labelling technique involves the attachment of a fluorescent label to the DNA strand such 
as FAM (6-carboxyfluorescein) which again is highly sensitive requiring very little 
quantities of DNA due to the highly fluorescent nature of the appended ligand.  A 
fluorescent dye used to specifically target quadruplexes called protoporphyrin IX (PPIX) 
has been used to identify bands linked to quadruplex formation and silver staining has also 
been used.
[38][39]
 
 
As mentioned above UV light alone was used to visualise the DNA following the PAGE 
experiment with the location of the bound complex to the DNA verified by extracting the 
DNA and complex from the gel spot and recording a UV-Vis spectrum.  The technique 
required a large amount of DNA (3 nmole) to be seen with ease using UV light (λ= 254 
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nm) due to the lack of sensitivity. The experiment however could be run much more 
quickly and cheaply without the need to label the DNA which may affect DNA folding and 
ligand binding.  For example the ligand may interact with the fluorescent dye (such as 
fluorescein) instead of the DNA.
[40] 
 
All the quadruplex forming DNAs used in the PAGE experiments were annealed before 
use in a potassium rich buffer (the running buffer contains 50 mM potassium also).  This 
should ensure that all of the DNA has been folded into its G-quadruplex structure allowing 
the investigation to determine how well the ibiq complexes bind to existing quadruplexes. 
 
G-quadruplex DNA (after annealing) was mixed with different ratios of each ibiq complex 
(platinum or palladium) and then incubated before loading the wells on the polyacrylamide 
gel (15%).  The controls used were the quadruplex DNA alone and also with the small 
percentage of DMSO that was required to dissolve the complexes.  Once loaded an electric 
potential was applied causing the DNA to migrate to the positive electrode.  G-
quadruplexes migrate fastest through the gel due to their compact structure, the type of 
quadruplex formed also has an effect on the mobility with antiparallel quadruplexes 
migrating faster than parallel quadruplexes.
[38][41]
  As with the agarose gel electrophoresis 
experiments the binding of a complex to the DNA structures will cause the migration 
across the gel to slow as the size of the structure has increased. 
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PAGE Results with htelo DNA 
The UV image for the gel obtained when loaded with annealed telomeric DNA (htelo) and 
both complexes; platinum ibiq complex (1:1 and 2:1, complex:DNA) and palladium ibiq 
complex (1:1) is shown in Fig. 3.51.  In lane 1 containing the annealed telomeric DNA 
alone, one band can be seen corresponding to the formation of a G-quadruplex.  Lane 2 
shows the two bands formed when the DNA is treated with one equivalent of the palladium 
complex; one corresponding to the G-quadruplex alone and a much lighter band above 
indicating that a small amount of the palladium complex has bound to the quadruplex 
lowering its electrophoretic mobility.  When treated with one equivalent of platinum 
complex in lane 3 the darker band is now the slower moving band with very little G-
quadruplex alone band visible.  This indicates as with the CD and FID experiments that the 
platinum complex is a better G-quadruplex binder than the palladium complex.  The 
control G-quadruplex DNA treated with DMSO in lane 4 displayed only one band as lane 
1 did ruling out any significant contribution of the DMSO to the electrophoretic mobility 
of the DNA.  Finally in lane 5 two equivalents of the platinum complex were added to the 
quadruplex to investigate the binding stoichiometry of the complex to the DNA.  The same 
bands were produced in both lanes 3 and 5 indicating that only one complex:DNA species 
is produced.  The addition of more complex doesn't appear to form higher ratios of 
complex:DNA  as this would have produced a slower moving band in the gel as the size of 
the species has increased.    
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As a further check to confirm that the presence of the slower band in the gel was caused by 
the complex binding to the htelo G-quadruplex each of the spots on the DNA were 
extracted using a crush and soak technique (see Experimental).  A solution of each spot on 
the gel was examined by UV-vis absorbance spectroscopy in order to link the presence of 
the complex with the DNA band on the gel.  The complex alone would not be able to move 
through the gel as it lacks the negative charge of the DNA.  Therefore for the complex to 
be seen with the DNA some form of interaction must be occurring between the two 
species.  This method can only be qualitative as it is difficult to extract all of the DNA 
from the gel.  In Fig. 3.52 and 3.53 the UV-vis spectra of the slower and faster migrating 
bands through the gel can be seen respectively. When the slower bands were analysed the 
platinum complex could clearly be seen in lanes 3 and 5 indicated by the CT peak seen at 
388 nm (see Chapter 3.5.2 for original UV-vis spectroscopy analysis).  The presence of a 
- 
Figure 3.51  UV picture of PAGE (15% polyacrylamide) at 25°C showing the migration of htelo through 
the gel alone and when mixed with the platinum complex (Pt = [Pt(ibiq)2][PF6]2) and the palladium 
complex (Pd = [Pd(ibiq)2][BF4]2).  Lanes 3 and 5 show the appearance of a new slower migrating band 
indicative of complex-quadruplex binding.     
+ 
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peak around 260 nm could also be observed for lanes 3 and 5 arising from the DNA.  In 
lane 2, where a very faint band appeared after treating the DNA with the palladium 
complex, a very small amount of DNA can be seen when compared to the blank control 
taken of a random piece of the gel the experiment was conducted on.  This indicates that a 
small amount of binding may have occurred however the concentration is so weak the 
palladium UV-vis trace cannot be seen.   
   
 
 
 
 
 
 
 
 
 
The faster migrating bands when analysed in the same way saw no metal complex presence 
in any of the lanes, which was expected as any complex binding would cause the migration 
across the gel to slow when compared with the G-quadruplex alone.  Lane 1 clearly shows 
the UV peak corresponding to the DNA around 260 nm, lanes 2 and 4 show the presence 
of DNA again but at a much lower concentration which is a result of the extraction process 
which is not quantifiable.  More importantly very little DNA can be seen in lanes 3 and 5 
as they look very similar to the UV-spectrum obtained for the blank control which 
Figure 3.52  Overlaid UV-vis spectra recorded from the slower migrating bands in the gel in Fig. 3.51.  
2, 3 and 5 correspond to the lanes where a band was present.  The spectra match with platinum complex 
for lanes 3 and 5 indicating that it has bound to the htelo quadruplex. 
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indicates that all of the DNA is bound to the platinum complex which migrates slower 
through the gel.  
 
 
 
 
 
 
 
 
 
 
 
Competitive PAGE Experiments - Work carried out by Hannah Pritchard at the 
University of Birmingham  
Platinum complex, htelo and ds26  
Further PAGE experiments were conducted at the University of Birmingham where a 
competitor in the shape of the duplex forming DNA, self complementary ds26, was used.  
Both types of DNA (htelo and ds26) were treated with the complex individually and also 
as a mixture in order to determine whether the complex would preferentially bind to one 
form of DNA over the other; the results of this PAGE experiment can be seen in Fig. 3.54.  
The duplex DNA ds26 alone is in lane 1 where two bands can be seen; the slower 
migrating one being that of the duplex form and the faster migrating band is the single 
stranded form.  In lane 3 ds26 has been treated with one equivalent of the platinum 
Figure 3.53  Overlaid UV-vis spectra recorded from the faster migrating bands in the gel in Fig. 3.50.  1, 
2, 3, 4 and 5 correspond to the lanes where a band was present.  DNA found in lanes 1, 2 and 4 however 
no peak corresponding to DNA could be seen in lanes 3 and 5 which had been treated with the platinum 
complex indicating that the majority of DNA must be bound to complex in the slower migrating band.   
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complex causing the slower migrating band to become more diffuse as it moves more 
slowly through the gel after interacting with the complex.  Lane 2 shows the htelo 
quadruplex DNA which is assumed to be in its quadruplex form and lane 4 shows the 
quadruplex DNA with the platinum complex and the formation of a new band indicating 
complex-quadruplex binding.  A mixture of both types of DNA can be seen in lane 5 and 
in lane 6 with the addition of the platinum complex.  The quadruplex-complex band can 
again be seen in the same place as with htelo DNA alone indicating that the presence of 
ds26 has not prevented this interaction.  More importantly when comparing the duplex 
band of the ds26+complex with the ds26+complex+htelo DNA the same diffuse band is 
not observed and it appears as it did without the complex present indicating that the 
complex is binding to the quadruplex DNA over the duplex ds26 DNA.  However the fact 
that the ss DNA (single stranded DNA ) and platinum complex+htelo run at a similar 
position makes quantification impossible.    
   
 
 
 
 
 
 
 
 
 
 
Figure 3.54  UV picture of PAGE (15% polyacrylamide) at 25°C showing the migration of 
htelo and ds26 when mixed with the platinum complex (Pt = [Pt(ibiq)2][PF6]2).   
 
+ 
- 
duplex 
ss 
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Platinum complex, c-myc and ds26 
When the same experiment was carried out with c-myc DNA a similar result was obtained 
as for the htelo DNA (Fig. 3.55).  In lane 5 where there is a mixture of the two types of 
DNA, two bands are seen; the slower being that of the duplex ds26 and the faster band is a 
mixture of the quadruplex DNA and the single stranded ss26.  Lane 6, which contains c-
myc DNA, ds26 and the platinum complex, sees the emergence of three bands where the 
duplex form of ds26 matches that without the complex added (lane 1) and the c-myc bands 
can be matched with the c-myc+complex lane 4 indicating that the platinum complex binds 
to c-myc DNA over duplex DNA.   
 
 
 
 
 
 
 
 
 
 
 
 
 
The co-running of ss26 and the c-myc DNA again prevent quantification however an 
attempt at quantification was still made in order to get an idea of the amount of quadruplex 
Figure 3.55  UV picture of PAGE (15% polyacrylamide) at 25°C showing the migration of c-myc and 
ds26 when mixed with the platinum complex (Pt = [Pt(ibiq)2][PF6]2. 
+ 
- 
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DNA in its bound state.  This was achieved using the software ImageJ where the gel 
analysis tool was used to obtain the ratio of ss to ds in lane 8.  The software is able to 
display the density of the bands and plots distance in pixels versus grey value producing a 
series of peaks from which the area can be calculated.  After calculating the ratio of ds to 
ss DNA (which came out as 1:1) the ratio was applied to lane 6 where the known area of 
the ds26 peak allowed the area of the hidden ss26 peak to be calculated.  This value was 
then subtracted from the area of the quadruplex combined with the ss26 band to give the 
area of the quadruplex only.  The area of the band corresponding to the quadruplex and 
complex was then added to the area of the quadruplex (G4) alone to give the total area of 
quadruplex DNA which should equate to 100 μM.  Dividing the concentration by the total 
area and then multiplying by the individual areas gave a 42 μM result for unbound G4 and 
58 μM for complex bound G4 indicating that 58 % of the c-myc DNA interacts with the 
complex in the presence of ds and ss 26 DNA (for data see Appendix 3).             
 
3.8   Förester Resonance Electron Transfer (FRET) using Complexes 5 and 7 
Work in collaboration with Dr. D. Rusling and Prof. K. Fox of the University of 
Southampton - Experiments prepared and conducted by Hannah Pritchard and D. 
Rusling.   
 
FRET can be used to investigate the distances between two different sites on a 
macromolecule such as DNA.  One part of the structure can be labelled with a donor whilst 
another part can be labelled with an acceptor.  The transfer efficiency between the donor 
and acceptor units can be monitored by measuring the quenching of the donor by the 
acceptor.
[43]
  In order for FRET to occur the emission spectrum of the donor must overlap 
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with that of the acceptor with the efficiency of this process depending on the degree of 
overlap, donor and acceptor orientations and distance, and donor quantum yield.
[43] 
 
The phenomenon of fluorescence resonance energy transfer can be explained by 
considering what happens to a molecule when it absorbs light. At the correct energy 
corresponding to the energy gap between its ground and excited states the molecule is 
excited from its ground state (S0) to its excited singlet state (S1) (Fig. 3.56).
[42]
 Although 
many excited states are open to the donor most of the emission occurs from the S1 state due 
to rapid vibrational relaxation by internal conversion from the other energy states.
[42]
  The 
excited donor under circumstances where an acceptor isn't present within range could then 
return to the ground state resulting in fluorescence.
[43]
 When an acceptor is within range 
(10 - 90 Å away) the excited donors' energy can then be transferred non-radiatively to the 
acceptor fluorophore.
[42] 
 This energy transfer is possible when the energy of the S1 → S0 
emission from the donor matches with the S0 → S1 energy gap of the acceptor.
[42]
 The 
excited acceptor can then return to the ground state with the observance of fluorescence. 
 
 
 
 
 
 
 
 
 
Figure 3.56  Jablonski diagram showing the absorption, vibrational relaxation, non-radiative transfer and 
emission steps involved in FRET.  
FRET 
S 1 
S 0 
S 1 
S 0 
Donor Acceptor 
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Manipulating FRET systems can be advantageous as fluorescence detection is very 
sensitive therefore will only require small amounts of labelled product.  The energy 
transfer between a donor and an acceptor occurs over a short timescale (nanosecond) and 
can be applied over a range of distances.
[42]  
The technique can be used to investigate the 
secondary structure (G-quadruplex) of guanine rich DNA sequences that have been 
labelled with the donor 6-carboxyﬂuorescein (FAM) at the 5' end and the acceptor 6-
carboxytetramethylrhodamine (TAMRA) at the 3' end.
[2]
  
 
 
 
 
 
 
 
 
The labelled DNA strand is annealed in the presence of a cation such as potassium and left 
to cool slowly allowing the most thermodynamically stable G-quadruplex to dominate.  
When the DNA is folded in its quadruplex form the two fluorophores, FAM and TAMRA 
will be relatively close to each other allowing FRET to occur.  The fluorescein is excited 
around 490 nm and its emission is recorded at 530 nm which is monitored throughout the 
experiment with the use of a Roche Lightcycler.
[2]
 TAMRA emits at 588 nm which could 
only be monitored at 640 nm using the same machine.
[2][40]
  The temperature of the DNA 
sample will then be gradually increased between 25 °C to 95 °C which will cause the DNA 
to unfold.  When the quadruplex melts becoming a single strand once more the donor and 
Figure 3.57  Chemical structures of FAM (6-carboxyfluorescein) and TAMRA (6-
carboxytetramethylrhodamine.  
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acceptor (FAM and TAMRA) will be far apart in space from each other hindering any 
FRET (Fig. 3.58).  This can be detected by observing an increase in the fluorescence of the 
donor as non-radiative transfer to the acceptor is prevented.
[42]
  If a G-quadruplex binding 
ligand is added and the system requires higher temperatures to unfold the quadruplex, the 
ligand is deemed able to bind to and stabilise a G-quadruplex. The extent of the melting 
temperature change denotes the stabilising strength of the binding ligand.  The melting 
temperature or Tm can be taken as the half way point on the melting curve where 50 % of 
the DNA is denatured (Fig. 3.59).  A more accurate determination can be achieved by 
plotting the first derivative of the melting curve.
[2] 
 
 
 
 
 
 
 
 
Figure 3.58  Folding of a labelled quadruplex forming oligonucleotide. 
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The htelo DNA sequence used in the experiments was chosen as it has been frequently 
reported in the literature to evaluate the folding of guanine rich oligos in the presence of 
compounds such as terpyridine and bis-indolecarboxamides (reported by Teulade-Fichou 
and Balasubramanian respectively).
[2][26]
  It has a melting temperature between 50 - 55°C 
that allows complete folding at lower temperatures and the analysis of stability within a 
viable temperature range when G-quadruplex stabilising complexes are added (quadruplex 
systems that are too stable will not melt within the measureable range).  It also offers a 
comparison of FRET melting temperatures with other G-quadruplex binding complexes 
currently in the literature.   
 
F21T: 5’-FAM - GGGTTAGGGTTAGGGTTAGGG  - TAMRA-3’ (htelo) 
 
 
The duplex competitor ds26 (self complementary strand) will also be used in the FRET 
melting experiments which has a higher melting temperature (70 °C).  If the presence of 
the competitor results in a decrease in melting temperature when with the complex and the 
Figure 3.59  General melting curve and first derivative of the melting curve that are produced by 
performing FRET melting experiments. 
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labelled quadruplex forming oligo (when compared with the system without the 
competitor); it is possible that the complex is binding to the duplex DNA instead of the 
quadruplex.  The complex is no longer stabilising the G-quadruplex hence the labelled 
oligo unfolds at a lower temperature.   
 
The ability the palladium and platinum ibiq complexes to stabilise the quadruplexes 
formed by the dual labelled htelo sequence was investigated using the FRET melting assay.  
Both of the complexes required DMSO-H2O mixtures in order to fully dissolve them and 
to ensure accurate melting temperatures were recorded, each experiment was carried out 
with two sequences of melt and anneal stages which were repeated three times.  A DNA 
concentration of 0.25 μM was treated with a range of complex concentration between 0.1 - 
2.0 μM.  The solvent alone did not affect the melting temperature of the DNA.  
 
3.8.1 [Pd(ibiq)2][BF4]2 FRET Melting Curves with htelo (F21T) 
The stabilisation effect the palladium ibiq complex had on G-quadruplexes formed with  
htelo DNA was very little.  Observation of the melting curve in Fig. 3.60 shows little 
movement of the curve with increasing amounts of the complex and in the first derivative 
plot of the curve in Fig. 3.61 the change in melting temperature (ΔTm) is only 2°C at 2 μM, 
with a Tm of 54.1 °C.  The results of the FRET melting experiment indicate that the 
palladium complex is a poor G-quadruplex stabiliser.  They also suggest that the complex 
may be quenching the fluorescence by binding to the fluorophores (see insert in Fig. 3.60) 
as the emission signal seen decreases as the complex concentration increases.  Thus 
introducing the fluorophores may have created a competitor binding site. 
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Figure 3.60  FRET melting curve generated from 0.25 μM of htelo DNA with different concentrations of 
the palladium complex (μM).  Inset image shows the raw data where a decrease in emission intensity can 
be seen as the concentration of the complex increases. 
Figure 3.61  First derivative plot of the palladium melting curves where the peaks represent the melting 
temperature Tm. 
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3.8.2 [Pt(ibiq)2][PF6]2 FRET Melting Curves with Htelo (F21T) 
The platinum complex, after initial observation of the normalised melting curve (Fig. 
3.62), appears to stabilise the G-quadruplex formed by the labelled oligo as the curve shifts 
to higher temperatures when the concentration of complex increases.  There is however, as 
for the palladium complex, a quenching of fluorescence upon each sequential addition of 
the complex making the effect more difficult to see.  Further analysis of the melting curve 
shows very little movement with increasing amounts of the complex in the first derivative 
plot (Fig. 3.63), where ΔTm is 2°C at 2 μM, with a Tm of 54. 1 °C.  Interestingly however, 
there is another peak which emerges after 0.7 μM of the complex has been added to the 
DNA whose apex cannot be seen as it is out of range of the recorded temperature range 
(>83°C).  The appearance of this peak could be the consequence of another highly 
stabilised quadruplex structure which forms alongside the other quadruplex with a melting 
temperature of 54.1 °C in a biphasic transition.  
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Figure 3.62 FRET melting curve generated from 0.25 μM of htelo DNA with different concentrations of 
the platinum complex.  Inset image shows the raw data where a decrease in emission intensity can be 
seen as the concentration of the complex increases. 
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3.8.3  Competitor ds26 Addition 
At a complex concentration of 1 μM, 10 μM of ds26 (duplex forming DNA) was added in 
order to assess how or if the FRET melting would change in its presence.  The results were 
ultimately disappointing for both complexes as both complexes saw a decrease in Tm when 
in a solution with duplex DNA.  Chart (a) in Fig. 3.64 shows the effect of duplex DNA 
addition to the palladium complex and labelled oligo mix where very little change has 
occurred to the melting curve of the two systems. A new melting temperature of 52.1 °C 
(ΔTm = -2 °C) was recorded for the palladium complex with the additional duplex.  In chart 
(b), for the platinum complex, the same change of melting temperature, ΔTm = -2 °C to 
52.1 °C, occurs and the biphasic peak ~85 °C no longer appears in the first derivative plot 
of the melting curve.     
 
 
Figure 3.63  First derivative plot of the platinum melting curves where the peaks represent the melting 
temperature Tm. 
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Both complexes exhibit π stacking surfaces therefore the possibility of fluorophore 
quenching is enhanced as the fluorophores also possess large aromatic surfaces which the 
stacking ibiq complex could interact with.  This may be the reason why the stabilisation 
abilities of the complexes do not live up to the ΔTm values of 29.5 °C and 17.3 °C reported 
by Vilar and Teulade-Fichou for their metal based salphen and terpyridine complexes 
respectively.
[15][22]
  As with all DNA binding experiments the response to complex-DNA 
binding activity is more pronounced for the platinum complex suggesting the platinum 
complex binds more favourably to quadruplexes than the palladium complex.    
 
3.9  Conclusions 
 
Presented in this chapter were the binding abilities of the synthesised palladium, platinum, 
rhenium and rhodium ibiq complexes to different types of DNA (quadruplexes and 
duplexes).  The extent of response seen is influenced by the geometry of the complex with 
Figure 3.64  FRET melting curves of; a. Palladium complex (1 μM) with htelo DNA (0.25 μM) 
compared with the palladium complex (1 μM) with both htelo (0.25 μM) and ds26 DNA (10 μM), b. 
Platinum complex (1 μM) with htelo DNA (0.25 μM) compared with the platinum complex (1 μM) with 
both htelo (0.25 μM) and ds26 DNA (10 μM). 
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the octahedral rhenium complex showing very little DNA interaction and the square planar 
palladium, platinum and rhodium complexes giving more positive indications of binding.   
 
The palladium and rhodium complexes showed good stabilities with the ct-DNA when 
examined by UV, compared with their less stable nature without the DNA presence, 
indicating that complex-DNA binding was occurring for these two complexes.  The 
platinum and rhenium complexes showed good stability results without the DNA which 
didn't change on the addition of the ct-DNA.      
 
Circular dichroism was used to investigate how each complex interacts with ct-DNA, htelo 
DNA, c-myc DNA and in some cases ds26 DNA.  The palladium complex showed a strong 
ICD response with both the ct-DNA and the htelo DNA in all buffer conditions.  It didn't 
however produce such a response when titrated into c-myc DNA and hence shows a degree 
of selectivity for antiparallel hybrid quadruplexes over parallel conformers.  The platinum 
complex interacted well with all types of duplex and quadruplex DNA with a negative ICD 
response seen for the c-myc interaction indicating that the mode of interaction with 
quadruplexes is end stacking.  The rhenium complex showed no response to either duplex 
or quadruplex DNA by CD and after examination using LD, which also yielded no induced 
signal, was investigated no further.   
 
Fluorescent indicator displacements (FID) and PAGE experiments were used to try to 
assess the selectivity of the palladium and platinum complexes for one type of DNA over 
another.  The platinum complex was able to displace the fluorescent indicator (thiazole 
orange) at fairly low concentrations (< 0.5 μM) from htelo and c-myc quadruplex DNA.  
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Displacement from duplex DNA however took considerably higher complex 
concentrations demonstrating the potential lack of binding affinity the complexes have for 
duplex DNA.  In the PAGE experiments when both types of DNA (quadruplex and duplex) 
were in a mixture the platinum complex could be seen to bind to the quadruplex DNA 
causing the formation of a new band in the gel without causing the dispersion of the duplex 
band which occurred when the duplex DNA was subjected to the complex alone.   
 
The palladium and platinum complexes bind to both duplex and quadruplex DNA, the 
platinum complex binding very well.  The bulky nature of the ibiq ligand was hoped would 
prevent duplex interaction as it is too big to intercalate however it is possible that the 
complexes are binding directly to the bases instead.  LD however, suggests that 
intercalation may be occurring between the palladium complex and duplex DNA.  End 
stacking is the proposed binding mode that is occurring between the platinum complex and 
the quadruplex DNA as evidenced by the strong ICD signal and the large red shifts seen in 
the UV-vis spectroscopy titrations.  For the palladium complex this is a little less clear as it 
interacts differently with each of the quadruplexes.  Coordinative loop binding is a possible 
binding mode which may explain the CD results where a stronger response is seen for the 
antiparallel hybrid quadruplex over the parallel conformer.       
 
3.10  Experimental 
 
General Methods 
In all of the DNA binding studies Ultrapure water (18.2 MΩ) purchased from Fisher 
Scientific was used to carry out the experiments. Calf thymus DNA (ct-DNA) was 
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purchased from Sigma Aldrich.  The htelo, c-myc and ds26 oligos were bought from 
Eurofins and the pBR322 plasmid DNA from New England Biolabs.  All types of DNA 
were kept frozen until use. The Tris-acetate-EDTA and Tris-HCl buffer were purchased 
from Fisher and agarose from USB Corporation.  The DNA oligonucleotides were purified 
using a NAP column (packed with Sephadex G-25 DNA Grade) before using in the NMR 
studies.  UV-Vis spectra were recorded on a Varian Cary 5000 UV-Vis spectrometer.  
 
Circular Dichroism Experiments 
ct-DNA 
A Jasco J-810 spectropolarimeter was used to record the CD measurements of the titration 
mixture contained within a quartz cuvette with a pathlength of 1cm (750-200 nm). Ct-DNA 
was prepared in a stock solution of 3000 μM which was kept frozen until the day of use.  A 
300 μM solution of DNA was required for carrying out the experiment which was made by 
diluting the stock solution with sodium chloride (1 M) and sodium cacodylate 
(Na(CH2)2AsO2.3H2O) buffer stock solutions, resulting in a 20 mM sodium chloride and 1 
mM sodium cacodylate solution (pH 6.8).  Accurate DNA concentrations were determined 
by UV-Vis analysis using the molar extinction coefficient of  ε260 = 6600 mol
-1
dm
3
cm
-1 
calculated per DNA base.  In total three solutions are required to conduct the CD titrations 
which are; solution A (300 μM of ct-DNA which contains sodium cacodylate (1 mM) and 
sodium chloride (20 mM)), solution B (600 μM ct-DNA which contains sodium cacodylate 
(2 mM) and sodium chloride (40 mM)) and solution C (500 μM of complex solution).  
When carrying out the titration a CD spectrum is initially recorded of solution A and then 
to this equal volumes of solution B and solution C are added.  This keeps the ct-DNA 
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concentration constant over the course of the experiment whilst increasing the complex 
concentration from a DNA:complex ratio of 60:1 to 3:1.     
 
htelo, c-myc and ds26 DNA 
The titrations using the shorter oligos were carried out in a similar way to the ct-DNA 
titrations however the DNA concentration for each oligo was calculated per strand instead 
of per base.  The UV-Vis molar extinction coefficients for the oligos htelo, c-myc and ds26 
are as follows; ε260 = 228000, 231000 and 414000 (duplex) mol
-1
dm
3
cm
-1
 and they were 
made into 3 μM solutions in 10 mM Tris-HCl with either 100 mM KCl, 100 mM NaCl (pH 
7.4) or no other metal ions depending on the salt condition used (solution A).  Prior to 
recording their concentration they were annealed at 95 °C for 5 minutes. Solution B was a 
6 μM DNA solution with 20 mM Tris-HCl and 200 mM of the required salt and solution C 
was a 150 μM complex solution. 
 
Linear Dichroism Experiments 
A flow couette cell (Krometek) with a 0.1 cm pathlength was used to carry out the LD 
experiments.  They were carried out with ct-DNA only following the same method as that 
for the CD measurements with the same solutions of A, B and C.   
 
Fluorescent Indicator displacements 
Experiments were carried out using a Shimadzu spectrofluorimeter in a 3 ml quartz cuvette 
with a 1 cm pathlength.  Htelo, c-myc and ds26 oligos were used in the experiments and 
prior to carrying out the titration they were diluted to 0.25 μM in a 10 mM Na cacodylate  
(pH 7.4) solution with 100 mM KCl and then annealed to 95 °C before leaving to cool to 
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room temperature.  A 1 mM stock solution of thiazole orange was prepared in milliQ water 
which was then diluted to the corresponding concentration with 10 mM Na cacodylate 
solution.  [Pd(ibiq)2][BF4]2 and [Pt(ibiq)2][PF6]2 solutions were made by diluting 1000 μM 
DMSO stock solutions with the 10 mM Na cacodylate solution to 20 μM.  The 
concentrations of TO required for each type of DNA (all at 0.25 μM) are as follows: htelo - 
TO = 0.5 μM, c-myc - TO = 0.5 μM and ds26 - TO = 0.75 μM.  Competitive displacements 
of the TO resulted in a ratio of 2:1 for quadruplex DNA and 3:1 for ds26 (TO:DNA).
[19]
  
These ratios favour the occupation of one binding site for the quadruplex DNA and two 
binding sites for ds26 helping to prevent the formation of mixtures of complexes in 
solution.
[19]
    
 
To conduct the experiment the DNA and TO mixture are placed in the cuvette before 
adding increasing amounts of the complex being investigated (0.12 to 10 μM, which is 0.5 
to 40 equivalents).  After each addition of complex the mixture was left to equilibrate for 3 
minutes before recording an emission spectrum between 510 and 700 nm, exciting at 501 
nm.  The trapezium rule
[44]
 was used to calculate the fluorescence area after each titration 
which was then converted into TO % displacement using % TO displacement = 100 - 
[(fluorescence area of sample/fluorescence area of DNA+TO alone) × 100]. 
 
UV-Vis Absorption Spectroscopy Titrations 
The htelo and c-myc oligos were made into 300 μM solutions in 10 mM Tris-HCl / 100 
mM KCl and annealed to 95 °C before use (solution B).  The complexes were diluted to 7 
and 14 μM solutions also using 10 mM Tris-HCl (pH 7.4) / 100 mM KCl (solution A and 
solution C).  Blank solutions were also made up to run alongside the DNA into complex 
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titration in order to subtract the DNA peaks from the complex spectra.  The experiment 
was carried out by placing solution A into a 1 ml cuvette and titrating in solutions B and C 
in equal amounts in order to keep the complex concentration constant.  The concentration 
of DNA was increased from 60:1 to 0.2:1.  All UV-Vis spectra were recorded on a Varian 
Cary 5000 UV-Vis spectrometer. 
 
1D 
1
H-NMR and DOSY Experiments 
DNA:complex NMRs were run in shigemi tubes on a Bruker AV700 instrument.  100 μM 
of the purified htelo DNA was prepared in a 50 mM KCl, 15 % d6-DMSO solution (and 
then annealed before use) which was kept constant in all the experiments.  The platinum 
complex was prepared using the same conditions, without annealing.  The proton spectra 
were recorded with a sweep width of 25 ppm, an acquisition time of 0.5 s, WATERGATE 
water suppression and 35 k scans.  The data was processed using the Bruker NMR 
software and analysed using TOPSPIN.  
 
Agarose Gel Electrophoresis  
To create the agarose gel 2 grams of agarose was heated in 1x Tris-acetate-EDTA buffer.  
Once fully dissolved the solution was then poured into a gel tray measuring 210 × 150 nm, 
with a 15 tooth comb already in place enabling the formation of sample wells, before 
leaving to set for 30 minutes.  The pBR322 plasmid DNA was prepared in a 93.3 µM 
solution and the complexes made into 60 µM stock solutions (also containing 15 % DMSO 
for the platinum and palladium complexes).  The two lots of solutions (DNA and complex) 
were then mixed together in ratios ranging from 100:1 to 2:1.  The samples were then left 
for 2 hours at room temperature before adding 4 μl of loading buffer (30% glycerol, 0.25% 
 Chapter 3: DNA Binding Studies 
 
 
219 
 
bromophenol blue) and mixing again.  They were then loaded into the gel wells, 
transferring 16 μl into each.  An electric potential was then applied to the gel in an 
electrophoresis submarine kit (Amersham Biosciences HE99X) submerged in 1 × Tris-
acetate-EDTA running buffer using an electrophoresis power supply-EPS 301 system set at 
a constant voltage of 120 V and 400 mA.  The gel was run for 3 hours after which time the 
gel was stained with a solution of ethidium bromide (0.5 mg ml
-1
, 200 ml) and left for a 
further 20 minutes.  The gel was then visualised using a UVtec-uvipro platinum 2.0 camera 
at a wavelength of 312 nm.  
 
Polyacrylamide Gel Electrophoresis (PAGE) 
Polyacrylamide gel preparation  
52.5 ml of ultra pure water, 10 ml of 10 × TB buffer (890 mM tris(hydroxyl)amino 
methane and 890 mM boric acid) and 37.5 ml of 40 % acrylamide (29:1) were mixed 
together to form the basis of a 15 % native polyacrylamide gel.  Potassium chloride was 
also added to achieve a concentration of 50 mM.  To initiate the cross linking which 
solidifies the gel 500 µl of 10% (w/v) ammonium persulfate and 75 µl 
tetramethylenediamine (TEMED) were added before pouring onto a set of glass plates and 
leaving to set for 40 minutes.  Once the gel had polymerised the wells were washed with 
running buffer and pre-run at 200 V for 5 minutes before starting the experiment with the 
samples.  
 
PAGE electrophoresis experiment   
Solutions of htelo, c-myc and/or ds26 with the complexes were prepared in TBN buffer (89 
mM tris(hydroxymethy)amino methane, 89 mM of boric acid and 100 µM KCl) to give 
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100 μM DNA and complex solutions (to be used together in a 1:1 ratio).  15 % DMSO 
solutions were required to fully dissolve the complexes.  When the competitor DNA was 
used the ratio of ds26:quadruplex DNA:complex was 1:1:1. The sample solutions were left 
to equilibrate for 1 hour at room temperature.  Before the samples were loaded into the gel 
5µl of 30 % glycerol was added.  Each well of the gel was then loaded with 13 µl of each 
sample.  The gel was run for 5 hours at 120 V, 150 mA using Gel System equipment 
(Thermo Scientific UK) and then visualised using UV light.  To perform the UV-vis 
experiments the DNA and complexes were extracted from the gel using a crush and soak 
technique where the gel bands containing the DNA are cut out using a razor blade under 
UV light and then suspended in 500 μl of the running buffer.  The gel pieces were left over 
night on a rotating wheel before centrifuging to remove the gel pieces.  The supernatant 
was then placed in a UV cuvette (0.1 ml) to measure its absorbance. 
 
FRET Melting Experiments 
A Roche Lightcycler 1.5 was used to run the experiments and the Roche Molecular 
BiochemicalsLightCycler Software Version 3 was used to process and analyse the data.  
The buffer used in the experiments was a 10 mM LiOH, 10 mM KCl, with H3PO4 pH 7.4.  
1 μM stock concentrations of the labelled oligos were prepared and protected from the 
light and 20 μM complex solutions were prepared by diluting a 1 mM stock solution in 
DMSO with buffer.  The competitor duplex DNA (ds26) was also prepared in a 20 μM 
concentration.  The concentration of labelled DNA in each experiment was kept constant at 
0.25 μM and treated with a range of complex concentrations from 0.1 μM to 10 μM.  Using 
a Roche Lightcycler 1.5 holding 32 capillary tubes each containing 20 μl of sample, the 
fluorescence of the samples was measured every 1 °C from 30 - 95 °C.  The experiment 
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consisted of a 1 hour slow melt followed by holding the temperature at 95 °C for 10 
minutes before conducting a 1 hour slow anneal followed by holding the temperature at 30 
°C for 10 minutes.  The melting temperature of melting and annealing curves could then be 
compared to check for any sign of hysteresis.  The fluorescence was recorded at 
wavelengths of 530 nm and 640 nm which monitors the increase in FAM emission and 
decrease in TAM fluorescence respectively. 
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Chapter 4:  RNA Binding Studies 
4.1   Introduction 
 
G-quadruplexes not only form in guanine rich strands of DNA, but also in guanine rich 
strands of RNA (within genomes).[1]  Early investigations found the RNA G-quadruplexes 
to be actively present in viral genomes (translational recoding in herpes and genome 
dimerisation in HIV) where selective binding of a viral protein to a RNA G-quadruplex 
structure was reported.[1]  More recently they have been found experimentally to be present 
in telomeric (TERRA) and non-coding sequence transcripts (5'-untranslated regions) 
playing essential roles in important cellular functions such as telomere regulation and gene 
expression.[2]  As with DNA the formation of the RNA G-quadruplexes can affect the 
binding of proteins and therefore control the regulatory mechanisms they are associated 
with.[2]  Both of the RNA sequences, TERRA and 5'-untranslated regions (UTRs), have 
potential links with cancer biology therefore there is much research into the biological 
effects of these structures along with the ability of small binders to selectively target 
them.[1] 
 
4.1.1  RNA G-Quadruplex Structure and Stability 
The structure of RNA is closely related to that of DNA, however there are differences 
between the two which result in the type of structure seen for each.  There are three main 
differences: RNA exists as a relatively short single stranded entity whereas DNA is 
primarily double stranded and very long; ribose replaces deoxyribose in RNA which has an 
additional hydroxyl group at position C2'; the base thymine is replaced by uracil which is 
the unmethylated version of thymine (Fig. 4.1 - a).[1] 
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G-rich sequences of RNA in vivo are more likely to fold into a G-quadruplex structure as 
they primarily exist as single stranded sequences, with no complementary strand to interact 
with, and also form very stable G-quadruplex structures (more so than DNA).[2] The 
increased stability exhibited by the RNA quadruplexes stems from the ribose C2' hydroxyl 
groups which form hydrogen bonds with the phosphate and oxygen atoms, N2 groups of 
the guanine bases (H-bond acceptors) and O4' sugar oxygen (Fig. 4.1 - b).[3] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1  a. Example of  RNA sequence UUA showing the sugar phosphate backbone, b. RNA G-
quadruplex showing the H-bonds between C2'-OH and O4' which help stabilise the structure  PDB: 
3IBK. [Reproduced from Ref 3] 
(a) 
(b) 
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All of the additional interactions, when compared with DNA quadruplexes, increase the 
thermodynamic stability of the RNA quadruplex by: 
 -  Lowering the cost of entropy as the ribose hydroxyl groups prefer to interact 
intramolecularly rather than with the surrounding water molecules.  This results in a 
decrease of ordered water molecules within the grooves of the RNA quadruplex.[1] 
 -   Increasing the enthalpic addition to the free energy of RNA G-quadruplex 
formation with the additional hydrogen bonding.[3] 
 
DNA and RNA G-quadruplexes also differ in the number of topologies that they can exist 
in.[3] DNA G-quadruplex structures are polymorphic and a single G-rich sequence can fold 
into a variety of quadruplex conformers depending on the concentration of the 
oligonucleotide and the buffer conditions.  RNA G-quadruplexes on the other hand prefer 
to exist in parallel quadruplex conformers regardless of the oligonucleotide concentration 
or the buffer conditions.[3] This is because of the steric hindrance inflicted by the C2' 
hydroxyl group in the RNA quadruplex which favours anti-glycosidic torsion angles hence 
a parallel quadruplex conformer.[1]   
 
4.1.2  RNA Quadruplexes in Telomeric Regions 
The guanine rich sequence that exists at the end of a DNA strand is shortened after every 
cell division unless counteracted by the enzyme telomerase which acts to extend the G-rich 
telomeric sequence.[2] The telomerase works by extending the 3' end of DNA by the reverse 
transcription of a small region of RNA called TERC or hTR producing an encoded version 
of the sequence.[2] DNA-dependent RNA polymerase II transcribes the C-rich strand of the 
DNA resulting in the formation of a non-coding G-rich RNA strand called TERRA which 
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has been implicated in the regulation of telomere length and telomerase inhibition (Fig. 
4.2).[2]  
 
The guanine rich TERRA RNA sequence is also able to fold into a G-quadruplex structure 
like its DNA equivalent sequence however it only exists as the parallel conformer.[3][4]  The 
transcription of TERRA is regulated by RNA surveillance mechanisms and reacts to 
changes in the telomere length.[5]  The overproduction of TERRA can cause problems with 
telomere replication resulting in an abrupt loss of telomere tracts.[5] 
 
 
 
 
 
 
 
 
 
4.1.3  RNA Quadruplexes in 5' Untranslated Regions 
Three important steps are involved in the translation of mRNA into its corresponding 
protein product which are: 
 -  Initiation; ribosome assembly on the mRNA 
 -  Elongation; synthesis of protein 
 -  Termination; removal of the ribosome  
 
Figure 4.2  Inhibition of telomerase by RNA TERRA 
sequence. 
Telomerase 
TERRA 
3' 3' 
Telomerase 
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The most regulated and rate limiting step of the entire process is thought to be initiation 
which occurs in the 5'-untranslated region (UTR) of the mRNA strand.[3] In this region 
translation initiation occurs where the small (40S) ribosomal subunit binds to the 5' end of 
the mRNA and scans the region in a 5' → 3' direction until the initiation codon (AUG) is 
reached.[2]  At this point the larger subunit of the ribosome (60S) joins the smaller unit to 
form the 80S ribosome to start the translation leading to gene expression.[2] 
 
Many 5'-UTR regions are predicted to contain G-rich sequences which are able to fold into 
G-quadruplexes.[2]  The presence of secondary structures, such as G-quadruplexes, in these 
regions of RNA help to regulate translational processes for growth factors, transcription 
factors and oncoproteins as their formation is able to block initiation preventing gene 
expression.[2][6]  One particular 5'-UTR is that of the neuroblastoma RAS viral oncogene 
(NRAS) whose encoded protein is responsible for cell proliferation and differentiation.[6] 
Mutations that are activated in the coding region of NRAS result in an elevated level of 
cell growth causing the development of tumours.[6]  As the NRAS 5'-UTR region is 
guanine rich, G-quadruplexes have the potential to form in this area and repress translation 
preventing the formation of the protein that causes cell proliferation.[7]    
 
4.1.4  Small Molecule RNA G-Quadruplex Binding 
The formation of G-quadruplexes in G-rich regions of RNA and their link with regulatory 
systems make them ideal targets in order to combat cancers caused by the up regulation of 
specific genes.  As with DNA, the formation and stabilisation of G-quadruplexes by small 
molecules can prevent the binding of proteins required for processes such as telomere 
extension or gene translation.  Small molecules that are designed to target 5'-UTR RNA G-
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quadruplexes can control or alter mRNA translation by: Stabilising the existing G-
quadruplex structure preventing the ribosomal subunit from scanning the untranslated 
region for the initiation codon; Destabilising the existing RNA quadruplex to allow 
translation or interfering in a G-quadruplex-protein binding event.[3] 
 
Two types of G-quadruplex binders that have been explored with both DNA and RNA 
quadruplexes are BRACO-19 and three tetrasubstituted naphthalene diimides (Fig. 4.3) 
where in each case the side chains are composed of two or more CH2 groups that terminate 
with an amine.[8] 
 
 
 
 
 
 
 
 
 
 
 
 
BRACO-19 was found to bind to DNA G-quadruplexes with a higher affinity than RNA 
G-quadruplexes.  This was also true for the naphthalene diimide ligands except for ligand 3 
where the RNA showed a similarly strong response to that of DNA.[8] The extra stability of 
Figure 4.3  DNA and RNA G-Quadruplex binders. Top. BRACO-19, Bottom. Tetrasubstituted 
naphthalene diimides. 
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the DNA quadruplex - BRACO-19 complex arises from interactions between the 3' 
thymine O4 atom with an amide group in the side chain of BRACO-19.[8] The same 
stabilising interaction does not occur in the RNA quadruplex - BRACO-19 complex 
because electrostatic repulsion is felt between the 2'-OH group on guanine (G17) and the 
O4 atom on uracil (U24).[8] The side chain of the BRACO-19 ligand in this complex is 
situated between the terminal uracil O4 atom and the 2'-OH (G17).[8]  The repulsion 
prevents the amide nitrogen of BRACO-19 interacting with the carbonyl atom, O4 (Fig. 
4.4).[8] 
 
 
 
 
 
 
 
 
 
 
 
The three naphthalene ligands which all bound to DNA quite well did not all bind to RNA 
with similar success.[8] Naphthalene ligands 1 and 2 both contain a similar amide side 
chain which interacts with the RNA like the BRACO-19 ligand.[8] Naphthalene ligand 3 on 
the other hand gave a 15 fold increase in ligand binding when compared with the amide 
versions indicating that the presence of a hydroxyl group in a ligand side chain may be 
Figure 4.4  Interactions between BRACO-19 (white) with; a. DNA - showing the amide O4 
interaction stabilising the structure, b. RNA - where the amide O4 interaction is prevented due to 
the presence of the 2'-OH group on the guanine (G17) base the ligand is stacking on top of. 
[Reproduced from Ref 8] 
(a) 
(b) 
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important for RNA quadruplex binding.[8] Only a 3 fold increase was seen when using the 
hydroxyl ligand with DNA.[8] 
 
When a human telomeric RNA sequence was treated with a triazoleacridine ligand a 
bimolecular G-quadruplex structure was formed from two strands of RNA with two 
acridine ligands.[9] The RNA G-quadruplexes formed were parallel in conformation with 
UUA loops.[9]  The presence of the additional 2'-OH groups means the loops are more 
constricted in space which in some cases (BRACO-19) may hinder some ligand side chain 
interactions.[9] The two acridine ligands in this system are stacked on each other in between 
two terminal G-quartets of two quadruplexes and stabilised by interactions with the 2'-OH 
groups in the RNA parallel loops (Fig. 4.5).[9] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5  a. Acridine compound N,N′-((1,1′-(acridine-3,6-diyl)bis(1H-1,2,3-triazole-4,1-
diyl))bis(3,1-phenylene))bis-(2-(diethylamino)acetamide), b. Crystal structure of acridine molecules 
on top of terminal G-quartet, c. Schematic of  two RNA G-quadruplex structures with two acridine 
molecules in between them. [b and c Reproduced from Ref 9]   
(a) 
(b) (c) 
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4.1.5  Interaction of Biisoquinoline Complexes with RNA G-Quadruplexes 
Two G-quadruplex forming strands of RNA were used in the following CD and FID 
experiments to investigate how they interacted with the palladium and platinum 
biisoquinoline complexes in comparison with DNA G-quadruplexes.  The RNA strands 
chosen were TERRA (telomeric linked) and NRAS (5′-UTR linked), shown below, both of 
which fold into G-quadruplexes in a parallel conformation . 
 
TERRA: 5'-UUA GGG UUA GGG UUA GGG UUA GGG-3' 
NRAS: 5'-GGG AGG GGC GGG UCU GGG-3' 
 
The biisoquinoline complexes were not designed with additional side arms to potentially 
react with the loops therefore will hopefully avoid any 2'-OH group interference from the 
ribose sugar.  The mode of interaction is likely to be end stacking, as with the DNA G-
quadruplexes, onto the terminal G-quartet with the complex being able to maximise its 
coverage on the whole guanine quartet surface.  The results of the circular dichroism and 
fluorescent indicator displacement experiments were expected to give an indication of the 
possible specificity of each complex for RNA or DNA.  The constriction of the loops in the 
RNA quadruplexes may; help binding by being closer in space to the G-quartet surface and 
hence the end stacking complexes (maximising interactions between the two) or hinder by 
being too restrictive for the complex to fit on top of the G-quartet making it a too tight a fit 
to sit planarly.  
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4.2   Circular Dichroism with Complexes 5 and 7  
 
The principles of circular dichroism can be found in Chapter 3.2 which relate to the 
experiments carried out using RNA instead of DNA. RNA G-quadruplexes are inherently 
more stable than their DNA analogues, due to their additional hydroxyl hydrogen bonding 
substituent and closer loop structure minimising water association, therefore are able to 
form in very dilute salt concentrations.  Despite this the same salt conditions were used in 
the RNA experiments as for the DNA in order to obtain a more accurate comparison of 
binding in solution.  Two buffer solutions were used to investigate the TERRA RNA oligo, 
10 mM Tris-HCl with 100 mM KCl and 10 mM Tris-HCl only.  The NaCl based buffer 
was omitted from these experiments as the potassium buffer is more biologically relevant.  
The RNA concentration used in each experiment was 1 μM (calculated per strand).  
Control titrations found the solvent to have no effect on the CD spectrum where the ICD 
peaks are found. 
 
4.2.1  [Pd(ibiq)2][BF4]2 - 5 
- TERRA RNA + 10 mM Tris-HCl + 100 mM KCl 
The initial peak seen with the TERRA RNA alone occurs at 262 nm which agrees with the 
formation of a parallel quadruplex conformer (Fig. 4.6).  The addition of the palladium 
complex resulted in a gradual decrease in the intensity of the peak at 262 nm which may 
have been due to the precipitation of RNA out of solution as more of the complex solution 
was added.  There is no sign of any induced circular dichroism peaks even at 12:1 
equivalents of complex:RNA which is very similar to what was seen for the palladium 
complex interaction with c-myc DNA quadruplexes.  Both the c-myc and TERRA 
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quadruplexes form parallel conformers that the palladium complex is not able to interact 
with in the same way it does with antiparallel quadruplex hybrids.  This leads to the 
assumption that the palladium complex is not interacting with the terminal G-quartet in an 
end stacking mode because if so it would be able to stack like this onto the parallel 
conformer also, as there are no loops hindering access across the top of the end quartet.   
 
- TERRA RNA + 10 mM Tris-HCl 
The same result was observed for the same titration conducted without the presence of 
potassium cations. The stable nature of the RNA parallel quadruplex conformer allows its 
formation even without the extra stabilising central cation as shown by the initial peak in 
the spectrum with TERRA RNA alone at 262 nm (Fig. 4.7).  A weak negative peak may be 
emerging at 292 nm however this may be a consequence of the broad base line produced 
by the apparatus that is more pronounced due to the low magnitude of CD signal observed.  
 
A CD titration using NRAS RNA could not be performed due to the lack of stock and time 
whilst in Zurich.  Based on previous results it is predicted that the palladium complex 
would show very little interaction with the parallel quadruplex formed from this type of 
RNA.  
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Figure 4.6  CD spectrum for 1 μM TERRA RNA in 10 mM Tris-HCl + 100 mM KCl titrated with 
Pd complex in ratios shown in the legend to the right. 
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4.2.2  [Pt(ibiq)2][PF6]2 - 7 
-  TERRA RNA + 10 mM Tris-HCl + 100 mM KCl 
The parallel quadruplex conformer is seen for the TERRA RNA when alone in the 
potassium rich buffer solution as evidenced by the CD peak at 262 nm (Fig. 4.8 - a).  
When the platinum complex is titrated into the RNA solution two negative ICD peaks 
begin to emerge at 282 nm and 392 nm after a complex:RNA ratio of 2:1.  As for the 
palladium complex the platinum complex shows a similar CD spectrum to that obtained for 
the same experiment with c-myc quadruplex forming DNA; which is as expected when 
considering they both form parallel type quadruplexes.  A great degree of similarity 
between the two spectra also assumes a lack of interaction with the loops. The RNA loops 
are more constricted having a smaller width and depth when compared with the DNA 
loops.  Therefore if the complex was interacting with them this may have caused more of a 
difference to be seen between the CD responses.    
 
Figure 4.7  CD spectrum for 1 μM TERRA RNA in 10 mM Tris-HCl titrated with Pd complex in ratios 
shown in the legend to the right. 
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-  TERRA RNA + 10 mM Tris-HCl 
Without the presence of potassium ions in solution there is much more of a decrease in the 
intensity of the ICD signal at 277 nm and 390 nm as the platinum complex is added (Fig. 
4.8 - b).  A positive peak at 250 nm emerges whilst the positive peak at 264 nm disappears 
at a complex:RNA ratio of 4:1.  As with the c-myc DNA quadruplex, the platinum 
complex is believed to be interacting through an end stacking mode.   
 
-  NRAS RNA + 10 mM Tris-HCl + 100 mM KCl 
When investigating the NRAS RNA quadruplex forming strand a much less intense 
response can be seen when compared with the TERRA RNA titrations.  Both of the RNA 
strands fold into parallel quadruplex conformers.  The initial peak for NRAS RNA alone in 
Fig. 4.8 - c at 260 nm is characteristic for this type of quadruplex.  However the NRAS 
quadruplex structure has different sized loops to the TERRA RNA quadruplex which may 
restrict access to the terminal G-quartet. Nevertheless negative ICD peaks emerge at 286 
nm and 387 nm similar to those seen for the TERRA RNA with KCl rich buffer (although 
much less intense) which means that the complex may be interacting with the RNA in a 
similar way (most probably by end stacking).  
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Figure 4.8  a. CD spectrum for 1 μM TERRA RNA in 10 mM Tris-HCl + 100 mM KCl titrated with 
Pt complex, b. CD spectrum for 1 μM TERRA RNA in 10 mM Tris-HCl titrated with Pt complex, c. 
CD spectrum for 1 μM NRAS RNA in 10 mM Tris-HCl + 100 mM KCl titrated with Pt complex.  
ICDs for selected wavelengths are shown to the right of each CD spectrum.  
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4.3  Fluorescent Indicator Displacements for Complexes 5 and 7  
 
The same fluorescent indicator displacement experiment (protocol used by Marie-Paule 
Teulade-Fichou[10]) conducted in Chapter 3.4 was used to investigate the displacement of 
thiazole orange (TO) from RNA quadruplex structures also, using both the palladium and 
platinum biisoquinoline complexes. The binding constant for the thiazole orange to the 
RNA quadruplexes has not been investigated.  However due to the similarities between the 
DNA and RNA quadruplex structures it was expected that the affinity would be similar for 
both.  This would be apparent from the results obtained because if the thiazole orange 
bound much more strongly to the RNA than DNA the biisoquinoline complex would not 
be able to displace it and vice versa (if the thiazole orange binds very weakly, little 
complex would be needed to completely displace it).  The conditions used for the RNA 
experiments were exactly the same as for the DNA experiments therefore a direct 
comparison could be made between the two systems.   
 
4.3.1  Titrations with TERRA RNA 
When the palladium complex was added to the TERRA RNA-thiazole orange mixture the 
emission decreased by only small amounts upon each titration increment.  After adding the 
total amount of complex to make the concentration the full 2.5 μM the 50 % displacement 
mark was not reached therefore the results had to be extrapolated. The platinum complex 
however was able to quench the fluorescence of the system after very little had been added 
to the titration mixture (at 1 μM nearly 100 % of the emission signal had been quenched).  
The ability therefore of the platinum complex to displace the thiazole orange from the 
RNA TERRA quadruplex appears to be much greater than that of the palladium complex.  
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Figure 4.9 a. Emission spectrum for the palladium complex when titrated into 0.25 μM TERRA RNA 
solution containing  100 mM KCl / 10 mM Na cacodylate + 0.5 μM TO, b. Emission spectrum for the 
platinum complex when titrated into 0.25 μM TERRA RNA solution containing  100 mM KCl / 10 mM Na 
cacodylate + 0.5 μM TO. c. Percentage TO displacement comparison. 
This may be because of the topology of the quadruplex formed which is similar to the c-
myc DNA quadruplex studied in Chapter 3.4.2.  The platinum complex is able to interact 
with parallel quadruplex conformers (like c-myc and TERRA) whereas the palladium 
complex is less able to displace TO from this type of quadruplex.  This is probably due to 
its poorer binding affinity which most likely relates to how accessible the loops are for it to 
coordinatively bind.  The percentage displacement after the addition of each of the 
complexes was plotted using the equation below; the plot shown in Fig. 4.9 shows the 
results.  
% Displacement = 100 - [(FA-FA0) × 100] 
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4.3.2  Titrations with NRAS RNA 
The FID results for the palladium complex show that it binds slightly better to NRAS 
quadruplexes when compared with TERRA quadruplexes even though both form parallel 
quadruplex conformers.  Despite this it is still a poor binder when compared with the 
platinum complex which was able to quench the fluorescence at much a lower 
concentration and hence ratio of complex:RNA (at a complex concentration of 1 μM the 
emission had decreased by nearly 100 %).  The plot of the concentration of complex versus 
TO percentage displacement in Fig. 4.10 shows the large difference in displacement 
between the two complexes. 
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Figure 4.10 a. Emission spectrum for the palladium complex when titrated into 0.25 μM NRAS 
RNA solution containing  100 mM KCl / 10 mM Na cacodylate + 0.5 μM TO, b. Emission 
spectrum for the platinum complex when titrated into 0.25 μM NRAS RNA solution containing  
100 mM KCl / 10 mM Na cacodylate + 0.5 μM TO, c. Percentage TO displacement comparison. 
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4.3.3  Comparison of DC50 Values 
In Table 4.1 the DC50 values (concentration at which TO fluorescence has reduced by 50 
%) calculated for the palladium and platinum complexes, with TERRA and NRAS RNA, 
have been calculated.  As this is a direct comparison with DNA quadruplex binding the 0.5 
μM threshold will still be used to decide whether a complex can be considered as a good 
quadruplex binder or not.  The palladium complex for each of the types of RNA had DC50 
values which far exceed the limit and therefore is a poor RNA quadruplex binder.  The 
platinum complex on the other hand showed DC50 values below the threshold making it an 
excellent potential RNA quadruplex binder.  Despite the excellent binding results obtained 
for the platinum complex it suffers with regards to its selectivity as it has very similar DC50 
values to those obtained for DNA quadruplexes (c-myc 0.31 μM and  htelo 0.55 μM).  
 
 DC50 μM 
TERRA NRAS 
[Pd(ibiq)2][BF4]2 2.57 ± 0.40
* 1.90 ± 0.14 
[Pt(ibiq)2[PF6]2 0.30 ± 0.10 0.41 ± 0.03 
 
 
 
An overview of the selectivity of the complexes for one type of quadruplex over another is 
displayed in Table 4.2.  On comparing how each of the complexes interact with each type 
of RNA they both show very little difference between the two types, showing how the 
complexes cannot discriminate one type of RNA quadruplex from another.  This however 
is no surprise as the RNA sequences both form parallel conformers.  More interestingly the 
Table. 4.1 DC50 values calculated for palladium and platinum FID complex titrations with TERRA 
and NRAS RNA. *estimated value as result extrapolated due to 50 % displacement mark not being 
reached. 
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palladium complex shows a degree of selectivity for htelo DNA quadruplexes over 
TERRA RNA complexes. The main reason for this is likely to be the type of quadruplex 
conformer formed, antiparallel hybrid (DNA) versus parallel (RNA).   
 
 
 
Selectivity [DC50(A)/DC50(B)] 
NRAS / TERRA TERRA / NRAS htelo / TERRA TERRA / htelo 
[Pd(ibiq)2][BF4]2 - 1.35 ± 0.23 - 4.51 ± 1.18 
[Pt(ibiq)2[PF6]2 1.37 ± 0.47 - 1.83 ± 0.77 - 
 
 
4.4   Conclusions 
  
The binding abilities of each of the biisoquinoline complexes to the RNA quadruplexes, 
after studying with circular dichroism and fluorescent indicator displacement experiments, 
compares very closely with the DNA quadruplex binding results.   
 
The ability of each of the complexes to bind depends on how well they are able to stack 
onto the terminal G-quartet of a G-quadruplex or bind to the loops.  There is very little 
difference between the structure of the platinum and palladium complex when examined 
by x-ray crystallography (Chapter 2).  The difference in binding between the two 
complexes highlighted here stems from how available the loops are for the palladium 
complex to coordinatively bind.  RNA quadruplexes form parallel conformers like the c-
myc DNA which the palladium complex (after losing a ligand) cannot bind to as the loop 
size is too restrictive (RNA tetrad loops more so than DNA tetrad loops).  It is likely that 
Table. 4.2  Selectivity comparison between the different types of RNA and DNA investigated. 
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that the platinum complex does not dissociate from one of its ligands and therefore binds 
through end stacking generating the response seen in both the CD and FID experiments.   
 
4.5  Experimental 
 
General Methods 
In the RNA binding studies Ultrapure water (18.2 MΩ) purchased from Fisher Scientific 
was used to carry out the experiments.  The TERRA and NRAS oligos were bought from 
Microsynth and kept frozen until use. All other reagents were purchased from Fisher 
Scientific.  
 
Circular Dichroism Experiments 
A Jasco J-810 spectropolarimeter was used to record the CD measurements of the titration 
mixture contained within a quartz cuvette with a pathlength of 1 cm (750-200 nm). The 
concentration of each RNA oligo was calculated per strand.  The UV-Vis molar extinction 
coefficients for the oligos TERRA and NRAS are ε260 = 281,200 and 202,300 mol-1 dm3 
cm-1 respectively which were made into solutions A, B and C.  Solution A contained a 
1μM solution of the RNA in 10 mM Tris-HCl (pH 7.4) with 100 mM KCl or no other 
metal ions depending on the salt condition used. Before recording the concentration they 
were annealed to 95 °C. Solution B was a 2 μM RNA solution with 20 mM Tris-HCl plus 
200 mM of the required salt and solution C was a 150 μM complex solution made from the 
dilution of a 1000 μM stock solution for each complex.  When carrying out the titration a 
CD spectrum is initially recorded of solution A and then to this equal volumes of solution 
B and solution C are added.  This keeps the RNA concentration constant throughout the 
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experiment whilst increasing the complex concentration from a RNA:complex ratio of 
0.5:1 to 0.08:1.     
 
Fluorescent Indicator displacements 
Experiments were carried out using a Perkin Elmer luminescence spectrometer L55OB in a 
3 ml quartz cuvette. TERRA and NRAS oligos were used in the experiments and prior to 
carrying out the titration they were diluted to 0.25 μM in a 10 mM Na cacodylate solution 
(pH 7.4) with 100 mM KCl and then annealed to 95 °C before leaving to cool to room 
temperature.  A 1 mM stock solution of thiazole orange was prepared in milliQ water 
which was then diluted to the corresponding concentration with 10 mM Na cacodylate 
solution.  [Pd(ibiq)2][BF4]2 and [Pt(ibiq)2][PF6]2 solutions were made by diluting 1000 μM 
DMSO stock solutions with the 10 mM Na cacodylate solution to 20 μM.  The 
concentrations of TO required for each type of DNA (all at 0.25 μM) are as follows: 
TERRA - TO = 0.5 μM and NRAS - TO = 0.5 μM. 
 
The experiments were conducted by placing the RNA and TO mixture in a cuvette before 
adding increasing amounts of the complex being investigated (0.12 to 10 μM, which is 0.5 
to 40 equivalents).  After each addition of complex the mixture was left to equilibrate for 3 
minutes before recording an emission spectrum between 510 and 700 nm, exciting at 501 
nm.  The trapezium rule[11] was used to calculate the fluorescence area after each titration 
which was then converted into TO % displacement using % TO displacement = 100 - 
[(fluorescence area of sample/fluorescence area of DNA+TO alone) × 100]. 
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Chapter 5:  Cellular Studies 
5.1   Introduction  
 
There is much interest in the development of complexes that do not demonstrate genotoxic 
or mutagenic behaviour. Although a successful anticancer agent, cisplatin is unspecific and 
can damage healthy DNA causing mutations within the cell by coordinately binding to two 
adjacent guanine bases.[1] The targeting of another type of DNA or RNA structure such as 
the G-quadruplex offers a different mode of action to the duplex binding cisplatin which is 
useful when circumventing cisplatin resistance.[2] G-quadruplexes are formed during active 
processes such as translation and replication which make them ideal targets when 
considering proliferative cancer cells where the frequency of these processes is up-
regulated.[2]    
 
Complexes intended for use in cells must be able to get into the cell in order to reach their 
desired target, which means the complex will need to cross cell membranes and also the 
nuclear membrane when DNA is the cellular target.[3]  The complex can enter the cell 
through the cell membrane by several pathways, the choice of which will affect how fast 
the complex uptake occurs and also how it will be distributed within the cell.[3]  Three 
examples of how complexes could be transported into the cell include: 
 - Passive diffusion: The movement of molecules through the phospholipid bilayer 
which occurs down a concentration gradient. [3] 
 - Transport proteins:  Expression in cells varies and carry only particular 
substituents.[3]  The transport can be energy dependent (ATP powered pumps) or energy 
independent (channels and passive carriers). [3]    
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 - Endocytosis:  Complex uptake will involve vesicles formed from the plasma 
membrane. [3]        
  
The phospholipid membrane is hydrophobic therefore complexes with lipophilic 
substituents will be able to cross more easily into the cell.[3]  Covalently attaching 
conjugated moieties to complexes such as B vitamins, hormones and peptides can also be 
used to help with the cellular uptake of the complex by exploiting uptake mechanisms used 
for these biomolecules. [3]    
 
There are a variety of G-quadruplex binders which have been studied in various cancer cell 
lines to study their cytotoxic effects.  A few of these include (shown in Table 5.1 with their 
IC50 values in selected cancer cell lines); 3,6,9-trisubstituted acridine inhibitors (a) which 
are predicted to interact specifically with human G-quadruplexes in the telomeric region of 
DNA[4], metal salphen complexes (b) prohibit cell proliferation through telomeric 
quadruplex binding and also through binding to other genomic quadruplex sites[5], 
platinum Schiff base complexes (c) which have been found to bind to the c-myc G-
quadruplex DNA by end stacking onto the terminal G-quartet using NMR, UV-vis 
absorption and emission molecular docking experiments[6], and palladium terpyridine 
complexes (d) that interact with quadruplexes through end stacking and metal to base 
binding.[7]    
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Complex Cell line investigated and IC50 / μM 
 
 
 
 
 
 
 
IC50 = 2.65 uM  
Cell line =  A2780 [4] 
 
 
 
 
 
 
 
 
 
 
 
 
 
IC50
[5] Cell Line [5] 
2.3 μM MCF7 
2.3 μM A549 
2.3 μM RCC4 
2.3 μM RCC4-VHL 
2.3 μM 786-0 
2.3 μM Mia-PaCa-2 
2.4 μM W138 
 
 
 
 
 
 
 
 
 
 
 
 
IC50
[6] Cell Line [6] 
1.28 ± 0.33 μM HeLa 
1.09 ± 0.14 μM HepG2 
1.04 ± 0.21 μM SUNE-1 
4.8 ± 0.56 μM NCI-H460 
46.11 ± 0.53 μM CCD-19 Lu 
(a) 
(b) 
(c) 
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IC50
[7] Cell Line [7] 
0.10 ± 0.02 μM KB 
0.065 ± 0.021 μM A549 
0.12 ± 0.021 μM MCF7 
 
 
 
 
All the reported complexes show a good interaction with G-quadruplex DNA in some or 
all of the following techniques; CD, UV-Vis, FRET and FID.  It is hoped that the observed 
toxicity levels are a result of the complexes binding to the DNA quadruplex structure.  It is 
still possible however that the activity of the complex in the cell may be due to interactions 
with other cellular targets with a different mode of action not yet examined.  
 
The cytotoxicity of the palladium and platinum biisoquinoline complexes (Fig. 5.1 - a and 
b) were investigated with two different cancer cell lines, A2780 (ovarian) and T47D 
(breast) by conducting an MTT assay to obtain an IC50 value for each of the complexes.  
Cisplatin (Fig. 5.1 - c) was also used as a well studied comparison.    
 
Table 5.1  G-quadruplex binding complexes and their IC50 values in a number of different cell types. 
Cancer cell lines include; A2780 (ovarian), MCF7 (breast), A459 (lung), RCC4 (renal), 786-0 (renal), Mia-
PaCa-2 (pancreatic), HeLa (cervical), HepG2 (hepatocellular), SUNE-1 (nasopharyngeal), NCI-H460 
(lung), KB (keratin forming tumour cell line of HeLa).  Normal cell lines; W138 (human fibroblast), 
CCD-19 Lu (lung fibroblast). 
(d) 
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5.2   MTT Cytotoxicity Assay 
 
A MTT (or a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay can be 
used to investigate how toxic a complex is to a particular cell line by measuring the value 
of its half maximal inhibitor concentration (IC50).  The IC50 value will be the measure of 
the complex concentration it takes to reduce the cell viability by 50 % therefore the lower 
this value is the more potent the complex will be. 
 
When cells are treated with the yellow complex MTT, the cells that are able to respire will 
be able to reduce the MTT compound (by electron transport processes involving 
mitochondrial reductase) forming violet formazan crystals within the cells (Fig. 5.2).[9]  
The results for the MTT assay are determined colourimetrically as the intensity of the 
Figure 5.1  Crystal structures of; a. [Pd(ibiq)2][BF4]2, b. [Pt(ibiq)2][PF6]2 [Reproduced from Ref 8], 
c. Structure of cisplatin. 
(a) (b) 
(c) 
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colour produced, by dissolving the formazan crystals, is an indicator of the proportion of 
functional mitochondria and therefore the proportion of living cells.[9]  Details of the assay 
including cell growth and incubation can be found in the experimental section, subchapter 
5.5.    
 
      
 
 
 
 
 
 
 
  
5.3   IC50 Results for Complexes 5, 7 and Cisplatin  
 
The human cancer cell lines (A2780 and T47D) were treated with complexes 5 (palladium 
complex), 7 (platinum complex) and cisplatin.  The results of the MTT assay for each are 
shown in both Chart 5.1 and Table 5.2 where the IC50 value is reported in μM.  A solution 
of 2% DMSO PBS was also used to treat the cells as a control, as well as PBS only, in all 
repeats.  Both controls showed no significant cytotoxic effects on either of the cell lines 
investigated.  See appendix section 4, for examples of raw cytotoxicity data.     
 
 
Figure 5.2  The reduction of MTT to formazan in living cells by mitochondrial reductase. 
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Immediately a striking difference can be seen between the activity observed when the cells 
were treated with cisplatin compared to when they were treated with the biisoquinoline 
complexes (Chart 5.1).  The cytotoxicity effects of the biisoquinoline complexes far 
surpass those seen for the cisplatin as they are in nanomolar range when compared with 
cisplatin which is in the micromolar range.  The greatest difference in cytotoxicity is seen 
between the platinum complex and cisplatin in the T47D cell line with the platinum 
complex being 81 times more cytotoxic than cisplatin.  An explanation for this could be the 
difference in DNA targets of each complex where the cisplatin is interacting with duplex 
DNA and the biisoquinoline complexes are interacting with G-quadruplexes.  This would 
indicate that binding to G-quadruplexes has a greater cytotoxic effect however from the 
other spectrographic studies conducted in Chapter 3 the biisoquinoline complexes also 
bind to duplex DNA.  The binding of the complex to both types of DNA could be the 
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Chart 5.1  IC50 results for complexes 5 (Pd), 7 (Pt) and cisplatin, smaller image 
shows the results for the Pd and Pt complexes enlarged. 
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reason for its heightened cytotoxicity value as it is able to stop DNA replication in two 
ways.  The experimental research in Chapter 3 has also revealed that when the two types of 
DNA are in the same system (in the PAGE studies) the biisoquinoline complexes bind to 
quadruplex DNA over duplex.  A stronger binding affinity to quadruplexes is also 
demonstrated in the FID experiments where the complex was able to displace the TO at a 
much lower concentration when compared with duplex DNA.  Further explanations for the 
cytotoxicity results seen could be linked to the mechanism of uptake, the extent of complex 
degradation and how toxic the degradation products are or interactions with other cellular 
structures such as proteins.  
 
When comparing the palladium and platinum complexes the cytotoxicity values obtained 
are very similar, with the platinum complex being only slightly more cytotoxic than the 
palladium complex.  This result was surprising as the platinum complex displayed more 
encouraging results for binding to quadruplex DNA in the CD and PAGE studies.  A 
possibility for the similar activity may be because of the conditions in the cell which are 
different to those used for the other experiments.  The molecular crowding effects in the 
cell were not accounted for.  This may alter how the complex exists and may change the 
extent of aggregation in the cell.  The other cellular components also provide potential 
binding platforms which may, when disrupted, have a cytotoxic affect on the cell.  The 
majority of experiments with telomeric DNA gave similar results for both palladium and 
platinum complexes therefore a telomeric quadruplex binding mode may be responsible for 
their cytotoxic nature.   
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In general, when compared with similar quadruplex binders, the biisoquinoline complexes 
show lower IC50 values hence high cytotoxicity levels.  This prompts the future 
investigation of the complexes synthesised in this thesis in order to find out where they 
localise in cells, how they get into cells and other methods to determine cell viability.  The 
cytotoxic effect of the complexes on primary cell lines is also important in establishing 
how selective the complex will be.  For example it is hoped that it is targeting processes 
where DNA replication is high (proliferating cancers) therefore having a minimal effect on 
healthy cells which will replicate at a slower rate. 
    
5.4   Conclusions 
 
Complexes, such as the terpyridine and salphen based structures discussed in the 
introduction of this chapter, that are designed to target G-quadruplexes can have a 
significant cytotoxicity effect.  This makes them an exciting prospect when treating 
cancers, especially those which are cisplatin resistant.  
 
Complex IC50 A2780 / μM IC50 T47D / μM 
[Pd(ibiq)2][BF4]2 0.2 ± 0.1 0.5 ± 0.1 
[Pt(ibiq)2][PF6]2 0.1 ± 0.02 0.3 ± 0.1 
Cisplatin 3.3 ± 1.9 24.3 ± 4.4 
Table 5.2  IC50 results for complexes 5 ([Pd(ibiq)2][BF4]2), 7 ([Pt(ibiq)2][PF6]2) and cisplatin. 
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Both biisoquinoline complexes were found to have IC50 values lower than that of cisplatin 
and therefore are potent anticancer agents.  This is likely to be due to them binding to other 
secondary DNA structures other than duplex DNA as determined by other spectrographic 
techniques.  There is little difference in activity between the palladium and platinum 
complexes which was not predicted as the platinum complex showed a better response in 
the DNA binding experiments.  This leads to the possibility that the cytotoxicity may not 
be due to G-quadruplex binding alone and there is another target within the cell which both 
complexes have a similar affinity for.  
 
Despite the cytotoxic success of the biisoquinoline complexes the actual mode of action 
cannot be proven as localisation of the complex was not be monitored in these 
experiments.  Therefore future development of this structure would involve modification 
with a fluorescent marker that would allow the use of confocal microscopy to help 
determine this.           
 
5.5  Experimental 
 
All cellular experimental supplements were purchased from Sigma Aldrich with the 
exception of the media which was obtained from PAA-The Culture Company and the fetal 
bovine serum (FBS) purchased from Invitrogen.  The actual cell lines were sourced from 
the European Collection of Cell Cultures (ECACC) which is a health protection agency 
culture collection.  Both the A2780 (human ovarian cancer cells) and T467D (human 
breast cancer) cell lines were grown in Roswell Park Memorial Institute (RPMI-1640) 
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media to which was added further reagents to make a 10 % FBS, 1 % L-glutamine, 1 % 
sodium pyruvate, 1 % hepes buffer and an antibiotics-antimycotic (1×) solution.   
 
The two cell lines were cultured in T75 flasks, kept in an incubator at 37 °C, 5% CO2 in a 
humid environment, and grown as monolayers.  Once cell coverage had reached 70 % 
confluency (cell optimum growth phase) the cells were unadhered from the flask using 1% 
tryspin-EDTA in PBS leaving single cell suspensions.  The density of cells in the 
suspensions were determined using a hemocytometer using the trypan blue exclusion test 
to determine the cell viability.  The cells were then seeded into 96 well microtiter plates 
(Corning Costar) transferring 100 μl of complete media cell suspension to each well; 
4,000 cells per well for A2780 and 25,000 cells per well for T47D.  The microtiter plates 
were then placed in the controlled incubator for 24 hours before treating in order to give 
the cells time to adhere to the bottoms of the wells.  The two biisoquinoline complexes 
[Pd(ibiq)2][BF4]2 and [Pt(ibiq)2][PF6]2 both required a small amount of DMSO (2 %) to aid 
the solubility in the complete medium, cisplatin dissolved in complete media alone.  Five 
different complex concentrations were prepared before adding 100 μl of complex to the 
100 μl cell solution in each of the wells (A2780 6.25 μM - 0.10 μM and T47D 100 μM - 
0.39 μM).  Control lanes were prepared by treating with complete media (control 1) and 2 
% DMSO 98% complete media (control 2).  Every experiment was run in quadruplicate 
and repeated over three times.  The treated microtiter plates were then placed back into the 
controlled incubator and left for 72 hours which were checked daily for signs of 
contamination.  After this time the cell viability was then established by administering 20 
μl of a 5 mg/ml MTT solution in PBS to each well, except to half of each control set 
of wells, and leaving for a further 2 hours in the incubator.  The medium was then removed 
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from the wells before adding 200 μl of DMSO to each to dissolve any formazan crystals 
produced from the MTT.  The plates were then left for 20 minutes and using a microplate 
reader (Bio-Rad) the absorbance of the DMSO and MTT solutions in each well were read 
at 590 nm.               
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Chapter 6:  Further Synthesis and Development of the Biisoquinoline 
Complex 
6.1  Introduction 
 
This chapter describes some initial synthetic attempts to introduce side arms onto the 
complex structure.  Although the desired target was not achieved the routes show potential 
for future development. 
 
The incorporation of side arms into the structure of a G-quadruplex binder provides 
another potential mode of binding between the DNA and the complex.  Complexes that 
initially π-stack onto the terminal G-quartet can now, with the correctly positioned side 
arms, interact with the loops and grooves of the G-quadruplex also.  Ideally the new 
linkages would be able to be protonated under cellular conditions providing electrostatic 
interactions between them and the DNA backbone.  
 
An example of a complex designed with potentially interactive side arms is the copper(II) 
salphen complex (Fig. 6.1 - a) reported by Vilar et al [1].  Despite being a symmetrical 
complex the two side chains interact differently with the quadruplex.[1]  One of them 
interacts with a quadruplex groove by extending downwards, causing the piperidine ring to 
be close enough to the quadruplex backbone to set up a water hydrogen bonding bridge 
(Fig. 6.1 - b).[1] The piperidine side arm on the other side of the molecule is close in space 
to the TTA loop however no interactions between the two have been reported.[1]      
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In order to provide a better interaction with the TTA loops future work with this complex 
involves the lengthening of one of the side chains.[1]  This will allow the binding 
established with the groove to be maintained whilst a further interaction can be exploited to 
create a better and more specific binder.[1]    
 
 
 
Figure 6.1  a. Structure of copper(II) salphen complex, b. Crystal structure of the copper(II) 
salphen complex with a telomeric G-quadruplex showing the positions of the two side chain 
piperidine rings with the groove binding side chain interaction enlarged to the right with the 
location of the water bridged H-bonding.[1]    
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The biisoquinoline complexes presented in this thesis have the potential to be developed by 
incorporating additional side chains into the structure of the complex.  At present they 
show good interactions with G-quadruplex DNA however they also interact with duplex 
DNA.  The selectivity of the complexes as determined by PAGE and TO FID show good 
indications that the platinum complex binds more specifically to G-quadruplexes over 
duplex DNA.  This selectivity however could be further enhanced by incorporating side 
chains that can interact with specific quadruplex loops. 
 
The initial side chain chosen to be incorporated into the biisoquinoline structure was 
piperidine which is the same side chain used in the salphen work.  Instead of providing two 
side chains to interact with the loops and grooves, attaching piperidine ligands to the 
biisoquinoline complexes will result in four side chains.  The method of attaching each 
side arm involves the formation of a triazole linked product (Fig. 6.2) through click 
chemistry.  Using the click chemistry mechanism allows the incorporation of a variety of 
side groups to quickly build up a library of complexes to investigate DNA and RNA 
quadruplex binding. [2][3][4]      
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6.2   Molecular Design 
 
The synthesis of the biisoquinoline ligand with incorporated piperidine side arms requires a 
different synthesis route to that of the initial ligand covered in Chapter 2.  At present there 
is no means to attach an additional group therefore a new synthesis route was developed, 
shown in Scheme 6.1, which ends with the precursor required for the click reaction to 
attach the piperdine side arms.  The proposed reaction mechanisms can be found in section 
2 of the Appendix. 
 
Figure 6.2  Target structure of platinum(II) biisoquinoline complex with additional triazole piperidine 
ligands. 
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Step a: The synthesis begins with the readily available 3-chloropropionyl chloride (acid 
chloride) and bromobenzene compounds which undergo a Friedel-Crafts acylation in the 
presence of aluminium chloride (Lewis acid).[5]  A stable acylium ion is formed from the 
acid chloride with Lewis acid catalysis before the attack on the bromobenzene through an 
electrophilic substitution mechanism producing an aromatic ketone (Appendix 2.1).[5]  The 
ortho-para directing bromo group on the benzene ensures that the major product is para as 
bromine sterically hinders the ortho groups.[5] 
   
Step b: The product is then subjected to harsh intramolecular ring closing conditions that 
once again involve a Fridel-Crafts alkylation (Appendix 2.2).  High temperatures and 
Scheme 6.1  Synthesis of 6-ethynyl-3,3-biisoquinoline under the following conditions; a - AlCl3, 
CH2Cl, b - AlCl3, NaCl, 200 °C, c - n-butylnitrite, EtOH, HCl, d - POCl3, PCl5, gaseous HCl, 6 h 
60 °C, e - P (red), HI, AcOH, 6 h 130 °C, f - PdCl2(PPh3)2, CuI, Et3N, (CH3)3SiC≡CH , N2, g - 
[NiCl2.6H2O], Zn dust, PPh3, DMF, 70°C 4 h, h - THF, MeOH, 1 M NaCl.  
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excess AlCl3, combined with NaCl generate an ionic melt with 'latent acidity', which is 
required to remove the terminal chloride resulting in the creation of an unstable 
carbocation.[6]  The NaCl is added to create a neutral buffered melt; for example if more 
acidic AlCl3 is added the NaCl dissolves and reacts to generate [AlCl4]
-.[6]  If a strongly 
basic compound  is added the Na+ dissolved in the solution reacts to reform NaCl and 
precipitates out of the neutral solution.[6]  When a weak Lewis base is added to the melt 
(such as 4-Bromophenyl 2-Chloroethyl Ketone) if the Na+ concentration is greater than the 
base concentration all of the base will react to form an AlCl3 adduct (Scheme 6.2).
[6]  The 
reaction of Na+ and Cl- drives the formation of the adduct which is generated when 
[AlCl4]
- forms an AlCl3 adduct with the base.
[6]   Ring closure can then follow through an 
electrophilic substitution mechanism with the formation of a 5 membered ring producing 
the indoline product. 
 
B: (l) + [AlCl4]
- (l) + Na+ (l) → B∙AlCl3 (l) + NaCl (s) 
 
 
    
Step c: The corresponding oxime is formed through the nitrosation of the indoline product 
produced in step b using n-butyl nitrite in ethanol under acid catalysis (Appendix 2.3).[7]  
The reaction proceeds through the tautomeric enol form (structure is subject to keto-enol 
tautomerism) generated under the acidic conditions and reacts with the nitrite in a reaction 
analogous to the halogenation of ketones.[8]  The nitrosation agent is generated from the 
hydrolysis of RONO under acid catalysis (effectively nitrous acid in its protonated form) 
shown in Scheme 6.3.[9]   
Scheme 6.2  Reaction occurring between NaCl and AlCl3 when a weak Lewis base is added to the 
neutral melt mixture.  
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Step d: The indone species can be converted into an isoquinoline through a modified 
Beckman rearrangement involving the expansion of the 5 membered ring into a 6 
membered ring with the inclusion of nitrogen through the formation of nitrillium ion.[7] 
Once the diketone product is generated further PCl5 is required in substitutive chlorination 
reactions to convert the ketone moieties into chlorides (Appendix 2.4).[7]   
 
Step e: The 1-chloro group can be removed by a selective hydrogenolytic reaction using 
HI (57 % wt in H2O) and red phosphorus heated to reflux in acetic acid.
[7]  The reduction 
mechanism by hydriodic acid is composed of two steps the first being the nucleophilic 
substitution of the chloride by iodide and the second the reduction of the alkyl iodide by 
hydriodic acid (Scheme 6.4).[10]  The regioselective reaction ensures that the 3-chloro group 
and bromo group are not reduced as the chloride situated in position 1 is the most electron 
deficient (disruption of aromaticity is required for positive charge to rest on the other 
positions). 
 
 
         
 
Scheme 6.3  Hydrolysis of RONO to produce nitrosation product NO+ 
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Step f: A Sonogashira coupling reaction is able to substitute the bromide group for the 
more useful alkyne group protected with TMS (ethynyltrimethylsilane).[11]  The catalytic 
cycle shown in Scheme 6.5 involves the oxidative addition of 6-bromo-3-chloro 
isoquinoline to a Pd(0) catalyst.[11]  The next step involves the transmetallation reaction 
between the newly formed Pd-alkyl halide complex and the Cu-alkyne resulting in a Pd 
complex containing both the alkyne and alkyl halide.[11] Reductive elimination then sees 
the formation of the coupled product and the palladium in its initial oxidation state.[11]  The 
use of triethylamine in the reaction is important as it is involved in the deprotonation step 
that forms the alkyne anion, which can then bind to the oxidised copper.[11]       
 
 
 
 
Scheme 6.4  Mechanism of chloride reduction and the reuse of iodine, (HI 57 % wt solution 
is the source of H2O).[10]   
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Step g: Before deprotecting, the 6-(2-trimethylsilyl)ethynyl-3-chloro isoquinoline 
compound is coupled with itself using the same conditions as for the 3-chloro isoquinoline 
compound to produce 3,3-biisoquinoline (nickel templated cycle - see Chapter 2).   
 
Step h: In the final step of the modified biisoquinoline unit it is proposed that the alkyne 
groups can be deprotected by removal of the TMS group using either potassium carbonate 
and methanol or THF, methanol and 1 M NaOH.[12][13]     
 
The addition of a piperidine ligand to each of the alkyne groups can then potentially be 
achieved using click chemistry.[2][3][4]  This involves the synthesis of an azide appended to 
the piperidine ligand which can then be clicked into place through a copper-catalyzed 
azide–alkyne cycloaddition with the formation of a triazole moiety linking the isoquinoline 
block to the piperidine side arm (Scheme 6.6). 
Scheme 6.5  Catalytic cycle of Sonogashira coupling.[11]   
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The copper catalysed reaction produces only one isomer, 1,4-disubstituted-1,2,3-triazole, 
and proceeds through the formation of a 5-triazolyl copper intermediate.[14]   As shown in 
Scheme 6.7 a carbon-nitrogen bond is formed between the nucleophilic β-carbon of the 
newly formed copper(I) acetylide and the electrophilic terminal nitrogen of the bound 
azide.[14]  
   
 
 
 
 
 
Scheme 6.6  Proposed synthesis of 6-piperidine-1,2,3-triazole-3,3-biisoquinoline under the 
following conditions; i - H2O 15 h 80 °C, KOH/Et2O, j - CuSO4, Na ascorbate,  H2O:t-butyl 
alcohol (1:1) 15 h.   
Scheme 6.7  Mechanism of triazole formation between an azide and an alkyne.[14]   
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Platinum and palladium metal centres can then potentially be utilised in the same way as 
the unmodified biisoquinoline complexes to produce the metal complexes that would go 
forward in further DNA binding experiments. 
 
6.3   Synthesis and Characterisation of Ligand Building blocks  
 
This section reports only the synthesis and characterisation for the building blocks shown 
in Scheme 6.1.  Difficulties in the deprotection of the modified biisoquinoline compound 
and time constraints prevented the completion of the fully modified compound and 
subsequent reactions to produce the palladium and platinum complexes.  The aim was to 
provide full analysis for each of the compounds however as compounds A, B, C, D, E and 
F have all been previously synthesised in the literature[15][16][17][18] this was not essential.  
 
6.3.1   4-Bromophenyl 2-Chloroethyl Ketone (A) 
Bromobenzene and 3-chloropropionyl chloride were individually mixed with 
dichloromethane and reacted together in the presence of aluminium chloride according to a 
literature procedure.[15]  After the reaction work up the product required purification by 
column chromatography giving a final yield of 82 %.  The reaction scheme for this 
reaction is shown in Scheme 6.8.       
 
 
 
 
Scheme 6.8  Synthesis of 4-bromophenyl 2-chloroethyl ketone.  
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The electron ionisation mass spectrum shows the fragmented compound at the following 
m/z peaks; 212.0 [C9H8OBr]
+, 183.0 [C7H4OBr]
+ and 157.0 [C6H4Br]
+ (further fragments 
can be seen in the mass spectrum found in the Appendix 1.10). The 1H-NMR spectrum (Fig 
6.3) was assigned using 2D COSY and NOESY (see Appendix 1.10).  The two groups of 
alkyl protons were easily distinguishable from the aromatic protons as they were seen at a 
much lower ppm as triplets.  The full assignment was deduced using NOESY where only 
protons H3 and H2 showed long range couplings between each other.       
 
 
 
 
6.3.2  5-Bromoindan-1-one (B) 
The next step of the building block synthesis involved the formation of an indoline 
following an intramolecular ring closing reaction (Scheme 6.9).  The reaction required a 
mixture of AlCl3 and NaCl to be melted by heating them to 200 °C before adding reagent A 
(4-bromophenyl 2-chloroethyl ketone), carried out according to literature procedure.[15]  No 
further purification of the product after work up was required giving a 58 % yield.   
Figure 6.3  H-NMR spectrum (300 MHz, CDCl3, 298 K) of 1,3-dione 4-bromophenyl 2-chloroethyl. 
ketone 
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Electron ionisation mass spectrometry resulted a number of fragmented peaks 
corresponding to the compound, the most abundant peaks being found at a m/z of 210.0 
[C9H7OBr]
+ corresponding to the intact compound and 103.1 [C8H7]
+ (see Appendix 1.11).  
The 1H-NMR spectrum  (Fig. 6.4) was partly assigned using the splitting pattern of the 
aromatic peaks and comparison with the NMR spectra for its precursor (A).  Proton H1 
would exist as a singlet as it has no adjacent protons whilst both protons H2 and H3 form 
doublets which couldn't be accurately assigned.  Both protons H2 and H3 would be 
identified at a later stage of the synthesis as it was not necessary to formally identify them 
at this step in order to proceed to compound C.  The proton NMR provides insight into the 
purity of the compound whereas the mass spectrum shows evidence of the compound 
formation.     
Scheme 6.9  Synthesis of 5-bromoindan-1-one. 
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6.3.3  6-Bromo-Indan-1,2-Dione-1-Oxime (C) 
The nitrosation of indoline (B) using n-butyl nitrite under acid catalysis resulted in the 
formation of the oxime shown in Scheme 6.10.  The reaction proceeds through compound 
B's tautomeric enol form whose formation is also the rate determining step of the 
reaction.[8]  The synthesis was adapted from the literature and required no further 
purification generating a yield of 60 %.[16]   
 
 
 
 
 
 
Figure 6.4  H-NMR spectrum (300 MHz, CDCl3, 298 K) of 5-bromoindan-1-one ketone. 
Scheme 6.10  Synthesis of 6-bromo-indan-1,2-dione-1-oxime. 
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The molecular ion peak at m/z 238.0 corresponding to [C9H6O2NBr]
+ was found when 
analysing the compound by electrospray ionisation mass spectrometry (see Appendix 1.12).  
In the 1H-NMR spectrum (Fig. 6.5) there is only one alkyl proton present which is no 
longer a triplet and instead a singlet (H4) as it can no longer couple to an adjacent proton.  
The newly added NOH group is in the place of proton H5. Protons H1, H2 and H3 are in 
similar positions with the same multiplicity to precursor compound B.   
 
 
6.3.4   6-Bromo-1,3-Dichloro-Isoquinoline (D) 
The oxime was converted into the dichlorinated isoquinoline in a modified Beckmann 
rearrangement using an excess of phosphorus pentachloride in phosphorus oxychloride 
(Scheme 6.11).[7][17]  The reaction mixture was saturated with gaseous hydrogen chloride 
which was produced in situ by the careful addition of concentrated HCl onto calcium 
carbonate. Extra care was taken to avoid any contact of water with reagents during the 
Figure 6.5  H-NMR spectrum (300 MHz, MeOD, 298 K) of 6-bromo-indan-1,2-dione-1-oxime. 
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reaction and when reducing in vacuo.  The yield obtained from this stage of the reaction 
after purification using column chromatography was a disappointing 18 %.  This may have 
been due to a leakage in the apparatus which after saturating with gaseous hydrogen 
chloride allowed air to leak into the system.       
 
 
 
 
 
 
The electron ionisation mass spectrometry spectrum displayed a molecular ion peak at a 
m/z of 276.9 consistent with the product formation (Appendix 1.13).  The 1H-NMR 
spectrum can be assigned by taking into account the ortho and meta contributions for each 
proton.  Short range couplings to ortho positions exhibit larger coupling constants whereas 
long range couplings to meta exhibit smaller coupling constants.   H3 has one proton ortho 
to it (para proton is too far away to make a contribution) and has a J-coupling value of 6.9 
Hz while H1 which has one proton meta to it has a J-coupling value of 2.0 Hz (Fig. 6.6).  
H2 meanwhile has a proton both ortho and meta to it therefore produces a doublet of 
doublets in the spectra with J-coupling values of 6.9 Hz and 2.0 Hz.  Proton H4 is part of 
the other aromatic ring and has no ortho or meta protons to interact with, therefore is seen 
as a singlet in the spectrum. 
Scheme 6.11  Synthesis of 6-bromo-1,3-dichloro-isoquinoline. 
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6.3.5   6-Bromo-3-Chloro-Isoquinoline (E) 
The method used in Chapter 2 to abstract the same chloro substituent using tin from 1,3-
dichloroisoquinoline was not repeated due to very little product being produced that was 
also heavily contaminated with tin salts.  In this experiment the dichlorinated product (D) 
was refluxed with hydriodic acid and red phosphorus in acetic acid in order to remove the 
1-chloro substituent (Scheme 6.12).[7][17]  The product synthesised required purification by 
column chromatography producing the product in a 27 % yield. Despite the % yield being 
very low the unreacted starting materials were more easily obtained than for the synthesis 
using tin.    
 
 
 
 
 Scheme 6.12  Synthesis of 6-bromo-3-chloro-isoquinoline. 
Figure 6.6   H-NMR spectrum (300 MHz, MeOD, 298 K) of 6-bromo-1,3-dichloro-isoquinoline. 
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The molecular ion peak corresponding to the formation of he compound was found at a 
m/z of 242.9 [H + C9H5NClBr]
+ (see Appendix 1.14).  The 1H-NMR spectrum in Figure 
6.7 shows the emergence of a fifth proton environment after the removal of the 1-chloro 
substituent.  Proton H5 is seen furthest downfield (singlet peak) as it is closest to the 
electronegative nitrogen atom.  H4 is also shown as a singlet due to lack of coupling 
protons further upfield as it is further from nitrogen.  H1, H3, and H2 exist in a similar 
pattern to that seen in compound D where ortho and meta proton couplings dictate the 
magnitude of peak splitting.     
 
 
 
 
6.3.6  6-(2-Trimethylsilyl)Ethynyl-3-Chloro-Isoquinoline (F) 
The bromide group in position 6 was removed and replaced with ethynyltrimethylsilane in 
the palladium catalysed cycle, shown at the beginning of this subchapter, in a reaction 
mixture containing PdCl2(PPh3)2, copper(I) iodide and triethylamine (Scheme 6.13).
[11][18]   
Figure 6.7  H-NMR spectrum (300 MHz, MeOD, 298 K) of 6-bromo-3-chloro-isoquinoline. 
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Operating in an inert atmosphere the Sonogashira coupling reaction produced, after column 
chromatography using silica gel, a 63 % yield.    
 
 
 
 
 
 
 
Electron ionisation mass spectrometry data produced a molecular ion peak at 259.1 
corresponding to [C14H14NClSi]
+ (see Appendix 1.15).  Clear evidence is seen in the 1H-
NMR spectrum in Figure 6.8 for the formation of the required product.  The singlet peak at 
0.27 ppm has an integration of nine and is representative of the trimethylsilane part of the 
newly added substituent.  The protons H3 and H1 have also switched places when 
compared with compound E.  The bromine atom would have had a more significant 
deshielding effect on the adjacent proton than the carbon replacing it hence H1 seen 
slightly further upfield.  Protons H3 and H2 can be assigned based on their ortho and meta 
coupling patterns (H3 is a doublet and H2 is a doublet of doublets).    
Scheme 6.13  Synthesis of 6-(2-trimethylsilyl)ethynyl-3-chloro-isoquinoline. 
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6.3.7   6-Ethynyl-3,3-Biisoquinoline (G) 
The coupling of the two modified isoquinoline units was carried out using a nickel 
complex as a template with triphenylphosphine and zinc dust in DMF (Scheme 6.14).  The 
experiment proceeded as for the unmodified isoquinoline units with the reduction of the 
nickel complex by the zinc dust (turning the solution from green to red) and then adding 
the compound and leaving it to react for four hours.  Column chromatography was used to 
purify the product, the main contaminant being triphenylphosphine oxide, before 
deprotecting using a 18 ml solution of THF:MeOH (2:1) and 1 M NaOH (6 ml).[13]  
Unfortunately the deprotection step was not completely successful and the product 
contained a mixture of protected and deprotected biisoquinoline compounds.  The probable 
cause of this was the lack of solubility of the compound and length of reaction time, both 
of which could be addressed in further experimental work.  The overall yield for the 
mixture of protected and deprotected compound was 0.4 % which although a little bit 
Figure 6.8  H-NMR spectrum (300 MHz, MeOD, 298 K) of 6-(2-trimethylsilyl)ethynyl-3-chloro-
isoquinoline. 
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disappointing, was only the first attempt at this synthesis which with more starting material 
may be optimised.   
 
 
The final 1H-NMR spectrum contains a mixture of the deprotected and protected modified 
biisoquinoline compounds (Fig. 6.9) which can also be seen in the mass spectrum 
(Appendix 1.16) with molecular ion peaks at 449.2 and 305.1 (protected and deprotected 
respectively).  There is also a small amount of monodeprotected compound which has a 
molecular ion peak at 399.1.  An attempt at assigning the 1H-NMR peaks was made by 
considering the integration of the newly formed alkyne peak and comparing with both 
peaks belonging to proton H5.  Only one of these peaks matches the integration therefore 
the other peak must be from the protected compound and hence will correlate with the 
integrated TMS peak.  The protons H2 and H3 could not be fully assigned for each 
compound as they shift very little between forms and therefore have too great an overlap to 
integrate separately.  The presence of the monodeprotonated compound will also have an 
effect on the spectrum (however the concentration of this species is much lower) which 
Scheme 6.14  Synthesis of 6-ethynyl-3,3-biisoquinoline. 
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further prevents the full assignment of the spectrum.  This can only be acheived upon 
purification of the mixture.     
 
 
 
 
 
6.4   Conclusions  
 
The development of the biisoquinoline complex used in the DNA and RNA binding and 
cell toxicity experiments was explored resulting in a molecular design incorporating 
protonatable side arms that have the potential to interact with the loops of a G-quadruplex.  
Piperidine type appendages have been used in other quadruplex binding complexes in the 
Figure 6.9  H-NMR spectrum (300 MHz, CDCl3, 298 K) of the protected (red) and deprotected  
(black) forms of 6-ethynyl-3,3-biisoquinoline, only deprotected structure displayed.  
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literature therefore work was started to combine them with the well fitting stackable 
biisoquinoline complex unit  
 
The same synthetic route for the unmodified biisoquinoline ligand could not be followed as 
to incorporate the new side arms a 6-bromo moiety was required, therefore a new reaction 
scheme was designed.  Despite the synthesis requiring many steps, once the ethylene 
modified biisoquinoline compound can be synthesised a whole host of possibilities for side 
arm addition can be considered by utilising click chemistry.   
 
Unfortunately due to lack of time the synthesis of the completed ligand with the additional 
clicked piperidine side arms was not achieved.  Despite this 6-ethynyl-3,3-biisoquinoline 
was produced and characterised by mass spec and 1H-NMR, although not in an entirely 
pure form due to the presence of the TMS protected compound.  The presence the 
deprotected compound suggests the deprotection step was partially successful and can be 
modified in order to produce a pure yield.    
  
6.5   Experimental  
 
General Methods 
All characterisation techniques took place within the University of Birmingham.  NMR 
spectra were recorded in CDCl3 and CD3OD.  1D 
1H NMR and COSY spectra were 
recorded on BrukerAV(III) 300 and AV(III) 400 instruments operating at 300 MHz and 
400 MHz respectively.  13C NMR and HSQC spectra were recorded on a BrukerAV(III) 
400 instrument operating at 100 MHz.  Electrospray ionisation was performed on a Waters 
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LCT Time of Flight Spectrometer and electron impact mass spectrometry on a VG 
ZabSpec mass spectrometer.  A  Varian  Cary 5000 UV‐Vis spectrometer was used to 
obtain UV-Vis spectra for the complexes and infrared spectra were recorded on a Perkin 
Elmer Spectrum 100 FT-IR spectrometer.  Full characterisation, although aimed for, was 
not necessary for compounds A - F as they have been previously synthesised in the 
literature.[15][16[17][18]   
 
The compounds and solvents used were obtained from Fisher, Sigma Aldrich, Scientific 
Laboratory Supplies and Acros organics.  All the solvents were of a laboratory reagent 
grade and were used without further purification 
 
4-Bromophenyl 2-Chloroethyl Ketone (A) [15] 
Molecular weight = 247.52 gmol-1 
Molecular Formula = C9H8OClBr 
 
To a suspension of aluminium chloride (26.1 g, 0.2 mol) and dichloromethane (45ml) was 
added a solution of 3-chloropropionyl chloride (20 ml, 0.2 mol) in dichloromethane (13 
ml).  The mixture was allowed to stir at room temperature for 15 minutes before adding a 
solution of bromobenzene (20 ml, 0.2 mol) in dichloromethane (13 ml) portion wise over 
the course of 1 h.  After stirring at room temperature for 16 h the mixture was poured onto 
a mixture of ice and 1M hydrochloric acid.  The organic phase was then washed with water 
and then an aqueous solution of sodium bicarbonate, dried over magnesium sulfate and 
dried in vacuo.  The residue was then purified by column chromatography (silica gel, 15:1, 
petroleum ether:ethyl acetate, Rf 0.2) to leave a pale orange powder, 40.5 g, 82 % yield. 
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1H NMR (400 MHz, CDCl3): δ 7.82 (d, 2H, J = 8.8, H2), 7.63 (d, 2H, J = 8.4, H1), 3.91 (t, 
2H, J = 6.8, H4), 3.43 (t, 2H, J = 6.8, H3). 
13C NMR (100 MHz, CDCl3): δ 132.1 (CH1), 129.6 (CH2), 41.2 (CH3), 38.5 (CH4). 
IR (Solid): ν = 1612 (s), 1507 (m), 1463 (s), 1126 (s), 1088 (s), 1036 (s), 860 (w), 757 (s)   
cm-1. 
Mass analysis (EI, +ve): m/z = 212.0 [C9H8OBr]
+, 183.0 [C7H4OBr]
+, 157.0 [C6H4Br]
+. 
 
5-Bromoindan-1-one (B) [15] 
Molecular weight = 210.15 gmol-1 
Molecular Formula = C9H7OBr 
 
Aluminium chloride (54.0 g, 0.4 mol) and sodium chloride (11.8 g, 0.2 mol) were mixed 
together and heated to 200°C.  When the compounds had melted 4-bromophenyl 2-
chloroethyl ketone (A) (10 g, 0.04 mol) was added over a period of 10 min before leaving 
to react at 200°C for 2 h.  The hot mixture was poured into a beaker of ice and 1M 
hydrochloric acid and extracted with ethyl acetate.  It was washed with a sodium 
bicarbonate solution, followed by water, dried over magnesium sulfate and then dried in 
vacuo. 4.86 g, 58 % yield. 
 
1H NMR (400 MHz, CDCl3): δ 7.66 (s, 1H, H1), 7.61 (d, 1H, J = 8.4, H3/2), 7.51 (d, 1H, J = 
8.4, H2/3), 3.14 (t, 1H, J = 5.6, H5), 2.70 (t, 1H, J = 6.0, H4). 
13C NMR (100 MHz, CDCl3): δ 131.0 (CH2), 130.0 (CH1), 125.0 (CH3), 36.2 (CH4), 25.5 
(CH5). 
IR (Solid): ν = 1698 (m), 1571 (w), 1435 (w), 1318 (w), 1267 (w), 836 (w), 813 (w) cm-1. 
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Mass analysis (EI, +ve): m/z = 210.0 [C9H7OBr]
+, 103.1 [C8H7]
+. 
 
6-Bromo-Indan-1,2-Dione-1-Oxime (C) [16] 
Molecular weight = 238.05 gmol-1 
Molecular Formula = C9H6O2NBr 
 
A solution of 5-bromoindan-1-one (B) (3.1 g, 0.015 mol) in ethanol (250ml) was heated to 
40°C before adding drop wise n-butylnitrite (1.9 ml, 0.016 mol) followed by the drop wise 
addition of concentrated HCl (1.3 ml).  The solution was then left to stir for 1.5 h at 40°C 
before reducing in vacuo.  The resulting orange solid was washed with water and left to 
dry under vacuum.  2.12 g, 60% yield. 
 
1H NMR (300 MHz, MeOD): δ 7.87 (s, 1H, H1), 7.73 (d, 1H, J = 8.0, H3/2), 7.67 (d, 1H, J = 
8.0, H2/3), 3.87 (s, 2H, H4). 
13C NMR (100 MHz, MeOD): δ 132.6 (CH2), 131.6 (CH1), 126.4 (CH3), 29.0 (CH4). 
IR (Solid): ν = 3251 (br, m), 1730 (m), 1655 (w), 1598 (m), 1419 (w), 1316 (m), 1258 (m), 
1035 (w), 903 (s), 827 (m), 741 (m) cm-1. 
Mass analysis (ESI, +ve): m/z = 238.0 [C9H6O2NBr]
+. 
 
6-Bromo-1,3-Dichloro-Isoquinoline (D) [17] 
Molecular weight = 276.94 gmol-1 
Molecular Formula = C9H4Cl2NBr 
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6-Bromo-Indan-1,2-Dione 1-Oxime (C) (1.6 g, 6.7mmol) was suspended in POCl3 (41.5 
ml) before carefully treating with PCl5 (1.6 g, 7.7 mmol).  A stream of HCl gas was 
generated by dripping hydrochloric acid onto calcium carbonate which was then 
introduced to the solution until it was saturated.  Only then was the mixture heated to 60°C 
and left to stir for 6 h.  The dark brown solution generated was reduced in vacuo, taking 
care not to bring the solution into contact with water, before hydrolysing the residue with 
water, extracting with ethyl acetate, washing with brine then water, drying over 
magnesium sulphate and finally reducing in vacuo.  The crude product was purified by 
column chromatography (silica gel, 9:1, hexane: ethyl acetate, Rf 0.7). 0.34 g, 18 % yield. 
 
1H NMR (300 MHz, MeOD): δ 8.24 (d, 1H, J = 9.2, H3), 8.22 (d, 1H, J = 2.0, H1), 7.89 
(dd, 1H, J = 9.2, 2.0, H2), 7.87 (s, 1H, H4). 
13C NMR (100 MHz, MeOD): δ 133.8 (CH2), 130.1 (CH1), 129.1 (CH3), 120.4 (CH4). 
IR (Solid): ν = 1607 (m), 1549 (m), 1471 (m), 1336 (w), 1286 (m), 1155 (w), 1060 (m), 
980 (s), 891 (s), 854 (m), 809 (s) cm-1. 
Mass analysis (EI, +ve): m/z = 276.9 [C9H4Cl2NBr]
+ . 
 
6-Bromo-3-Chloro-Isoquinoline (E) [17] 
Molecular weight = 240.93 gmol-1 
Molecular Formula = C9H5NClBr 
 
6-Bromo-1,3-dichloro-isoquinoline (D) (2.87 g, 0.01 mol (from multiple batches of D), red 
phosphorus (0.77 g, 0.02 mol), hydriodic acid (4.7 ml, 0.10 mol) and acetic acid (17 ml) 
were mixed together and heated at reflux for 8 h.  The mixture was then hot filtered 
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through celite and then reduced in vacuo.  A 1 M sodium hydroxide solution was used to 
basify the residue before extracting with ethyl acetate, washing with brine, drying over 
magnesium sulfate and reducing again in vacuo. The crude product was then purified by 
column chromatography (silica gel, 7:3, hexane: ethyl acetate, Rf 0.6). 0.64 g, 27 % yield. 
 
1H NMR (300 MHz, MeOH): δ 9.09 (s, 1H, H5), 8.15 (s, 1H, H1), 8.03 (d, 1H, J = 8.7, H3), 
7.86 (s, 1H, H4), 7.78 (d, 1H, J = 8.7, H2). 
IR (Solid): ν = 1615 (m), 1479 (m), 1383 (m), 1269 (w), 1058 (m), 943 (s), 805 (m), 788 
(m) cm-1. 
Rf value: 0.6 (7:3, hexane: ethyl acetate) 
Mass analysis (EI, +ve): m/z = 242.9 [H + C9H5NClBr]
+ . 
 
6-(2-Trimethylsilyl)Ethynyl-3-Chloro Isoquinoline (F) [18] 
Molecular weight = 259.06 gmol-1 
Molecular Formula = C14H14NClSi 
 
 
PdCl2(PPh3)2 (22.6 mg, 0.03 mmol) and copper(I) iodide (18 mg, 0.1 mmol) were added to 
a solution of 6-bromo-3-chloro-isoquinoline (E) (0.64 g, 2.7 mmol) in triethylamine (13 
ml).  Nitrogen was bubbled through the solution for 1 minute to degas it before adding 
ethynyltrimethylsilane (0.2 ml, 1.4 mol) and heating the mixture to 50°C for 1 h.  The 
solvent was then removed in vacuo before purifying by column chromatography (silica gel, 
5:95, ethyl acetate: hexane, Rf 0.2).  0.44 g, 63 % yield. 
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1H NMR (300 MHz, MeOD): δ 9.09 (s, 1H, H5), 8.08 (d, 1H, J = 8.7, H3), 8.00 (s, 1H, H1), 
7.89 (s, 1H, H4), 7.64 (d, 1H, J = 8.4, H2), 0.28 (s, 9H, Si(CH3)3) 
13C NMR (100 MHz, MeOD): δ 153.9 (CH5), 131.7 (CH2), 130.7 (CH1), 129.4 (CH3), 121.0 
(CH4). 
IR (Solid): ν = 2967 (w), 1619 (m), 1611 (w), 1481 (m), 1430 (m), 1372 (m), 1242 (m), 
1191 (m), 1072 (m), 839 (s) cm-1. 
Mass analysis (EI, +ve): m/z = 259.1 [C14H14NClSi]
+, 244.1 [C13H11NClSi]
+ 
 
6-Ethynyl-3,3-Biisoquinoline (G) 
Molecular weight = 302.84 gmol-1 
Molecular Formula = C22H12N2 
 
Part 1 
As for 3,3-biisoquinoline, under an argon atmosphere [NiCl2.6H2O] (826 mg, 3.48 mmol), 
PPh3 (3.67 g, 14.0 mmol) and (washed) zinc dust (246 mg, 3.76 mmol) were added to a 
Schlenk tube.  DMF (39 ml) was then added by syringe into the sealed vessel.  The brick 
red solution that formed was left to stir at 70°C for an hour before adding a degassed 
solution of 6-(2-trimethylsilyl)ethynyl-3-chloro isoquinoline (F) (0.9 g, 3.47 mmol) in 
DMF (20 ml).  The mixture was then left to heat at 70°C for 4 h.  After heating, the 
mixture was allowed to cool to room temperature before pouring onto a 7 % ammonium 
hydroxide solution (19 mL) – a small amount of concentrated (28 %) ammonium 
hydroxide was added to ensure all the ligand has been removed from the metal.  The 
product was then extracted in dichloromethane and diethyl ether (2:1, 3 x 65 ml) before 
removing the solvent from the organic layer in vacuo.  The brown oil that remained was 
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diluted with dichloromethane (40 ml) and washed with water (4 x 13 ml) and brine (26 ml) 
before drying over MgSO4 and reducing in vacuo to a brown solid.   This was purified by 
column chromatography (silica gel, CH2Cl2 followed by ethyl acetate, Rf 0.4) to give a 
yellow solid.  This was followed by another column to remove any traces of 
triphenylphosphine oxide (silica gel, diethyl ether) which again left a yellow solid. 
 
Part 2[13] 
The coupled product was immediately taken through to the de-protection step by 
dissolving the product in THF (12 ml) and then diluting this with methanol (6 ml).  1 M 
NaOH solution (6 ml) was then added to the reaction mixture and it was left to stir for 30 
min.  After this time diethyl ether was added (30 ml) and the solution left to stir again for a 
further 15 min.  The product was then extracted, washed with brine and dried over sodium 
sulfate.  The product still remained a mixture of protected and de-protected products.  2 
mg, 0.4 % yield.     
 
Protected Compound 
 
 
 
 
1H NMR (300 MHz, CDCl3): δ 9.22 (s, 1H, H5), 8.71 (s, 1H, H4), 7.97 (s, 1H, H1), 7.89 - 
7.83 (m, 1H, H2 or 3), 7.57 - 7.51 (m, 1H, H3 or 2), 0.20 (s, 9H, Si(CH3)3).  
Mass analysis (ESI, +ve): m/z = 449.2 [H(C28H28N2Si2)]
+, 471.1 [Na(C28H28N2Si2)]
+. 
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De-protected Compound 
 
 
 
1H NMR (300 MHz, CDCl3): δ 9.24 (s, 1H, H5), 8.75 (s, 1H, H4), 8.02 (s, 1H, H1), 7.89 - 
7.83 (m, 1H, H2 or 3), 7.57 - 7.51 (m, 1H, H3 or 2), 3.18 (s, 1H, alkyne).  
Mass analysis (ESI, +ve): m/z = 305.1 [H(C22H12N2)]
+, 327.1[Na(C22H12N2)]
+. 
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Chapter 7: Conclusions and Future Work 
7.1  Conclusions 
 
Specific targeting of cellular processes by complexes has led to designs based on the 
associated DNA.  Notable examples of such complexes include the supramolecular iron 
helicate which targets three way and Y-shaped junctions and [Rh(bpy)2chrysi]
3+
 which 
targets DNA mismatches.
[1][2]
  G-quadruplexes are another type of DNA structure that have 
been linked to processes that control replication and transcription.  Complexes seen in 
research conducted by Vilar and Teulade-Fichou are designed to target G-quadruplexes by 
incorporating a large end stacking surface area with an overall positive charge (from a 
central metal ion) to maximise interactions with the terminal G-quartet of the quadruplex.  
Quadruplex only binders will prevent the B-DNA structure from being unnecessarily 
damaged by unspecific targeting.  The synthesis of a highly specialised complex that can 
prevent the continuous replication of cancerous cells (by preventing telomerase action) or 
stop oncogene promoter regions from over producing transcription factors is advantageous.  
This is especially true if the complex can offer specific binding to mutated DNA whilst 
maintaining the health of B-DNA; offering an effective anticancer alternative to 
conventional duplex binders.         
 
The aim of this thesis was to focus on the targeting of the G-quadruplex structure by 
synthesising a simple metal complex capable of specifically binding to a G-quartet.  
Biisoquinoline was chosen as the aromatic ligand to form 2:1 complexes with palladium 
and platinum that potentially have an excellent size and shape match for a G-quartet.  This 
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was hoped to result in enhanced selectivity as the ligands should be too bulky to interact by 
intercalating between base pairs.  Rhodium and rhenium biisoquinoline complexes were 
also investigated.  The interactions of the complexes with both duplex and quadruplex 
forming DNA were investigated using DNA binding experiments.  This helped to 
determine how the complexes bound to G-quadruplexes and if they were selective for one 
type of DNA over another.   
 
Both of the square planar complexes [Pd(ibiq)2][BF4]2 and [Pt(ibiq)2][PF6]2 were shown to 
interact well with duplex DNA and antiparallel hybrid quadruplex forming htelo DNA 
when examined by circular dichroism.  Strong ICD peaks were seen in each of the 
titrations conducted with the two types of DNA.  When the same titrations were carried out 
using a c-myc oligo, which forms parallel quadruplex forming DNA, the platinum complex 
was observed to interact more than the palladium complex with the DNA.  Interestingly 
when the platinum complex was titrated in the c-myc DNA without the additional K
+
 or 
Na
+
 cations in the buffer the CD spectrum became a mirror image of itself at high complex 
concentrations.  The octahedral rhenium complex showed no interaction with either ct-
DNA or htelo DNA which demonstrated how important the square planar geometry was 
for efficient binding.   
 
The platinum biisoquinoline complex does bind to quadruplex forms of DNA as 
hypothesised in Chapter 2.  The formation of quadruplexes before the addition of the 
complex could be observed using CD therefore it is believed that the complex binds to 
preformed quadruplexes resulting in the presence of the intense CD bands in the MLCT 
region.  Work has been presented in this thesis that suggests an end stacking binding mode 
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is occurring (red shifts in UV-vis titrations).  However without the crystal structure of the 
complex with the DNA this mode of binding cannot be fully established. 
 
Unfortunately the platinum and palladium complexes also bind to duplex DNA as seen in 
the CD titration spectra with ct-DNA.  The size of the biisoquinoline ligand was expected 
to be too big to interact significantly with duplexes through an intercalative mode of 
action.  The strong ICD bands and the red shift observed in the UV-vis titration indicate 
both of the complexes are able to directly coordinate to the duplex DNA.  Groove binding 
is a possibility at low complex concentrations as the red shift is only observed at high 
complex loading.  This is especially true for the palladium complex in the gel 
electrophoresis where changes in the bands occur only at high complex loadings.               
 
The palladium biisoquinoline complex differs from the platinum complex in its response to 
c-myc DNA (which forms a parallel G-quadruplex conformer).  The reason for this may be 
that the palladium is actually binding co-ordinatively to the bases in the loops instead of 
end stacking and cannot bind to the loops when in this conformation.  However further 
analysis using UV-vis titrations found the complex to produce a similar response with both 
types of quadruplex forming DNA (htelo and c-myc).  The large red shifts can indicate 
both an end stacking and coordinative mode of interaction.  
 
To further investigate the selectivity of the complexes for quadruplex forming DNA over 
duplex DNA fluorescence indicator displacements (FID) and polyacrylamide gel 
electrophoresis experiments (PAGE) were carried out.  The complexes were both able to 
displace the thiazole orange at concentrations below the 0.5 μM threshold in both types of 
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quadruplex forming DNA.  More significantly the same complexes were less able to 
displace the TO from the duplex forming DNA, ds26, requiring concentrations above 2 
μM.  The palladium complex struggled to displace the TO from the c-myc quadruplex 
which again may be linked to how it binds.  If in solution with the DNA, the majority is in 
its dissociated form it is no longer going to be able to successfully displace the TO as it 
becomes a poorer π stacker and cannot access the parallel quadruplex loops to coordinate.  
The PAGE experiments, for the platinum complex only, demonstrated that when both 
types of DNA are present (duplex and quadruplex) the complex appears to bind to the 
quadruplex DNA over the duplex DNA.  Evidence lies in the undisturbed duplex band that 
is seen when combined with the complex and the quadruplex forming DNA.  The band 
seen with duplex DNA and the complex only is more dispersed suggesting that binding is 
occurring.                
 
Another possible difference between the binding ability of the platinum complex and the 
palladium complex may be linked to the extent of planarity each complex is able to 
achieve and how this fits with the surface of the terminal G-quartet.  Only very subtle 
differences however were actually found between the platinum and palladium complex 
crystal structures.  The platinum complex appears to be the better match of the two despite 
it actually being slightly less planar than the palladium complex (26° between planes 
instead of 24°), indicating that the  G-quartet is slightly distorted too.  The anions present 
may have also contributed to the difference in binding however this wasn't investigated in 
this thesis.           
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In Chapter 4 the interactions of the palladium and platinum complex were investigated 
with RNA oligos TERRA and NRAS which fold into parallel quadruplex conformations, 
as the c-myc DNA did.  Unsurprisingly, the platinum complex showed a similar interaction 
to that observed with the c-myc DNA and the palladium complex showed very little 
response in both the CD and FID experiments.  This further suggests that the platinum 
interacts in an end stacking mode whilst the palladium complex loses a ligand.  Instead of 
targeting the quadruplex in an end stacking mode the palladium prefers to bind 
coordinatively with the loops which is hindered in parallel quadruplex conformations. 
 
In the cell work reported in Chapter 5 both of the platinum and palladium complexes show 
cytotoxicity values in the nM range against ovarian and breast cancer cell lines.  The 
similar cytotoxic abilities of the two complexes suggests that they both have the same 
mode of action.  When considering the preceding binding investigations the platinum 
complex was expected to have the greatest cytotoxic effect upon binding to DNA.  The 
complexes cytotoxic effect therefore may be due to a combination of duplex DNA and 
htelo DNA binding events as well as the possible disruption of other cellular processes that 
haven't been investigated in this work.   
 
The experimental work conducted in Chapter 6 aimed to develop the biisoquinoline 
complex by including additional side arms that have been seen to promote binding in the 
literature.
[3]
  The design and synthesis of the new ligand was reported; however due to the 
number of steps in the reaction scheme the modified ligand could not be completed on 
time.   
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7.2  Future Work 
 
The biisoquinoline complex in its present state lacks the visibility required for it to be seen 
in cells.  Therefore the appendage of a fluorescent arm would enable the localisation of the 
complex to be observed, which could be added to the complex in a similar way to the 
'clicked on' side arms in Chapter 6.  Confocal microscopy would then be used to visualise 
the complex in the cells where it would hopefully be found in the nucleus.  Further work 
into the overall synthesis of the biisoquinoline ligands is required in order to increase the 
yield of the final metal complexes.    
 
An attempt at calculating the binding constant was made using the circular dichroism and 
UV-vis spectroscopy results for some of the complex-DNA titrations.  A useful technique 
that could be used to confirm this is surface plasmon resonance (SPR).  The technique 
involves the immobilisation of DNA on a gold chip that is treated with the complex. The 
chip is exposed to incident light causing the oscillation of gold surface electrons (which are 
influenced by the mass at the surface).
[4]
  The association and dissociation rates of the 
ligand to the DNA can be recorded which are used to calculate the binding constant.    
 
Another biological assay that could determine the target of the complex is the scratch assay 
(or wound healing assay) where cells are grown until confluent before scratching the 
surface so that there is an area where no cells are present.  The cells would then be treated 
with the complex and if the complex is able to inhibit the SRC gene required to produce 
the SRC protein required for cell mobility, the cells would not be able to regrow over the 
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scratch formed.  The SRC proto-oncogene is G-quadruplex rich and quadruplex formation 
and stabilisation in this area can be linked to the inhibition of the mobility protein.
[5]
   
    
Further toxicity assays either monitoring ATP or using an enzyme linked immunosorbant 
assay (ELISA) need to be performed in order to be confident of the MTT assay results 
attained in Chapter 5.  It is thought that the media and its components can affect the 
amount of formazan produced giving an inaccurate cell viability determination.  Cell work 
using primary cell lines is also required to determine how toxic the complexes are.     
 
The platinum complex, [Pt(ibiq)]Cl2, here synthesised with limited solubility could be 
developed into a carboplatin type complex by replacing the chloride ligands with 1,1-
cyclobutanedicarboxylate (Fig. 7.1).  This exchange is hoped to increase the solubility of 
the complex that could then be used in further DNA binding experiments.   
 
 
 
  
 
 
 
 
 
Figure 7.1. Platinum biisoquinoline complex with a bidentate carboxylate group 
substituting the original chloride ligands. 
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The long term aim of this work would be to fully understand the interactions that occur 
between the biisoquinoline complexes and the quadruplex DNA in a cellular environment.  
This also involves the development of the biisoquinoline modifications so that the binding 
is specifically between quadruplexes and the complex, and targeted to towards cancerous 
cells.     
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Appendix 
 
1.  2D-COSY, NOESY and Mass Spectrometry Spectra (Including Crystallographic 
data for Pd and Re complexes) 
1.1  Isoquinoline 1,3-dione (1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COSY NMR (400 MHz, d6-DMSO, 298 K). 
NOESY NMR (400 MHz, d6-DMSO, 298 K). 
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1.2  1,3-Dichloroisoquinoline (2)   
 
 
 
 
 
 
 
 
 
 
 
 
EI Mass spectrum.  
COSY NMR (400 MHz, d6-DMSO, 298 K). 
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1.3  3-Chloroisoquinoline (3) 
 
 
 
 
 
 
 
 
 
 
 
 
EI Mass spectrum.  
COSY NMR (400 MHz, MeOD, 298 K). 
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1.4  3,3-Biisoquinoline (ibiq) (4) 
 
 
 
 
 
 
 
 
 
 
 
 
EI Mass spectrum.  
COSY NMR (400 MHz, MeOD, 298 K). 
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NOESY NMR (400 MHz, MeOD, 298 K). 
EI Mass spectrum.  
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1.5  [Pd(ibiq)2][BF4]2 (5) 
 
 
 
 
 
 
 
 
 
 
Crystallographic Data 
Empirical formula C36H24N4Pd, 2(BF4), C6H6 
Mr 870.72 
T [K] 100.00(10) 
Crystal system Triclinic 
Space group P -1 
Unit cell dimensions a = 7.3309(3) Å  α= 84.443(3)° 
b = 8.4090(3) Å  β= 89.964(3)° 
c = 14.3651(5) Å γ = 76.153(3)° 
V [Å
3
] 855.54(6) Å
3
 
Z 1 
Density(calc) (Mg/m
3
) 1.690 Mg/m
3
 
Absorption coefficient (mm-1) 5.114 mm
-1
 
ESI Mass spectrum.  
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Reflections collected 16249 
Independent reflections 3460 [R(int) = 0.0270] 
Goodness of fit on F
2
 1.059 
Final R indices [I>2σ(I)] R1 = 0.0202, wR2 = 0.0533 
R indices (all data) R1 = 0.0203, wR2 = 0.0534 
 
 
1.6  [Pt(ibiq)Cl2] (6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ESI Mass spectrum  
ESI Mass spectrum.  
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1.7   [Pt(ibiq)2][PF6]2 (7) 
 
 
 
 
 
 
 
 
 
 
1.8   [Re(CO)3(ibiq)(Py)][CF3SO3] (8) 
 
 
 
 
 
 
 
 
 
 
 
 
COSY NMR (400 MHz, MeOD, 298 K). 
ESI Mass spectrum.  
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NOESY NMR (400 MHz, MeOD, 298 K). 
ESI Mass spectrum.  
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Crystallographic Data 
Empirical formula C26H17N3O3Re, CF3O3S, 0.5(C6H6), 0.5(C6H6) 
Mr 832.80 
T [K] 100.00(10) 
Crystal system Triclinic 
Space group P -1 
Unit cell dimensions a = 11.2393(5) Å  = 66.417(4)° 
b = 11.9121(6) Å  = 79.312(3)° 
c = 14.0194(5) Å   = 62.531(5)° 
V [Å
3
] 1526.27(14) Å3 
Z 2 
Density(calc) (Mg/m
3
) 1.812 Mg/m3 
Absorption coefficient (mm-1) 9.040 mm-1 
Reflections collected 26600 
Independent reflections 6098 [R(int) = 0.0362] 
Goodness of fit on F
2
 1.037 
Final R indices [I>2σ(I)] R1 = 0.0207, wR2 = 0.0452 
R indices (all data) R1 = 0.0246, wR2 = 0.0463 
 
 
 
 
 
 
 Appendix 
 
 
308 
 
1.9  Rh(COD)(ibiq)]Cl2 (9) 
 
 
 
 
 
 
 
 
 
 
1.10   4-Bromophenyl 2-chloroethyl ketone (A) 
 
 
 
 
 
 
 
 
 
 
 
 
ESI Mass spectrum.  
COSY NMR (400 MHz, CDCl3, 298 K). 
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NOESY NMR (400 MHz, CDCl3, 298 K). 
EI Mass spectrum.  
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1.11    5-Bromoindan-1-one (B) 
 
 
 
 
 
 
 
 
 
 
 
1.12    6-Bromo-indan-1,2-dione-1-oxime (C) 
 
 
 
 
 
 
 
 
 
 
 
EI Mass spectrum.  
ESI Mass spectrum.  
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1.13    6-Bromo-1,3-dichloro-isoquinoline (D) 
 
 
 
 
 
 
 
 
 
 
 
 
1.14    6-Bromo-3-chloro-isoquinoline (E) 
 
 
 
 
 
 
 
 
 
 
ESI Mass spectrum.  
EI Mass spectrum.  
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1.15    6-(2-Trimethylsilyl)ethynyl-3-chloro isoquinoline (F) 
 
 
 
 
 
 
 
 
 
 
 
1.16    6-Ethynyl-3,3-biisoquinoline (G) 
 
 
 
 
 
 
 
 
 
 
 
ESI Mass spectrum.  
EI Mass spectrum.  
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2. Reaction Mechanisms 
2.1 
 
 
 
2.2 
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2.3 
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2.4 
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3. PAGE Quantification 
 
Lane 6 
 
 
 
 
 
 
 
Lane 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section Area 
1 31768.62 
2 20292.92 
3 16804.07 
Section Area 
4 10776.43 
5 10773.85 
Distance in Pixels 
Distance in Pixels 
Grey 
Value 
Grey 
Value 
1 
2 
3 
4 
5 
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4. Examples of Cytotoxicity Data  
[Pd(ibiq)2][BF4] and cell line A2780 
 
 
 
 
 
 
 
 
 
 
 
[Pd(ibiq)2][BF4] and cell line T47D 
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[Pt(ibiq)2][PF6] and cell line A2780 
 
 
 
 
 
 
 
 
 
 
 
[Pt(ibiq)2][PF6] and cell line T47D 
 
 
 
 
 
 
 
 
 
 
 
 
 
y = -8.093ln(x) - 85 
R² = 0.9923 
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Cisplatin and cell line A2780 
 
 
 
 
 
 
 
 
 
 
 
Cisplatin and cell line T47D 
 
 
 
 
 
 
 
 
 
 
 
  
 
y = -24.2ln(x) - 264.91 
R² = 0.9708 
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5. CD DMSO control titrations for htelo, cmyc and ct-DNA 
2.0% DMSO corresponds to a complex:DNA ratio of 9:1 for htelo and cmyc DNA, and 
0.3:1 for ct-DNA  
Htelo DNA (3 μM) 
 
cmyc DNA (3 μM) 
 
ct-DNA (300 μM)
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